

WO 00/50639

Continued

9 of 12

MAb, 81C6; MAb, cancer	Phase II		monoclonal antibody; biotechnology	cancer
MAb, alpha5 beta3 integrin	Discontinued		monoclonal antibody; biotechnology	cancer
MAb, boron complex, Preclinical Strathclyde Institute for Drug Research	Preclinical		monoclonal antibody; biotechnology	cancer
MAb, cancer-beta glucosidase; AGENT	Preclinical		monoclonal antibody; biotechnology	cancer
MAb, epidermal growth factor receptor; MAb, EGFR; MAb, E7.6.3; ABX EGF; ABX EGFR	Preclinical		monoclonal antibody; biotechnology	cancer
MAb, HMFG-1	Phase I		monoclonal antibody; biotechnology	cancer
MAb, platelet derived growth factor/basic fibroblast growth factor; MAb PDGF/bFGF; SMA PDGF/bFGF	Preclinical		monoclonal antibody; biotechnology	cancer; restenosis
MAb, tissue factor/factor VII; MAb, TF/factor VII; SMA TF/factor VII	Preclinical		monoclonal antibody; biotechnology	cancer
MAbs, folate receptors & immune effector cells; bispecific monoclonal antibodies, folate receptors & immune effector cells	Preclinical		monoclonal antibody; biotechnology	cancer

tumor stroma specific antibody	Preclinical		monoclonal antibody; biotechnology	cancer
MAb, vascular endothelium growth factor; MAb, vEGF; SMA vEGF	Preclinical		monoclonal antibody; biotechnology; angiogenesis inhibitor	cancer
MAb, VEGF; MAb, vascular epithelial growth factor	Phase II		monoclonal antibody; biotechnology; angiogenesis inhibitor	cancer; retinopathy
MAb, endoglin-tTF; immunotoxin, endoglin-tTF	Preclinical		monoclonal antibody; biotechnology; coagulation factor; immunotoxin	cancer
MAb, endoglin-dgA; immunotoxin endoglin-dgA	Preclinical		monoclonal antibody; biotechnology; immunotoxin	cancer
MAb, HMFG-1 fragment-yttrium 90; TheraFab	Preclinical		monoclonal antibody; biotechnology; radiotherapeutic	cancer
MAb, LL2-yttrium-90; yttrium-90-LL2; LymphoCide	Phase I		monoclonal antibody; biotechnology; radiotherapeutic	cancer
MAb, polymorphic epithelial mucin-yttrium 90; MAb, human-milk fat globulin-1 (HMFG1); THERAGYN	Phase III		monoclonal antibody; biotechnology; radiotherapeutic	cancer

N 3554S; N 1554	Preclinical	[S-(all-E)]-3,7,11,15,19,23,27,31,35,39-decamethyl-6,10,14,18,22,26,30,34,38-tetracontanonaen-1-ol, dihydrogen phosphate	N glycosylation stimulator	cancer
SR 48692	Phase II	2-[[[1-(7-chloro-4-quinoliny)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]tricyclo[3.3.1.13,7]deca-2-carboxylic acid	neurotensin antagonist	schizophrenia; cancer
NS 521	Discontinued		neurotrophic factor; growth factor	Alzheimer disease; neuropathy; cancer; diabetes
sodium borocaptate 10B; borocaptate sodium B 10; NASH; BSH; BOROLIFE	Suspended	1,2,3,4,5,6,7,8,9,10,11-undecahydro-12-mercaptoododecaborat e(2-)-10B12 disodium	neutron capture agent	cancer
nitric oxide-releasing anticancer agents, National Institutes of Health	Preclinical		nitric oxide donor	cancer
NCX 1101	Preclinical		nitric oxide donor; NSAID	cancer
hemoglobin-based scavenger; ENDOGLOBIN-HT; ENDOGLOBIN-CT	Discontinued		nitric oxide scavenger	hypotension; cancer

hemoglobin-based therapy, Apex NOX 100	Preclinical		nitric oxide scavenger	cancer; hypotension; septic shock
	Preclinical		nitric oxide scavenger	diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
NOX 101	Discontinued	Unspecified	nitric oxide scavenger	stroke; diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
NOX 51	Preclinical		nitric oxide scavenger	diabetes; cancer; cardiovascular disease; transplant rejection; septic shock
pyridoxylated hemoglobin polyoxyethylene conjugate; PHP-HT; PHP-CT	Phase II		nitric oxide scavenger	cancer; hypotension; septic shock
fotemustine; S 10036; MUPHORAN	Marketed	(+/-)-diethyl [1-[3-(2-chloroethyl)-3-nitrosouido]ethyl]p	nitrosourea; alkylating agent	cancer
nitrulyn; CRC 7805068	Phase II	hosphonate	nitrosourea; alkylating agent	cancer

SarCNU; NSC 364432	Preclinical	2-[[(2-chloroethyl)nitrosoamino]carbonyl]methyleno]acetamide	nitrosurea; alkylating agent	cancer
semustine; methyl CCNU; WR 220076; NSC 95441; ICIG 1110	Phase I	N-(2-chloroethyl)-N-(4-methylcyclohexyl)-N-nitrosourea	nitrosurea; alkylating agent	cancer
TA 077	Phase III	N-(2-chloroethyl)-N-(4-O-alfa-D-glucopyranosyl-beta-D-glucopyranosyl)-N'-(2-methylpropyl)-N-nitrosourea	nitrosurea; alkylating agent	cancer
tauromustine; TCNU; Phase III LS 2667; TAURICYT	2(((2-chloroethyl)nitrosoamino)carbonyl)amino)-N,N-dimethyl ethanesulfonamide	nitrosurea; alkylating agent	cancer	cancer
cell adhesion molecules intracellular inhibitors, ICOS/Abbott	Preclinical	NSAID		
drug discovery, Trega Biosciences; drug discovery, Chugai	Preclinical	NSAID	inflammation; diabetes; cardiovascular disease; neurological; cancer; infectious disease	
G-protein therapy, Cadus/Bristol-Myers Squibb	Preclinical	NSAID	inflammation; cardiovascular disease; cancer	

kinase modulators, ICOS	Preclinical		NSAID	cancer; inflammation
nitric oxide modulators, Duke University	Preclinical		NSAID	hypotension; cancer; rheumatoid arthritis
signal transduction modulators, Cancer Research Campaign	Preclinical		NSAID	cancer; inflammation; neurological
synthetic glycosaminoglycans	Preclinical		NSAID	cancer; neuropathy
drug delivery system, Registered HIT diclofenac; diclofenac HIT; HYAL AT2101; HYAL CT1101; HYAL AV2201; HYAL AT1201; HYANALGESE; HYANALGESE-D; SOLARASE; ORALEASE	Registered		NSAID; analgesic	pain; cancer; inflammation; skin disease; mucositis
P 54	Phase II		NSAID; analgesic	osteoarthritis; Crohn disease; cancer
apoptosis modulators, IDUN	Preclinical		NSAID; apoptosis inhibitor; apoptosis inducer; caspase inhibitor	cancer; neuropathy; inflammation
MDR inhibitors, BioResearch Ireland	Preclinical		NSAID; MDR inhibitor	cancer
proteasome inhibitors, ProScript	Preclinical		NSAID; transcription factor regulator	inflammation; cancer
EPI 163; EpiCyte	Preclinical		nucleoside analogue	cancer

OGT 719	Phase I	5-fluoro-1-beta-L-galactopyranosyl-2,4(1H,3H)-pyrimidinedione	nucleoside analogue	cancer
thio-cytarabine derivatives, Southern Research Institute; thio-araC derivatives, Southern Research Institute	Preclinical		nucleoside analogue	cancer
Yunnanycin	Preclinical		nucleoside analogue	cancer
8-chloro-cAMP; 8-Cl-cyclic adenosine monophosphate; 8-Cl-cAMP	Discontinued	8-chloro-cyclic adenosine 3',5'-monophosphate	nucleoside analogue; antimetabolite	cancer
anticancer, Camerino University	Preclinical	1-beta-D-ribofuranosyl-1H-pyrrolo[3,2-c]pyridine-4,6-diamine	nucleoside analogue; antimetabolite	cancer
CNDAC	Preclinical	4-amino-1-(2-cyano-2-deoxy-beta-D-arabinosylfuranosyl)-2(1H)-pyrimidinone	nucleoside analogue; antimetabolite	cancer
DMDC	Phase II	2-deoxy-2'-methylencytidine	nucleoside analogue; antimetabolite	cancer
drug delivery system, 5 fluoropyrimidone; 5 fluoropyrimidone delivery system	Phase I		nucleoside analogue; antimetabolite	cancer; viral infection

fludarabine; FaraAMP; fludarabine phosphate; SH 573; SH 584; SH 586; NSC 312887; NSC 328002; 2-F araAMP; NSC 118218; NSC 118218-H; 2-F-araA; ZK 153851; FLUDARA	Marketed	9-beta-D-arabinofuranosyl-2'-fluoroadenine-5'- (dihydrogen phosphate)	nucleoside analogue; antimetabolite	cancer
gemcitabine; dFdC; difluorodeoxycytidine; LY 188011; DDFC; GEMZAR	Marketed	2'-deoxy-2',2'-difluorocytidine	nucleoside analogue; antimetabolite	cancer
RL 0018; CYTOVERT	Preclinical		nucleoside analogue; antimetabolite	cancer
sulfimidine; fin; SULFINOSINE	Preclinical	2-amino-9-beta-ribofuranosyl-9H-purine-6-sulfonamide	nucleoside analogue; antimetabolite	cancer
UK 25	Preclinical	5-fluoro-3,4-dihydro-2,4-dioxo-N-[6-[[[(1-oxo-2-propylpentyl)amino]acetyl]amino]hexyl]-1(2H)-pyrimidinecarboxamide	nucleoside analogue; antimetabolite	cancer
IPdR	Preclinical	5-iodo-pyrimidinone-2'-deoxyribose	nucleoside analogue; antimetabolite; radiosensitizer	cancer

troxacicabine; BCH 4556	Phase II	(2S-ois)-4-amino-1-[2-(hydroxymethyl)-1,3-dioxolan-4-yl]-2(1H)-pyrimidinone	nucleoside analogue; DNA polymerase inhibitor	cancer
N 10146	Phase I	5-amino-3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,4H)-dione	nucleoside analogue; immunostimulant; biological response modifier	cancer; viral infection
nucleoside analogues, Nabi; nucleotide analogues, Nabi	Preclinical			
TAS 106	Preclinical			
FES 12	Preclinical			
CS 682	Phase I	N-[1-(2-cyano-2-deoxy-beta-D-arabinofuranosyl)-1,2-dihydro-2-oxo-4-pyrimidinyl]hexadeca namide	nucleoside; DNA polymerase inhibitor	cancer
adenosine triphosphate; ATP	Discontinued	adenosine 5'- (tetrahydrogen triphosphate)	nucleotide	cancer; cachexia
oligonucleotide, cancer immunotherapy	Preclinical		oligonucleotide; biotechnology; immunostimulant	cancer
ribozyme, dysprosium-texaphyrin, cancer; Dy-Tex	Preclinical		oligonucleotide; biotechnology; ribozyme	cancer

drug delivery system, sustained release DepoFoam morphine; morphine DepoFoam; C 0401; DepoMorphine	Phase II	opiate agonist; mu agonist; analgesic	pain; cancer
naloxone + pentazocine; pentazocine + naloxone	Pre-registration	opiate agonist; opiate antagonist; analgesic	pain; cancer
CP 100356	Preclinical	4-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinoliny)-N-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxy-2-quinazolinamine	P glycoprotein inhibitor cancer
LY 335979; RS 33295	Phase II	[6(R)-1a alpha,6alpha,10b alpha]-4-(1,1-difluoro-1,1a,6,10b-tetrahydronibenzo[a,e]cyclopropa[c]cyclohepten-6-yl)-alpha-[(5-quinolinyloxy)methyl]-1-piperazineethanol, trihydrochloride	P glycoprotein inhibitor cancer

N 1379; L 623	Discontinued	hydroxybutanedioic acid cmpd with N,N'-bis[3,4-dimethoxyphenyl]methyli-N-(3,7,11,15,19,23,27,3,1,35-nonamethyl-1,2,6,10,14,18,22,26,30,34,hexatetracontanonaenyl)-1,2-ethanediamine (1:1)	P glycoprotein inhibitor	cancer
XR 9576	Phase II	N-[2-[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinoliny)ethyl]phenyl]amino]carbonyl]-4,5-dimethoxyphenyl]-3-quinolinecarboxamide	P glycoprotein inhibitor; MDR inhibitor	cancer
rohitukine; L 868275	Preclinical	cis-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidiny)-2-methyl-4H-1-benzopyran-4-one	p34 kinase inhibitor	cancer
SDZ 62434; SDZ 62-434	Discontinued	2,3-dihydro-5-[4-(1-piperidinylmethyl)phenyl]imidazo[2,1-a]isoquinoline dihydrochloride	PAF antagonist	cancer
plasminogen activator	Preclinical		PAI inhibitor	cancer
inhibitor antagonists, Corvas				

plasminogen activator inhibitor-1 inhibitor, Xenova; PAI-1 inhibitor, Xenova	Preclinical	PAI inhibitor	cancer
BIM 44002	Phase I	parathyroid hormone antagonist peptide	hypercalcemia; cancer
antifreeze protein, cancer cryosurgery, A F Protein	Preclinical		cancer
axinastatin 1; malaysatin; pseudoaxinellin	Preclinical	axinastatin 1 peptide	cancer
axinastatin 2	Preclinical	5-L-leucine-axinastatin 1 peptide	cancer
axinastatin 3	Preclinical	4-L-isoleucine-5-L-leucine-axinastatin 1 peptide	cancer
BST 1002	Preclinical		cancer
BST 1003; COLLAMER	Preclinical	peptide	cancer
cancer therapy, Aptein	Preclinical	peptide	cancer
cancer therapy, Magainin	Preclinical	peptide	cancer
cancer therapy, PSP 94, Procyon	Preclinical	beta-Inhibin (human reduced)	cancer
cell permeable peptides	Preclinical	peptide	cancer
corticotropin-releasing factor; corticotropin-releasing hormone; CRF; XERCEPT CYC 100	Phase II	peptide	cancer; stroke; trauma
	Preclinical	peptide	cancer

CYC 101	Preclinical	peptide	cancer
CYC 102	Preclinical	peptide	cancer
CYC 103	Preclinical	peptide	cancer
D 22631	Discontinued	peptide	cancer
drug delivery system, anticancer peptide	Preclinical	peptide	cancer
GPX 200	Phase I	peptide	cancer
GW 395058	Preclinical	peptide	cancer; thrombocytopenia
insulin-like growth factor-1 receptor inhibitor; IGF-1 receptor inhibitor; IGF-1 JB3	Preclinical	peptide	restenosis; cancer
laminin peptides, National Institutes of Health	Preclinical	peptide	cancer
MF 13	Preclinical	L-prolyl-3-[bis(2-chloroethyl)amino]-L-phenylalanyl-L-norvaline ethyl ester monohydrochloride.	cancer
monocyte attracting peptide	Preclinical	peptide	cancer; bacterial infection
MSI 103	Discontinued	Lys Ile Ala Gly Lys Ile Ala Lys Ile Ala Gly Lys Ile Alaninamide	cancer
MSI 500	Discontinued	peptide	cancer

NA 22598; NA 22598A1	Preclinical	N-[2,3-diamino-8-[2-amino-1-(aminocarbonyl)-4,5-dihydro-1H-imidazol-5-yl]-2,3,4,5,8-penta(deoxyoctonoyl)-L-alanyl-L-valine	peptide	cancer
NSC 630176; FR 901228	Phase I	N-[3S,4E]-3-hydroxy-7-mercaptopro-1-oxo-4-heptenyl]-D-valyl-D-cysteiny-(2Z)-2-amino-2-butenoyl-L-valine (4-1)-lactone cyclic (1-2)disulfide	peptide	cancer
p16 analogue	Preclinical	peptide	cancer	
prohibitin	Preclinical	peptide	cancer	
PTL 03001	Preclinical	peptide	cancer	
somatotropin; PTR 3046	Preclinical	cyclo(Phe-N2-Tyr-D-peptide Trp-Lys-Val-Phe-C3)Thr-NH2		pancreatitis; cancer; restenosis
thiocoraline	Preclinical	peptide	cancer	
urokinase receptor antagonist cyclopeptide, Wilex Biotechnology	Preclinical	peptide	cancer	
IM 862	Phase II		peptide; angiogenesis inhibitor	cancer
D2AT21	Preclinical		peptide; antibiotic	bacterial infection; trichomoniasis; cancer
breast cancer therapy, Cytoclonal	Preclinical		peptide; antiestrogen	cancer

BRCA1, recombinant transcription factor, vascular endothelial growth factor gene	Preclinical		peptide; biotechnology	cancer
alpha-conopeptides	Preclinical		peptide; cholinergic agonist; nicotinic agonist	schizophrenia; Parkinson disease; cancer; urinary incontinence
fibroblast growth factor, basic, antagonists, NIH	Preclinical	peptide; FGF antagonist	peptide; FGF antagonist	cancer
fibroblast growth factor receptor inhibitor; FGF receptor inhibitor	Preclinical	peptide; FGF antagonist; angiogenesis inhibitor	restenosis; cancer	
splenopentin; diacetyl-splenopentin; berlopentin; DA SPS; DA-Sp 5; BCH 069	Preclinical	N2-acetyl-L-arginyl-N6-acetyl-L-lysyl-L-alpha-glutamyl-L-valyl-L-tyrosine	peptide; immunostimulant	cancer
integrin-specific peptides, Integra LifeSciences	Preclinical		peptide; integrin antagonist; cell adhesion inhibitor; angiogenesis inhibitor	osteoporosis; cancer; restenosis
antagonist D	Preclinical		peptide; substance P antagonist	cancer
auristatin PE	Preclinical		peptide; tubulin polymerase inhibitor	cancer
C3B Cdc25 inhibitors, Mitotix	Preclinical	Unspecified	phosphatase inhibitor	cancer
	Preclinical		phosphatase inhibitor	cardiovascular disease; cancer

CT 2584; APRA	Phase II	1-[1-(dodecylamino)-10-hydroxyundecyl]-3,7-dihydro-3,7-dimethyl-1H-purine-2,6-dione	phosphatidic acid inhibitor	cancer
benzochlorins	Preclinical		photosensitizer	cancer
benzophenothiazines, Rowland Institute; benzophenothiazines, Ergo Science	Preclinical		photosensitizer	cancer
benzoporphyrin derivatives, third generation; QLT 0074	Preclinical		photosensitizer	cancer
boronated porphyrin compounds; BOPP	Phase I		photosensitizer	cancer
chlorins	Preclinical		photosensitizer	cancer
cis-porphyrin	Preclinical	cis-meso-bis(N-methyl)-4-(pyridinium)diphenyl porphyrin	photosensitizer	cancer
drug delivery system, Discontinued			photosensitizer	cancer
liposome zinc phthalocyanine; zinc phthalocyanine liposome; CGP 55847				
drug delivery system, RFS aminolevulinic acid; 5-ALA RFS; aminolevulinic acid, RFS	Preclinical		photosensitizer	cancer

drug delivery system, transdermal 5-aminolevulinic acid; 5-aminolevulinic acid transdermal; drug delivery system, transdermal ALA PDT	Discontinued	photosensitizer	cancer
ER 470	Discontinued	photosensitizer	cancer
HAT D01	Preclinical	photosensitizer	cancer; diagnosis
HPHH	Phase I	photosensitizer	cancer
hypericin; VIM/Rxyn; CYCLO-WERROL; CYCLOSAN	Phase II	1,3,4,6,8,13-hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-]opraqylene-7,14-dione	psoriasis; cancer
JM 2929	Discontinued	(OC-6-12)-bis[3-(diphenylphosphino-kappaP)benzenesulfonylato][29H,31H-phthalocyaninato(2-)kappaN29,kappaN30,kappaN31,kappaN32]ruthenate(2-), dipotassium	cancer
lutetium texaphyrin; Lu Tex; PCI 0123; LUTRIN; Lu-Tex; OPTRIN; ANTRIN	Phase II	photosensitizer	cancer; atherosclerosis; eye disease; skin disease

NP-e6; NP-e6, ME 2906	Phase II	N-[3-[2S,3S]-18-carboxy-20-(carboxymethyl)-8-ethenyl-13-ethyl-2,3-dihydro-3,7,12,17-tetramethyl-21H,23H-porphin-2-yl]-1-oxopropyl]-L-aspartic acid tetrasodium salt	photosensitizer	cancer
photodynamic immunotherapy, Pacific; PDT	Preclinical		photosensitizer	cancer
photodynamic therapy, Anutech; drug delivery system, photosensitizer	Preclinical		photosensitizer	cancer
photodynamic therapy, plant-derived, Steba Beheer	Preclinical		photosensitizer	cancer; bacterial infection
porfimer sodium; polyporphyrin; CL 184116; PHOTOFRIN; PHOTOFRIN II	Marketed	photofrin porfimer sodium	photosensitizer	cancer
purpurins	Preclinical		photosensitizer	cancer
SC 102	Preclinical		photosensitizer	cancer
SQN 400; SQ 400	Preclinical		photosensitizer	cancer
tellurapytium; USB 006	Discontinued		photosensitizer	cancer
temoporfin; m-THPC; Phase III EF 9; FOSCAN	3,3',3"-3""-(2,3-dihydro-21H,23H-porphine-5,10,15,20-tetrayl)tetraakis phenol	photosensitizer	cancer	

tin ethyl etiopurpurin; Phase III SnET2; PURLYTIN	tin [ethyl 3,4,20,21-tetrahydro-4,9,14,19-tetraethyl-18,19-dihydro-3,8,13,18-tetramethyl-20-phorbinecarboxylato(2-)-kappa.N23,kappa.N24,kappa.N25,kappa.N26]-,(SP-4-2)-verdins	photosensitizer prostate hypertrophy; retinopathy	cancer; benign prostate hypertrophy; retinopathy
zinc phthalocyanine aminolevulinic acid, photodynamic therapy; 5-ALA PDT; LEVULAN	Preclinical Discontinued Pre-registration	photosensitizer photosensitizer photosensitizer; contrast medium	cancer cancer psoriasis; skin disease; endometriosis; cancer; diagnosis
verteporfin; benzoporphyrin derivative; BPD-MA; CL 318952; BPDR; VISUDYNE	Phase III	trans-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo[b]porphine-9,13-dipropanoic acid monomethyl ester	photosensitizer; NSAID cancer; psoriasis; arthritis; retinopathy
anagrelide; anagrelide hydrochloride; BL 4162A; AGRYLIN; AGRELIN	Marketed	6,7-dichloro-1,5-dihydroimidazo[2,1-b]quiazolin-2(3H)-one	platelet antiaggregant thrombosis; cancer
AP 5070	Preclinical	platinum complex	cancer

B 850040	Discontinued	1,3-diamino-2-methoxy/methyl-2-methyl-propan-N,N,N-cyclobutan-1,1-dicarboxylate	platinum complex	cancer
BBR 2207	Discontinued	hydrogen [mu-[benzenepentacarboxylato(5-)O1,O2,O4,O5]]bis(1,2-cyclohexanediamine-N,N')diplatinum (1-), stereoisomer	platinum complex	cancer
BBR 3464	Phase I		platinum complex	cancer
cisplatin analogue, II Yang	Preclinical		platinum complex	cancer
cycloplatam	Phase I	amine(cyclopentanamine)hydroxybutane dioato(2-)O1,O4]-platinum	platinum complex	cancer
drug delivery system, ATRIGEL sustained release cisplatin; cisplatin ATRIGEL	Preclinical		platinum complex	cancer
drug delivery system, cisplatin; cisplatin Therapeutic Implant; MPI 5010; IntraDose INJECTABLE GEL; IntraDose-CDDP; INTRADOSE-CDDP; IntraDose	Phase III		platinum complex	cancer

drug delivery system, Preclinical			platinum complex	cancer
cisplatin biodegradable polymer implant;				
cisplatin biodegradable polymer implant				
drug delivery system, Phase II			platinum complex	cancer
liposomal L-NDDP; L-NDDP liposomes; AR 726; PLATAR				
drug delivery system, Preclinical			platinum complex	cancer
liposome carboplatin; carboplatin liposome				
drug delivery system, Preclinical			platinum complex	cancer
liposome carboplatin; carboplatin liposome				
drug delivery system, Preclinical			platinum complex	cancer
microsphere cisplatin; cisplatin microsphere				
drug delivery system, Phase I			platinum complex	cancer
NDDP liposome; NDDP liposome				
drug delivery system, Phase II			platinum complex	cancer
STEALTH cisplatin; cisplatin STEALTH delivery system; SPI 77; SPI 077				
GB 21; W 164; E 92/114	Preclinical	poly-[(trans-1,2- diamino- cyclohexane)platinum]-carboxyamyllose		

JM 221	Discontinued	(OC-6-43)-amminebis(butanoato O)dichloro(cyclohexanamine)platinum	platinum complex	cancer
JM 335	Discontinued	(OC-6-12)-amminedichloro(cyclohexanamine)dihydroxyplatinum	platinum complex	cancer
JM 473	Preclinical	(SP-4-3)-amminedichloro(2-methylpyridine)platinum	platinum complex	cancer
KHPC 001	Phase I	[SP-4-2-(1R-trans)-(1,2-cyclohexanediamine-kappaN,kappaN')[1,3-propanediylibis[diphenylphosphine-kappaP]]-platinum(2+),dinitrate	platinum complex	cancer
KHPC 002 KI 30606	Phase I	poly[[(+/-)-trans-1,2-diaminocyclohexane][1,3-dicarboxylatopropylamido(nitrido)phosphoric acidplatinum (II)]]	platinum complex	cancer

KP 1250	Preclinical	(SP-4-2)-dichloro(5,7,8,10,11,13,14,16,17,19,20,22-dodecahydro[1,4,7,10,1,3,16]-hexaoxacyclodocosin[19,18-b:20,21-b']dipyridine-[N1,N26]platinum	platinum complex	cancer
lipophilic platinum compounds; Aronex	Discontinued		platinum complex	cancer
lobaplatin; D 19466	Registered	cis-(trans-1,2-cyclobutanebis(amine N,N')(2-hydroxypropionato(2-O1,O2)platinum	platinum complex	cancer
miboplatin; loboplatin; DWA 2114R; DWA 2114A; NEOPLAT	Discontinued	[SP-4-3-(1R-cis)]-[1,1-cyclobutanedicarboxylato(2-)(2-pyrrolidinemethanamine-Nalpha,N1)platinum	platinum complex	cancer
nedaplatin; latoplatin; Marketed S 254; 254 S; NSC 375101D; AQUPLA	Marketed	(SP-4-3)-diammine[(hydroxy-kappa,O)acetato(2-kappa,O)platinum	platinum complex	cancer
ormoplatin; tetraplatin; TCDCP; NSC 276017; NSC 363812; NSC 363812D; U 77233	Phase I	[OC-6-22-(trans)-tetrachloro(1,2-cyclohexanediamine-N,N')platinum	platinum complex	cancer

oxaliplatin; oxalatoplatin; L- OHP; ACT 078; ELOXATINE; L- OHP; TRANSPLATIN; ELOXATIN PADP	Marketed	[SP-4-2-(1R-trans)- (1,2- cyclohexanediamine)- N,N")]ethanediato(2-)-O,O"]platinum	platinum complex	cancer
platinum complex, Cancer Research Center	Phase I	phosphonoaceto-1, 2-diaminocyclohexane platinum (II)	platinum complex	cancer
platinum compounds, Discontinued Georgetown University	Preclinical	cis-diamine(nitrilotris(methylphosphonato)(2-)- O1,N1)platinum II	platinum complex	cancer
platinum-triamine complex; DPR	Preclinical	(SP-4-3)- diamminechloro[2-(diethylamino)ethyl- 4-aminobenzoate- N4]platinum(1+) chloride monohydrochloride	platinum complex	cancer
polymer platinum compounds, London School of Pharmacy	Preclinical		platinum complex	cancer

RL 0013; NSC 328005; Pt 268; CYPLATE	Preclinical	(SP-4-3)-(1,2-cyclohexanediamine-N,N')-[N-(phosphonoacetyl)-L-asparto(4-O1,O4)platinum(2-)dihydrogen	platinum complex	cancer
satraplatin; JM 216; BMS 182751; BMY 45594	Phase III	(OC-6-43)-bis(acetato-O)amminedichloro(cyclohexanamine)platinum	platinum complex	cancer
sebriplatin; NK 121; CI 973; SEVRIPLATIN	Discontinued	[SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)(2-methyl-1,4-butanediamine-N,N')platinum	platinum complex	cancer
SKI 2034R	Discontinued		platinum complex	cancer
SKI 2053R; SK 12035R	Phase II	[SP-4-2-[4R-(2alpha,4alpha,5beta)-]-[2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine-kappaN4,kappaN5][propandioato(2-)kappaO1,kappaO3]platinum	platinum complex	cancer
SM 11355; DACHPM	Discontinued	(trans-cyclohexane-1,2-diamine)bis(myristate)platinum (II)	platinum complex	cancer

TRK 710	Discontinued	[SP-4-3-1(S)-3(R-trans)]-3-acetyl-5-methyl-2,4(3H,5H)-furandionato-O3,O4)(1,2-cyclohexanediamine-N,N')-platinum(1+), salt with (S)-3-acetyl-5-methyl-2,4(3H,5H)furandione (1:1), tetrahydrate (1:1), tetrahydrate	platinum complex	cancer
ZD 0473; AMD 473	Phase I	(SP-4-3)-amminedichloro(2-methylpyridine)platinum	platinum complex	cancer
zeniplatin; 2,2-bis(aminomethyl)-1,3-propanediol platinum complex; 1,1-cyclobutanedicarboxylic acid platinum complex; CL 286558	Phase II	(SP-4-2)-[2,2-bis(aminomethyl)-1,3-propanediol-N,N'][1,1-cyclobutanedicarboxylato(2-)]platinum	platinum complex	cancer
PD 128763	Preliminary	3,4-dihydro-5-methyl-1(2H)-isoquinolinone	poly (ADP ribose) polymerase inhibitor	cancer
diethylhomospermine; DEHOP; DE 444	Phase II	N,N'-bis[4-(ethylamino)butyl]-1,4-butanediamine	polyamine analogue	diarrhea; hypertension; cancer; psoriasis; ulcerative colitis
diethylhomospermine; DENSPM; CI 1006; DE 333	Phase II	N1,N11-diethylnorspermine	polyamine analogue	cancer; psoriasis; Alzheimer disease

linear polyamine analogue, SunPharm MDL 28314	Preclinical		polyamine analogue	cancer; Alzheimer disease
	Discontinued	N,N'-bis[3-(ethylamino)propyl]-1,7-heptane diamine	polyamine analogue	cancer
polyamine analogues, National Institutes of Health	Preclinical		polyamine analogue	cancer
mitoguazone; methylglyoxal bisguanylhydrazone; MGBG; NSC 32946; ZYRKAMINE	Marketed	1,1'-[[(methyllethanediylide)ne]dinitrilo]diguanidine	polyamine synthesis inhibitor	cancer
polyclonal antibody, complement inhibitor protein; gammaglobulin, complement inhibitor protein; PASS-CaB	Preclinical		polyclonal antibody; immunoglobulin	cancer
actinoplanone A; R 304G	Discontinued	[1S-(1alpha,3alpha,4beta,8alpha)-13-amino-11-chloro-3,4,8a,13-tetrahydro-3,15,16-trihydroxy-1,4-dimethoxy-12-methyl-1H-xantheno[4',3',2':4,5][1,3]benzodioxino[7,6-g]isoquinoline-14,17(2H,9H)-dione	polycyclic xanthone; bacterial infection; cancer	

actinoplanone B; R 304H	Discontinued	[1S-(1alpha,3alpha,4beta,8alpha)-11-chloro-3,4,8a,13-tetrahydro-1,4-dimethoxy-12-methyl-1H-xantho[4'3',2':4,5][1,3]benzodioxino[7,6-g]isoquinoline-14,17(2H,9H)-dione	polycyclic xanthone; bacterial infection; cancer
actinoplanone C; R 304J	Discontinued	[1S-(1alpha,3alpha,4beta,8alpha)-13-amino-3,4,8a,13-tetrahydro-1,4-dimethoxy-12-methyl-1H-xantho[4'3',2':4,5][1,3]benzodioxino[7,6-g]isoquinolone-14,17(2H,9H)-dione	polycyclic xanthone; bacterial infection; cancer

actinoplanone G; R 304F	Discontinued	[1S-(1alpha,3alpha,4beta,8alpha,13fa)]-3,4,8a,13-tetrahydro-3,15,16-trihydroxy-1,4-dimethoxy-12-methyl-13-[(1-methyl-2-oxopropylidene)aminol]-1H-xantheno[4',3',2':4,5][1,3]benzodioxino[7,6-g]isoquinoline-14,17(2H,9H)-dione	polycyclic xanthone; cancer
CARN 700; CARRAVEX	Phase I	Unspecified	polysaccharide cancer
CKD 606	Preclinical		polysaccharide cancer; liver disease
sizofiran; sizofilan; neoschizophylan; SONIFILAN; SONIFIRAN	Marketed	poly[3--(O-beta-D-glucopyranosyl-1--3)-O-[beta-D-glucopyranosyl-1--6]-O-beta-D-glucopyranosyl-1--3)-O-beta-D-glucopyranosyl-1]	polysaccharide; immunostimulant cancer; viral infection
CM 101; ZD 0101	Phase II	Unspecified	polysaccharide; immunostimulant; angiogenesis inhibitor cancer
AM 5	Discontinued		polysaccharide; radioprotectant cancer
LG 2527; LG 2716	Preclinical		progesterogen; hormone replacement therapy hormone deficiency; cancer

progesterone receptor therapy, Ligand/Wyeth Ayerst	Preclinical		progesterone; hormone replacement therapy	hormone deficiency; contraception; cancer
prolyl hydroxylase inhibitor, Cornell Research Foundation	Preclinical		prolyl hydroxylase inhibitor; angiogenesis inhibitor	retinopathy; cancer; skin disease; atherosclerosis
TEI 9826	Preclinical		prostaglandin	cancer
OC 3186	Preclinical	(5Z,13E,15S)-15-hydroxy-9-oxo-prosta-5,8(12),13-trien-1-oic acid (acetoxyloxy)methyl ester homopolymer	prostanoid	cancer
prostaglandin J2; PG J2	Preclinical		prostanoid	cancer; viral infection
YM 11	Preclinical	(5S,6S,7Z,12alpha,14Z)-5,6-bis(acetoxyloxy)-10-chloro-12-hydroxy-9-oxoprosta-7,10,14-trien-1-oic acid methyl ester	prostanoid	cancer
YM 3	Preclinical	(7E,12xi)-10-chloro-12-hydroxy-9-oxoprost-7,10-dien-1-oic acid methyl ester	prostanoid	cancer

cicaprost; cicaprost clathrate; ZK 114923; SH 574; SH 490	Discontinued	[3aS-[2E,3aalpha,4alpha(3R*,4R*)]-5beta,6alpha-antaggregant]-[2-[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1,6-nona diynyl)-2(1H)-pentalenylidene]ethoxy]acetic acid	prostanoid; vasodilator; platelet antiaggregant	thrombosis; peripheral vascular disease; cancer
bryostatin; bryostatin I; BMY 45618; NSC 339555	Phase II	bryostatin 1	protein kinase activator; protein kinase C activator	cancer
hexamethylene bisacetamide derivative; HMBA derivative	Preclinical		protein kinase activator; protein kinase C activator	cancer
Y 27632	Preclinical	[4(R)-trans]-4-(1-aminoethyl)-N-(4-pyridinyl)cyclohexane carboxamide	protein kinase inhibitor	hypertension; asthma; cancer
cancer therapy, Kinetix	Preclinical		protein kinase inhibitor; angiogenesis inhibitor	cancer
CP 564959	Preclinical		protein kinase inhibitor; angiogenesis inhibitor	cancer
H 87	Discontinued	N-[2-[3-(4-bromophenyl)-2-propenyl]ethylamino]-5-isoquinolinesulfonamide	protein kinase inhibitor; protein kinase A inhibitor; MDR inhibitor	cancer

BM 41400	Discontinued		protein kinase inhibitor; protein kinase C inhibitor	cancer
calphostin C; calphostin; UCN 1028; UCN 1028C	Discontinued	2-[12-[2-(benzoyloxy)propyl]-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl]-1-methylethyl 4-hydroxyphenyl carbonic acid ester	protein kinase inhibitor; protein kinase C inhibitor	cancer
diacylglycerol analogues, National Institutes of Health midostaurin; benzoylstaurosporine; N-benzoylstaurosporin; CGP 41251; CGP 41231	Preclinical		protein kinase inhibitor; protein kinase C inhibitor	cancer
NK 860276	Discontinued		protein kinase inhibitor; protein kinase C inhibitor	cancer

NSC 646958	Preclinical		protein kinase inhibitor; protein kinase C inhibitor	cancer
protein kinase C inhibitor, microalgal, Martek	Preclinical		protein kinase inhibitor; protein kinase C inhibitor	cancer; psoriasis
protein kinase C inhibitor, Xenova	Discontinued		protein kinase inhibitor; protein kinase C inhibitor	cancer
safingol; safingol hydrochloride; SPC 100270; mSPC 100271; KYNACAC; KYNACYTE SPC 100221	Phase II	(2S,3S)-2-amino-1,3-octadecanediol	protein kinase inhibitor; protein kinase C inhibitor	psoriasis; dermatitis; cancer
SPC 101591	Preclinical	[R-(R*,S*)]-2-amino-1,3-octadecanediol	protein kinase inhibitor; protein kinase C inhibitor	cancer
RK 1409B	Preclinical	[9S-(9alpha,10alpha,11beta)-9,13-epoxy-12,13-hexahydro-11-hydroxy-10-methoxy-1H,9H-diindolo[1,2,3- 4]pyrrolo[3,4-j][1',7]benzodiazepin-1-one	protein kinase inhibitor; protein kinase C inhibitor	cancer; ischemia; reperfusion injury

CGP 60474	Phase I	protein kinase inhibitor; protein kinase C inhibitor; cyclin dependent kinase inhibitor	cancer
MLR 52; (+)-MLR-52	Discontinued	[9S-(9alpha,10beta,11alpha,12alpha,13alpha)-2,3,10,11,12,13-hexahydro-11,12-dihydroxy-10-methoxy-9-methyl-9,13-epoxy-11H,9H-diindolo[1,2,3-gh;3',2',1'-im]pyrrolo[3,4-j][1,7]benzodiazepin-1-one	protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant
balanol; (-)-balanol; azepinostatin; ophiocordin	Preclinical	(3R-trans)-4-(2-carboxy-6-hydroxybenzoyl)-3,5-dihydroxybenzoic acid 1-[hexahydro-3-[(4-hydroxybenzoyl)amin o]-1H-azepin-4-yl] ester	protein kinase inhibitor; protein kinase C inhibitor; NSAID
SPC 100840	Preclinical		protein kinase inhibitor; protein kinase C inhibitor; NSAID

UCN 01; UCN 1; KW/Phase I 2401	(3alpha,9beta,10alpha,11 alpha,13beta)-(+)- 2,3,10,11,12,13- hexahydro-3- hydroxy-10-methoxy- 9-methyl-11- (methylamino)-9,13- epoxy-1H,9H- diindol[1,2,3- gh;3',2',1'- lm]pyrrolo[3,4- j][1,7]benzodiazepin- 1-one	protein kinase inhibitor; protein kinase C inhibitor; NSAID	cancer; inflammation; allergy
MDL 27032	Suspended	4-propyl-5-(4- pyridinyl)- 2(3H)oxazolone	protein kinase inhibitor; protein kinase C inhibitor; vasodilator
BE 233372M	Discontinued	(E)-5-(3,4- dihydroxyphenyl)-3- [(3,4- dihydroxyphenyl)met hylene]-2(3H)- furanone	protein kinase inhibitor; tyrosine kinase inhibitor
CGP 53716	Phase II	N-[4-nethyl-3-[(4-(3- pyridinyl)-2- pyrimidinyl)amino]phosphamido benzamido	protein kinase inhibitor; tyrosine kinase inhibitor
CGP 59326B	Preclinical		protein kinase inhibitor; tyrosine kinase inhibitor; EGF receptor inhibitor

KRN 5500	Phase I	4-deoxy-4-[[[(14-methyl-1-oxopentadecyl)amino]acetyl]amino]-N-1H-purin-6-yl-L-glycero-beta-L-manno-heptopyranosylamine	protein synthesis inhibitor	cancer
Pseudomonas exotoxin A linked to F(ab')2 fragment of MAb 1H10-PE; 1H10-PE	Preclinical		protein synthesis inhibitor	cancer
didemmin B; NSC 325319; IND 24505	Phase II	(S)-N-[1-(2-hydroxy-1-oxopropyl)-L-propyl]didemmin A	protein synthesis inhibitor; antifungal; peptide	cancer; bacterial infection; mycosis; viral infection
B 428	Preclinical	4-iodobenzo[b]thiophene-2-carboximidamide monohydrochloride	proteinase inhibitor	cancer
Bowman Birke inhibitor concentrate; BBIC	Phase II		proteinase inhibitor	benign prostate hypertrophy; cancer
KT 512	Preclinical		proteinase inhibitor	cancer
P 35011	Preclinical		proteinase inhibitor	cancer
urokinase inhibitor, 3 Dimensional Pharmaceuticals	Preclinical		proteinase inhibitor	cancer
urokinase inhibitors, Axys	Preclinical		proteinase inhibitor	cancer
urokinase inhibitors, Coryas	Preclinical		proteinase inhibitor	cancer

PS 341	Phase I	[S-(R*,S*)]-[3-methyl-1-[[1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid	proteinase inhibitor; apoptosis inducer	cancer
cathepsin B inhibitors, Arys AG 3433	Preclinical		proteinase inhibitor; cathepsin B inhibitor; protease inhibitor; matrix metalloproteinase inhibitor	cancer
CGS 27023A	Phase II	(R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl](3-pyridinylmethyl)aminol-3-methylbutanamide	proteinase inhibitor; matrix metalloproteinase inhibitor	cancer
CH 4815	Preclinical		proteinase inhibitor; matrix metalloproteinase inhibitor	cancer
metalloproteinase inhibitors, Glycomed	Preclinical		proteinase inhibitor; matrix metalloproteinase inhibitor	cancer
cysteine proteinase inhibitor, SynPhar/British Biotech	Preclinical		proteinase inhibitor; NSAID	rheumatoid arthritis; osteoporosis; cancer; osteoarthritis

peledesine; BCX 34; BCX 34B	Phase II	2-amino-1,5-dihydro-7-(3-pyridinylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one	purine nucleoside phosphorylase inhibitor; immunosuppressant; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection; eye disease; dermatitis; HIV infection
CH 799	Discontinued		purine nucleoside phosphorylase inhibitor; NSAID	rheumatoid arthritis; inflammatory bowel disease; cancer
CI 1000; PD 141955	Phase I	2-amino-1,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one	purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis
purine nucleoside phosphorylase inhibitors, Chiroscience; PNP inhibitors, Chiroscience	Discontinued		purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection
Helicobacter pylori therapy, RPMS Technology	Discontinued		quinoline; antibiotic	gastrointestinal ulcer; bacterial infection; cancer
A 84441	Preclinical	6-[3-[(2-amino-1-oxopenty)amino]-1-pyrrolidinyl]-5-fluoro-3-oxo-3H-pyrido[3,2,1-k]phenoxazine-2-carboxylic acid	quinolone; antibiotic	

KB 5246	Discontinued	6-fluoro-5-(4-methyl-1-piperazinyl)-8-oxo-3H,8H-4-oxa-1-thia-9b-azacyclopental[cd]phenalene-9-carboxylic acid monohydrochloride quinaldopeptin; BMY 28662; BU 3845T	quinolone; antibiotic quinomycin; antibiotic	cancer; pruritis; hypertension; HIV infection; gastrointestinal ulcer; hyperlipidemia; bacterial infection
WR 168643; NSC 333839	Preclinical	4,4'-trithiobis-1-butanesulfonic acid, disodium salt	radioprotectant	cancer
anticancer radiosensitizers; Telik AQ4N radiation enhancer; AQ4N	Preclinical	1,4-bis[[2-(dimethylloxidoamino)ethyl]amino]-5,8-dihydroxy-9,10-anthracenedione	radiosensitizer	cancer
broxuridine; BuDR; BROXINE; NEOMARK	Pre-registration		radiosensitizer	cancer; diagnosis
CT 2412 cuprinol; RL 5077; CURPRINYL	Preclinical	(2,2'-bipyridine-N,N')[propanedioato(2-O,O')copper	radiosensitizer	cancer
etanidazole; SR 2508; Phase III NSC 301467; RADINYL	Discontinued	N-(2-hydroxyethyl)-2-nitro-1H-imidazole-1-acetamide	radiosensitizer	cancer
KIN 804	Preclinical	N-methoxy-2-nitro-1H-imidazole-1-acetamide	radiosensitizer	cancer

KIN-831	Preclinical	N-hydroxy-2-nitro-1H-imidazole-1-propanamide	radiosensitizer	cancer
KU 2285	Preclinical	alpha, alpha-difluoro-N-(2-hydroxyethyl)-2-nitro-1H-imidazole-1-propanamide	radiosensitizer	cancer
metoclopramide; AHR 3070 C; DEL 1267; SENSAMIDE; NEU-SENSAMIDE; AEROFLAT; ANANDA; ANASIN; ANTIMET; BENAGASTRON; PRIMPERAN; DIGENOR; REGLAN	Marketed	4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide	radiosensitizer	emesis; cancer
MPI 5020	Phase II			
nimorazole	Discontinued	4-[2-(5-nitroimidazol-1-yl)-ethyl]morpholine	radiosensitizer	cancer
PD 130908	Preclinical	N-(2-bromoethyl)-2-nitro-1H-imidazole-1-propanamine monohydrobromide	radiosensitizer	cancer
radiosensitizer, NCI	Preclinical			
RK 28	Discontinued	4-[2-nitro-1H-imidazol-1-yl)methoxy]-2-buten-1-ol	radiosensitizer	cancer

RP 170	Preclinical	2-[(2-nitro-1H-imidazol-1-yl)methoxy]-1,3-propanediol	radiosensitizer	cancer
RSU 1164	Discontinued	cis-alpha-[(2,3-dimethyl-1-aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol	radiosensitizer	cancer
RSU 1165	Discontinued	trans-alpha-[(2,3-dimethyl-1-aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol	radiosensitizer	cancer
SN 24699	Preclinical	N-[2-(2-methyl-5-nitro-1H-imidazolyl)ethyl]-4-(2-nitro-1H-imidazolyl)butanamide	radiosensitizer	cancer
SPI 40	Preclinical			
SR 2545	Discontinued	N-[2-(acetoxyethyl)-2-nitro-1H-imidazole-1-acetamide	radiosensitizer	cancer
SR 2555; NSC 314-055	Discontinued	N,N-bis(2-hydroxyethyl)-2-nitro-1H-imidazole-1-acetamide	radiosensitizer	cancer
tirapazamine; WIN 59075; SR 4233; TIRAZONE	Phase III	3-amino-1,2,4-benzotriazine-1,4-dioxide	radiosensitizer	cancer

gadolinium texaphyrin; Gd Tex; PCI 0120; Gd-Tex; XCYTRIN	Phase III	(PB-7-11-233)2'4'-bis(acetato-O)[9,10-diethyl-20,21-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]4,15-dimethyl-8,11-imino-3,6:16,13-dinitriolo-1,18-benzodiazacycloeicosine-5,14-dipropanolato-N1,N18,N23,N24,N25]-gadolinium	radiosensitizer; chemosensitizer	cancer
lobenguane; lobenguane sulfate I123; MIBG; MIBG-I123	Marketed	[[3-(iodo-131I)phenyl]methyl]guanidine	radiosensitizer; contrast medium; radiodiagnostic; radiotherapeutic	cancer; diagnosis
PK 110	Preclinical	N-[4-(fluorophenyl)methyl]-imidazole-2-nitro-1H-imidazole-1-acetamide	radiosensitizer;	cancer
PK 130	Preclinical	N-[(2-nitro-1H-imidazol-1-yl)acetyl]-L-phenylalanine, methyl ester	radiosensitizer; imidazole	cancer
RB 6145; PD 144872; Phase I PD 144871; PD 130571; CI 1010	Phase I	alpha-[[2-(bromoethyl)amino]methyl]-2-nitro-1H-imidazole-1-ethanolmonohydrobromide	radiosensitizer; imidazole	cancer

nitric oxide-releasing radiosensitizer, National Institutes of Health	Preclinical		radiosensitizer; nitric oxide donor	cancer
cytochlor	Preclinical	5-chloro-2': deoxyxycytidine	radiosensitizer; nucleoside analogue	cancer
doramidazole; RP 343; Phase I PR 350	(R*,S*)-3-[(2-nitro- 1H-imidazol-1- yl)methoxy]-1,2,4- butanetriol	(R*,S*)-3-[(2-nitro- 1H-imidazol-1- yl)methoxy]-1,2,4- butanetriol	radiosensitizer; nucleoside analogue; antimetabolite	cancer
117m Sn DTPA; pentetate 117m Sn rhenium Re 186 etidronate; 186-Re HEDP; 186-Re BETAMET	Phase II		radiotherapeutic; analgesic	cancer; pain
strontium-89 chloride; METASTRON	Marketed	strontium chloride (89SrCl2)	radiotherapeutic; analgesic	pain; cancer
ALRT 1455	Preclinical		radiotherapeutic; analgesic	pain; cancer
AGN 192792; LG 100382	Preclinical		RAR agonist; retinoid agonist	cancer
CP 609754	Preclinical		RAR agonist; RXR agonist; retinoid; retinoid agonist	cancer
ras inhibitors, Agouron	Suspended		RAS inhibitor	cancer
Ras inhibitors, Bristol-Myers Squibb	Preclinical		RAS inhibitor	cancer
ras farnesyl transferase inhibitor, Xenova; XR 3005 series	Discontinued		RAS inhibitor; farnesyl protein transferase inhibitor	cancer

ras FT inhibitor, Genentech	Discontinued		RAS inhibitor; farnesyl protein transferase inhibitor	cancer
ras inhibitors, Onyx/Bayer	Preclinical		RAS inhibitor; signal transduction inhibitor	cancer
cancer therapy, retinoids, Cornell Research Foundation	Preclinical		retinoid	cancer; psoriasis
drug delivery system, Pre-liposome tretinoin; tretinoin liposome; AR 623; ATRAGEN	Pre-registration		retinoid	cancer
NIK 333	Preclinical			
polyprenoic acid; E 5166	Discontinued	(all-E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid	retinoid	cancer
RII retinamide	Marketed		retinoid	cancer
tazarotene; AGN 190168; ZORAC; TAZORAC	Marketed	6-[(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester	retinoid	acne; cancer; psoriasis
tretinoin; Ro 015488/115; NSC 122758; VESANOID	Marketed	(all-E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid	retinoid	acne; cancer

AM 580	Discontinued	4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]amino]benzoic acid	retinoid agonist	psoriasis; cancer
MX 33511; MX33511; MX 33501	Preclinical	6-(7-tricyclo[3.3.1.13,7]dec-1-yl-1,3-benzodioxol-5-yl)-2-naphthalenecarboxylic acid	retinoid agonist	cancer
tarimaterotene; AM 80	Discontinued	4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino]carbonyl]benzoic acid	retinoid agonist	psoriasis; cancer
LGD 1550; ALRT 1550; LG 100550; AGN 193101; LG 1550; ALRT 550	Phase II	(all-E)-7-[3,5-bis(1,1-dimethylethyl)phenyl]agonist	retinoid agonist; RAR	cancer; skin disease
AGN 190521; LG 030106	Preclinical	-3-methyl-2,4,6-octatrienoic acid.	retinoid agonist; retinoid	cancer; skin disease
ER 38925	Preclinical	5,6,7,8-tetrahydro-3,5,5,8,8-pentanethyl-2-naphthalenecarboxylic acid 4-carboxyphenyl ester	retinoid agonist; RARalpha agonist	cancer; psoriasis
		4-[5-(4,7-dimethyl-2-benzofuranyl)-1H-pyrrol-2-yl]benzoic acid		

ER 65250	Preclinical	4-[5-(7-ethyl-4-methyl-2-benzofuranyl)-1H-pyrrol-2-yl]benzoic acid	retinoid agonist; RARalpha agonist	cancer; psoriasis
ER 69029	Preclinical	4-[5-[7-fluoro-4-(trifluoromethyl)-2-benzofuranyl]-1H-pyrrol-2-yl]benzoic acid	retinoid agonist; RARalpha agonist	cancer; psoriasis
AGN 190121; LG 030042	Preclinical	(E)-4-[4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-1-ynyl]benzoic acid	retinoid agonist; RARbeta agonist; RARgamma agonist; retinoid	cancer; viral infection
AGN 191379; LG 030053	Preclinical	4-[(3,4-dihydro-2,2,4,4-tetramethyl-2H-1-benzopyran-6-yl)ethynyl]benzoic acid	retinoid agonist; RARbeta agonist; RARgamma agonist; retinoid	cancer; skin disease
bexarotene; LGD 1069; LG 100069; LG 1069; LDG 1069; TARGETIN	Phase III	4-[1-(3,5,5,8-pentamethyl-5,6,7,8-tetrahydro-2-naphtheny)-1-ethyl]benzoic acid	retinoid agonist; retinoid; differentiation inducer; RXR agonist	cancer; diabetes; psoriasis; skin disease
LGD 1324; ALRT 324	Preclinical		retinoid agonist; RXR agonist	diabetes; cancer
AGN 4310; ALRT 4310	Preclinical		retinoid antagonist	psoriasis; cancer
TAC 101; AM 555s	Phase I	4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid	retinoid antagonist	cancer

fenretinide; HPR, 4; 4HPR; RAHA; McN R1967	Phase III	N-(4- hydroxyphenyl)retina imide	retinoid; NSAID	rheumatoid arthritis; cancer
apurinic acid	Preclinical		reverse transcriptase inhibitor	HIV infection; cancer
P 30 protein; P 30; ONCONASE	Phase III	ribonuclease (Rana pipiens reduced)	ribonuclease	cancer
LY 309887	Phase I	(R)-N-[[5-[2-(2- amino-1,4,5,6,7,8- hexahydro-4- oxopyrido[2,3- d]pyrimidin-6- y)ethyl]-2- thienyl]carbonyl]-L- glutamic acid	ribonucleotide formyltransferase inhibitor; antifolate; antimetabolite	cancer
amidox; VF 236	Preclinical	N,3,4- trihydroxybenzenecar boximidamide	ribonucleotide reductase inhibitor	cancer
didox; VF 147; NSC 324360	Phase II	N,3,4- trihydroxybenzamide	ribonucleotide reductase inhibitor	cancer; HIV infection
OCX 189; OCX 0189	Discontinued		ribonucleotide reductase inhibitor	cancer
OCX 191; OCX 0191; 3AP; TRIAPINE	Phase I	2-[(3-amino-4- methyl-2- pyridinyl)methylene] hydrazinecarbothioam ide	ribonucleotide reductase inhibitor	cancer
OCX 191 prodrugs, Vion tridox	Preclinical		ribonucleotide reductase inhibitor	cancer
			ribonucleotide reductase inhibitor	HIV infection; cancer

KW 2331 FMdC; MDL 101731; Phase II	(E)-2'-fluoromethylene-2'-deoxycytidine (FMdc)	ribonucleotide reductase inhibitor; nucleoside analogue	cancer
parabacitin LGD 1268; ALRT 268	Preclinical	ribonucleotide reductase inhibitor; polyamine analogue RXR agonist; retinoid agonist	cancer
ALRT 620; AGN 192620; LG 100268	Preclinical	6-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)cycloropyl]-3-pyridinecarboxylic acid	RXR agonist; retinoid; retinoid agonist
CGP 35753	Discontinued	2-[[3-(aminoiminomethyl)p phenyl]methylene]-N-hydroxyhydrazinecarboximamide	S adenosylmethionine decarboxylase inhibitor
CGP 39937	Discontinued	[2,2-bipyridine]-6,6'-dicarboximidamide	S adenosylmethionine decarboxylase inhibitor
sardomozide; CGP 48664; SAM 486	Phase II	2-[4-(aminoiminomethyl)-2,3-dihydro-1H-inden-1-ylidene]hydrazinecarboximamide	S adenosylmethionine decarboxylase inhibitor
cancer therapy, Cortecs	Preclinical		signal transduction inhibitor

GW 7072	Preclinical		signal transduction inhibitor	cancer
signal transduction inhibitor, National Academy of Science	Preclinical		signal transduction inhibitor	cancer
signal transduction inhibitors, NCI	Preclinical		signal transduction inhibitor	cancer
signal transduction inhibitor, SUGEN/ArQuile	Preclinical		signal transduction inhibitor; immunosuppressant	cancer; diabetes; neurological; autoimmune disease
BIBX 1382	Phase II		signal transduction inhibitor; tyrosine kinase inhibitor; EGF receptor inhibitor	cancer
Ianreotide; BIM 23014; DC 13116; BIM 23014C; BN 52030; SOMATULINE; ANGIOPEPTIN; DERMOPEPTIN; IPSITYL	Marketed	3-(2-naphthalenyl)-D-somatostatin analogue	alanyl-L-cysteinyl-L-tyrosyl-D-triptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2,7)-disulfide	cancer; acromegaly; retinopathy; diabetes; psoriasis; restenosis
TT 232; TT 2-32	Preclinical	D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-triptophyl-L-lysyl-L-cysteinyl-L-threoninamide cyclic (2->6)-disulfide	somatostatin analogue	cancer

TT 250; TT 2-50	Preclinical	D-Phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-leucyl-L-cysteinyl-L-threonimamide cyclic (2->7)-disulfide	somatostatin analogue	cancer
octreotide; octreotide acetate; SMS; SMS 201995; SMS 201995ac; SMS 995; SANDOSTATIN; SANDOSTATINE; SANDOSTATINA; LONGASTATINA; SAMILSTATINA	Marketed	[R-(R*,R*)]-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2-7)-disulfide	somatostatin analogue; analgesic	Alzheimer disease; cancer; viral infection; psoriasis; diarrhea; diabetes; pain; acromegaly
vapreotide; octastatin; Phase II RC 160; BMY 41606	Preclinical	D-Phe-Cys-Trp-D-Trp-Lys-Val-Cys-Trp-NH2	somatostatin analogue; cancer; pain analgesic	
stem cell inhibitor	Preclinical		stem cell division inhibitor; hematopoiesis inhibitor; hematoprotector; chemoprotectant	cancer
BAY 129566	Phase III	(S)-4'-chloro-gamma-oxo-alpha-[(phenylthio)methyl][1,1'-biphenyl]-4-butanoic acid	stromelysin inhibitor; proteinase inhibitor; matrix metalloproteinase inhibitor; NSAID	osteoarthritis; cancer

stromelysin inhibitors, Agouron	Preclinical	stromelysin inhibitor; proteinase inhibitor; matrix metalloproteinase inhibitor; arthritis
antagonist G; PTL 68300B	Phase I	Arg-DTrp-NMePhe-DTrp-Leu-Met-NH2 substance P antagonist; peptide; growth factor modulator
DW 2282	Preclinical	sulfonylurea; antineoplaston
LaneBase	Preclinical	target based screening
screening technology, Cellomics cancer	Preclinical	target based screening
screening technology, Discontinued granulocyte colony-stimulating factor mimetic	Preclinical	target based screening
screening technology, Preclinical human papillomavirus therapy, Harvard Medical School	Preclinical	target based screening
screening technology, Preclinical NuMA	Preclinical	target based screening
screening technology, Discontinued thrombopoietin mimetic	Preclinical	target based screening
screening technology, Preclinical cox-2 gene suppression	Preclinical	target based screening; biotechnology

screening technology, Preclinical	Preclinical		target based screening; MDR inhibitor	drug design technology; cancer
MDR inhibitors	Preclinical	[2aR- (2aalpha,4beta,4abeta, 6beta,9alpha,10beta,1 1alpha,12alpha,12aa1 pha,12balpha)]-12b- (acetoxy)-12- (benzoyloxy)- 1,2a,3,4,4a,6,9,10,11, 12,12a,12b- dodecahydro- 4,6,9,10,11- pentahydroxy- 4a,8,13,13- tetramethyl]-7,11- methano,5H- cyclodeca[3,4]benz[1, 2-bloket-5-one	taxane	cancer
baccatin III derivatives, Indena	Preclinical	[2aR- (2aalpha,4beta,4abeta, 6beta,9alpha,10beta,1 1alpha,12alpha,12aa1 pha,12balpha)]-12b- (acetoxy)-12- (benzoyloxy)- 1,2a,3,4,4a,6,9,10,11, 12,12a,12b- dodecahydro- 4,6,9,10,11- pentahydroxy- 4a,8,13,13- tetramethyl]-7,11- methano,5H- cyclodeca[3,4]benz[1, 2-bloket-5-one	taxane	cancer
BMS 184476	Phase I		taxane	

BP 179	Preclinical	[2aR-[2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12alpha,12beta]-[partial]-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-4-[(2,3-dihydroxypropoxy)carbonyloxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester	taxane cancer
--------	-------------	--	------------------

dihydrotaxol, 9-; 9-dihydrotaxol; TAXAN	Preclinical	[2aR-[2aalpha,4beta,9alpha, 5alpha,6beta,9alpha(a lphaR*,betaS*),11alpha ha,12alpha,12alpha, 12beta]]-beta- benzoylamino)-alpha- hydroxy- benzenepropanoic acid, 6,12b- bis(acetyl oxy)-12- (benzoyloxy)-12- 2a,3,4,4a,5,6,9,10,11, 12,12a,12b- dodecahydro-4,5,11- trihydroxy- 4a,8,13,13- tetramethyl-7,11- methano-1H- cyclodeca[3,4]benz[1, 2-b]oxet-9-yl ester drug delivery system, LDS microemulsion paclitaxel; paclitaxel LDS microemulsion	taxane	cancer
drug delivery system, liposome paclitaxel; paclitaxel liposome	Phase I	taxane	cancer	
IDN 5109; SB T101131	Preclinical	taxane	cancer	
paclitaxel analogues, Virginia Tech RPR 109881	Preclinical Phase I	taxane	cancer	

TAXOPREXIN IDX 258 bromotaxol	Phase II Marketed	Phase I Preclinical	taxane taxane taxane; microtubule assembly promoter	cancer cancer cancer
docetaxel; RP 56976; NSC 628503; TAXOTERE			<p>beta-[(1,1-dimethyllethoxy)carboamino]-alpha-hydroxybenzenepropanoic acid [2aR-[2aalpha,4beta,4abeta,6beta,9alpha(alphaR*)-betaS*]-11alpha,12alpha,12aa[12alpha,12beta]-12b-(acetoxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-do d-ecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]olet-9-yl ester</p>	cancer; malaria
drug delivery system, biodegradable polymer paste paclitaxel; paclitaxel biodegradable polymer paste	Preclinical		taxane; microtubule assembly promoter	cancer

drug delivery system, CYTOPORTER paclitaxel	Preclinical		taxane; microtubule assembly promoter	cancer
drug delivery system, intralosomal paclitaxel; paclitaxel anhydrous delivery vehicle; ADV paclitaxel; MPI 5018	Preclinical		taxane; microtubule assembly promoter	cancer
drug delivery system, liposome paclitaxel; paclitaxel liposome	Discontinued		taxane; microtubule assembly promoter	cancer
drug delivery system, liposome paclitaxel; paclitaxel liposome	Preclinical		taxane; microtubule assembly promoter	cancer
drug delivery system, Discontinued ONCHOLAB paclitaxel; paclitaxel ONCHOLAB	Preclinical		taxane; microtubule assembly promoter	cancer
drug delivery system, polyglutamic acid paclitaxel; paclitaxel polyglutamic acid; PG-TXL	Preclinical		taxane; microtubule assembly promoter	cancer
drug delivery system, polymer-bound paclitaxel; paclitaxel polymer-bound; PNU 166945	Phase I		taxane; microtubule assembly promoter	cancer
drug delivery system, polymeric micelle paclitaxel; paclitaxel polymeric micelle	Preclinical		taxane; microtubule assembly promoter	cancer

drug delivery system, PROCYTE microsphere paclitaxel; paclitaxel PROCYTE	Preclinical		taxane; microtubule assembly promoter	cancer
drug delivery system, ReGel paclitaxel; GENEXOL	Preclinical		taxane; microtubule assembly promoter	cancer
drug delivery system, vascular stent paclitaxel; paclitaxel vascular stent	Preclinical		taxane; microtubule assembly promoter	restenosis; cancer
paclitaxel; NSC 125973; BMS 181339; TAXOL; ANZATAK; YEWTAXAN	Marketed	[2aR][2aalpha,4beta,4abeta,6beta,9alpha[al phaR*,betaS*],11beta,12alpha,12aalpha,12balpha]]-beta-(benzoylamino)-alpha-hydroxybenzenpropanoic acid 6,12b-bis(acetoxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester	taxane; microtubule assembly promoter	cancer

paclitaxel analogue, Reading University	Preclinical		taxane; microtubule assembly promoter	cancer
paclitaxel derivatives, Preclinical EnzyMed			taxane; microtubule assembly promoter	cancer
polyethylene glycol paclitaxel; PEG- paclitaxel; paclitaxel macrogol	Preclinical		taxane; microtubule assembly promoter	cancer
ZYN-LINKER conjugated paclitaxel drug delivery system, Preclinical anticancer agents	Suspended		taxane; microtubule assembly promoter	restenosis; cancer
telomerase inhibitor, Telik	Preclinical		taxane; microtubule assembly promoter;	cancer
telomerase inhibitors, Preclinical Geron			DNA topoisomerase inhibitor	
telomerase inhibitors, Preclinical University of Texas			telomerase inhibitor	cancer
telomerase inhibitors, Preclinical Whitehead Institute for Biomedical Research			telomerase inhibitor	cancer
cancer therapy, Viscount Pharma	Preclinical		telomerase inhibitor; nucleoside analogue	cancer
acylfulvene, MGI Pharma/Dainippon	Phase I		terpene	cancer
betulinic acid; betulinic acid	Preclinical	(3. β .)-3-hydroxy- lup-20(29)-en-28-oic acid	terpene	cancer
caulerpenyne	Suspended		terpene	cancer

monoterpenes, Endorex	Preclinical		terpene	cancer
TGF beta antagonists, GLYCODesign; transforming growth factor beta antagonists	Preclinical		TGF beta antagonist; cicatrizant	cancer; viral infection; skin ulcer
thrombospondin inhibitor, Allelix	Discontinued		thrombospondin inhibitor; peptide; NSAID	inflammation; cancer; sickle cell anemia
CV 6504	Preclinical	2,3,5-trimethyl-6-(3-pyridinylmethyl)-2,5-cyclohexadiene-1,4-dione	thromboxane antagonist; 5 lipoxygenase inhibitor	cancer
ICI D8322; ZD 8322	Discontinued		thymidylate synthase inhibitor	cancer
ralitrexed; paltitrexed; ZD 1694; ICI D1694; TOMUDEX	Marketed	N-[[5-[(1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]-2-methylamino]-2-thienyl]carbonyl]-L-glutamic acid	thymidylate synthase inhibitor; antifolate; antimetabolite	cancer
AG 250	Discontinued		thymidylate synthase inhibitor; antimetabolite	cancer
AG 341	Discontinued		thymidylate synthase inhibitor; antimetabolite	cancer
AG 394	Discontinued		thymidylate synthase inhibitor; antimetabolite	cancer

BW 1843U89	Suspended	(S)-2-((1,2-Dihydro-3-methyl-1-oxobenzof[f]quimazolin-9-yl)methyl)amino)-1-oxo-2-isoindolinyl)glutamic Acid	thymidylate synthase inhibitor; antimetabolite	cancer
FTC 092	Discontinued	alpha, alpha, alpha-trifluoro-3'-O-(phenylmethyl)thymidine	thymidylate synthase inhibitor; antimetabolite	cancer
metesind; AG 331	Suspended	4-[(4-[(2-aminobenz[cd]indol-6-yl)methyl]amino)methyl]phenylsulfonyl]morpholine	thymidylate synthase inhibitor; antimetabolite	cancer
nolatrexed; no latrexed dihydrochloride; AG 337; THYMITAQ pemtrexed; pemtrexed disodium; LY 231514; MTA	Discontinued	2-amino-6-methyl-5-(4-pyridinylthio)-4(1H)-quinazolinone	thymidylate synthase inhibitor; antimetabolite	cancer

ZD 9331	Phase II	(2S)-[4-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(2-propynyl)amino]2-fluorobenzamido]4-(1H-tetrazol-5-yl)butyricacid	thymidylate synthase inhibitor; antimetabolite	cancer
titanocene dichloride buddotitane	Phase II Discontinued	CpTiCl ₂ diethoxybis(1-phenyl-titanium complex; 1,3-butanedionato-O,O')-titanium	titanium complex; alkylating agent	cancer cancer
CC 1080	Preclinical		TNF inhibitor; NSAID	arthritis; cancer; multiple sclerosis
thalidomide; BMS 205935	Phase II	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; angiogenesis inhibitor	retinopathy; cancer
thalidomide; SYNOVIR; THALOMID	Marketed	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	cachexia; diarrhea; leprosy; rheumatoid arthritis; transplant rejection; cancer; Crohn disease
CC 1069	Preclinical	beta-(3,4-dimethoxyphenyl)-1,3-dihydro-1,3-dioxo-2H-isoindole-2-propanamide	TNF modulator; NSAID	cachexia; arthritis; cancer
FRK inhibitor, Signal; fos regulating Kinase inhibitor, Signal	Discontinued		transcription factor regulator; MAP kinase inhibitor	cancer; hypothyroidism; Paget disease; periodontal disease
NF-kappaB inhibitor, Signal	Preclinical		transcription factor regulator; NSAID	inflammation; ischemia; cancer; autoimmune disease

AP-1 inhibitor, Signal; JNK inhibitor, Signal	Preclinical		transcription factor regulator; NSAID; immunosuppressant	inflammation; autoimmune disease; cancer
SC 104	Discontinued		triglyceride	cancer
halichondrin B	Preclinical	halichondrin B	tubulin polymerase inhibitor	cancer
NSC 654261	Preclinical		tubulin polymerase inhibitor	cancer
spongistatin 1 analogues, Hughes Institute	Preclinical		tubulin polymerase inhibitor	cancer
combratstatin analogue	Preclinical	3,4,5-trimethoxy-N-(4-methylphenyl)benzenemethanamine	tubulin polymerase inhibitor; microtubule assembly inhibitor	cancer
DDE 261	Preclinical		tubulin polymerase inhibitor; microtubule assembly inhibitor	cancer
dolastatin 10; NSC 376128	Phase I	N,N-dimethyl-L-valyl-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide	tubulin polymerase inhibitor; peptide	cancer

ALL-TK antagonists; Suspended acute lymphoblastic leukemia tyrosine kinase antagonists angelmanin B	Discontinued		tyrosine kinase inhibitor	cancer
BCR/ABL antagonists	Discontinued		tyrosine kinase inhibitor	cancer
CEP 2563; KT 8391	Phase I		tyrosine kinase inhibitor	cancer
CEP 701; KR 5555	Phase I		tyrosine kinase inhibitor	cancer
CEP 751; KT 6587	Suspended		tyrosine kinase inhibitor	cancer
CGP 52411	Discontinued	5,6- bis(phenylamino)-1H-inhibitor isoindole-1,3(2H)- dione	tyrosine kinase inhibitor	cancer
CGP 53353	Discontinued	5,6-bis[(4- fluorophenyl)amino]- 1H-isindole- 1,3(2H)-dione	tyrosine kinase inhibitor	cancer
CGP 57148; CGP 57148B	Phase I	4-[(4-methyl-1- piperazinyl)methyl]- N-[4-methyl-3-[[4-(3- pyridinyl)-2- pyrimidinyl]amino]ph eny]-1-benzamide	tyrosine kinase inhibitor	cancer
FGF-1 receptor inhibitors, Parke Davis/Auckland University	Preclinical		tyrosine kinase inhibitor	cancer

GW 282974; GW 974	Preclinical	N6,N6-dimethyl-N4-[1-(phenylmethyl)-1H-indazol-5-yl]pyrido[3,4-d]pyrimidine-4,6-diamine monohydrochloride	tyrosine kinase inhibitor	cancer
LFM-A13	Preclinical		tyrosine kinase inhibitor	cancer
Met tyrosine kinase antagonist	Preclinical		tyrosine kinase inhibitor	cancer
PD 157655	Preclinical		tyrosine kinase inhibitor	cancer
PD 158294	Preclinical		tyrosine kinase inhibitor	cancer
PD 158780	Preclinical	N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine	tyrosine kinase inhibitor	cancer
PD 164199	Preclinical	6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer; atherosclerosis; restenosis
PD 164771	Preclinical	6-(2,6-dichlorophenyl)-8-methyl-2-(4-pyridinylamino)pyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer; atherosclerosis; restenosis

PD 166285	Preclinical	6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer; atherosclerosis; restenosis
PD 167978	Preclinical		tyrosine kinase inhibitor	cancer
PD 173956	Preclinical		tyrosine kinase inhibitor	cancer
SU 101	Phase III	5-methyl-1-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	tyrosine kinase inhibitor	cancer
SU 101 analogues	Preclinical		tyrosine kinase inhibitor	cancer
SU 102	Preclinical		tyrosine kinase inhibitor	cancer
SU 65847	Preclinical		tyrosine kinase inhibitor	cancer
tyrosine kinase inhibitors, Cephalon	Discontinued		tyrosine kinase inhibitor	benign prostate hypertrophy; cancer
tyrosine kinase inhibitors, Novartis	Preclinical		tyrosine kinase inhibitor	cancer
tyrosine kinase inhibitors, Xenova	Discontinued		tyrosine kinase inhibitor	cancer
ZD 4190	Preclinical		tyrosine kinase inhibitor	cancer

SU 1433	Discontinued	4-(6,7-dimethyl-2-quinoxaliny)-1,2-benzenediol	tyrosine kinase inhibitor; angiogenesis inhibitor; signal transduction inhibitor	cancer; retinopathy
SU 1498	Discontinued	(E)-2-cyano-3-[4-hydroxy-3,5-bis(1-methylethyl)phenyl]-N-(3-phenylpropyl)-2-propenamide	tyrosine kinase inhibitor; angiogenesis inhibitor; signal transduction inhibitor	cancer; retinopathy
CGP 59326A	Phase I	N-(3-chlorophenyl)-5,6-dimethyl-1H-pyrrrol[2,3-d]pyrimidin-4-amine monohydrochloride	tyrosine kinase inhibitor; EGF receptor inhibitor	cancer
CP 358774	Phase II	N-(3-ethylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine	tyrosine kinase inhibitor; EGF receptor inhibitor	cancer
PD 153035	Preclinical	N-(3-bromophenyl)-6,7-dimethoxy-4-quinazolinamine	tyrosine kinase inhibitor; EGF receptor inhibitor	cancer
PD 183805; CI 1033	Preclinical		tyrosine kinase inhibitor; EGF receptor inhibitor	cancer
ZD 1839	Phase I		tyrosine kinase inhibitor; EGF receptor inhibitor	cancer
tyrosine kinase inhibitors, AstraZeneca	Discontinued		tyrosine kinase inhibitor; signal transduction inhibitor	cancer
WHI P131	Preclinical		tyrosine kinase inhibitor; signal transduction inhibitor	cancer

WHI P154	Preclinical	tyrosine kinase inhibitor; signal transduction inhibitor	cancer
DAB 720	Preclinical	tyrosine kinase inhibitor; signal transduction inhibitor	cancer
PD 169540	Preclinical	tyrosine kinase inhibitor; signal transduction inhibitor; EGF receptor inhibitor	
BML0V	Discontinued	bis(maltolato) oxovanadium	tyrosine phosphatase inhibitor
cancer-associated protein tyrosine phosphatase inhibitor, Ontogen	Discontinued		tyrosine phosphatase inhibitor
AG 213; RG 50964; typhostin AG 213; RG 50864 (no stereo)	Phase I	(E)-2-cyano-3-(3,4-dihydroxyphenyl)-2-propenethioamide	typhostin
AG 555	Preclinical	(2E)-2-cyano-3-(3,4-dihydroxyphenyl)-N-(3-phenylpropyl)-2-propenamide	typhostin
typhostins	Preclinical		typhostin
AG 490	Discontinued	(E)-2-Cyano-3-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-2-propenamide	typhostin; tyrosine kinase inhibitor

UBC inhibitors, Mitotix; ubiquitin conjugating enzyme inhibitors	Preclinical		ubiquitin conjugating enzyme inhibitor; NSAID	cancer; inflammation
urate oxidase; SR 29142	Phase III		urate oxidase; biotechnology; enzyme	gout; cancer
eptaloprost; eptaprost; Discontinued ZK 97959	3aS-	[2E,3a α ,4 α](3R*,4R*)5 β ,6 α]-4-(2-hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1,6-nona diynyl-2(1H)-pentalenylidene)ethoxybutanedioic acid	vasodilator; prostanoid	thrombosis; peripheral vascular disease; cancer
SR 49059	Phase II	[2R-[2 α (S*),3 β]]-1-[[5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide	vasopressin antagonist; diuretic	gynecological; cancer; hypertension; heart failure; emesis
VRCTC 310 anhydrovinblastine	Preclinical	Unspecified	venom	cancer
	Phase I	3',4'-didehydro-4'-deoxyvincaleukoblastine	vinca alkaloid	cancer

drug delivery system, liposome vincristine; vincristine liposome; VincaXome	Preclinical	vinca alkaloid	cancer
drug delivery system, ONCHOLAB vincristine; vincristine ONCHOLAB	Discontinued	vinca alkaloid	cancer
drug delivery system, STEALTH liposome vincristine; vincristine STEALTH	Preclinical	vinca alkaloid	cancer
drug delivery system, vinblastine; vinblastine Therapeutic Implant; MPI 5017	Discontinued	vinca alkaloid	cancer
drug delivery system, vincristine; vincristine drug delivery system; Onco TCS	Phase II	vinca alkaloid	cancer
vinflunine; F 12158; L 0070	Phase I	4'-deoxy-20',20'-difluoro-C"-norvincaleukoblastine	cancer
vinorelbine; vinorelbine tartrate; PM 259; DC 1; KW 2307; BW 7Y89; KW 3407; NAVELBINE; EUNADES; NABELBIN	Marketed	3',4'-didehydro-4' deoxy-C"-norvincaleukoblastine	cancer

vinxaltine; S 12363	Phase I	[3(S)]-O4-deacetyl-3-de(methoxycarbonyl)-microtubule assembly inhibitor	vinca alkaloid; cancer
		3-[[1-(diethoxyphosphinyl)-2-methylpropyl]amino]carbonyl]vincalukoblastine	
superactive vasoactive intestinal peptide antagonist; NCI	Preclinical		VIP antagonist
LR 103	Preclinical		
alpha-hydroxyvitamin D2; 1alpha-D2; one-alpha D2; TSA 870; HECTOROL	Pre-registration		vitamin D analogue
CB 1267	Discontinued	[1R-[1alpha(R**),3abeta,4E(1R*,3S*,5Z),7aalpha]-4-methylene-5-[[octahydro-7a-methyl-1-[1-methyl-2-[[5,5,5-trifluoro-4-hydroxy-4-(trifluoromethyl)-2-pentynyl]oxy]ethyl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol	vitamin D3 analogue

ILX 23- Preclinical	1,25(OH)2-16ene- 23yne-26,27 hexafluorovitamin D3	vitamin D3 analogue	cancer
EB 1089 Phase II	1(S),3(R)-dihydroxy- 20(R)-(5'-ethyl-5- hydroxy-hepta- 1'(E),3'(E)-dien-1'- yl)-9,10-secopregna- 5(Z),7(E),10(19)- triene	vitamin D3 analogue	cancer
J 1901 Phase I	(1R,3S,5Z)-4- methylene-5-[(2E)- [(1R,3aS,7aR)- octahydro-1- [(1R,5E)-7-hydroxy- 1,7-dimethyl-5- octenyl]-7a-methyl- 4H-inden-4- ylidene]ethylidene]- 1,3-cyclohexanediol	vitamin D3 analogue; differentiation inducer	cancer; psoriasis

vinxaltine; S 12363	Phase I	[3(S)]-O4-deacetyl-3-[de(methoxycarbonyl)-microtubule assembly inhibitor 3-[[[1-(diethoxyphosphinyl)-2-methylpropyl]amino]carbonyl]vincalukoblastine	vinca alkaloid; cancer
superactive vasoactive intestinal peptide antagonist, NCI	Preclinical	VIP antagonist	cancer
LR 103	Preclinical	vitamin D analogue	cancer
alpha-hydroxyvitamin D2; 1alpha-D2; one-alpha D2; TSA 870; HECTOROL	Pre-registration	vitamin D2 analogue	osteoporosis; hyperparathyroidism; cancer
CB 1267	Discontinued	vitamin D3 analogue [1R-[1alpha(R*),3abeta,4E(1R*,3S*,5Z),7aalpha]-4-methylene-5-[[octahydro-7a-methyl-1-[1-methyl-2-[5,5,5-trifluoro-4-hydroxy-4-(trifluoromethyl)-2-pentyoxy]ethoxy]ethyl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol	cancer

ILX 237553; ILX 23-7553	Preclinical	1,25(OH)2-16ene-23yne-26,27 hexafluorovitamin D3	vitamin D3 analogue	cancer
seocalcitol; EB 1089	Phase II	1(S),3(R)-dihydroxy-20(R)-(5'-ethyl-5'-hydroxy-hepta-1'(E),3'(E)-dien-1'-yl)-9,10-secopregn-5(Z),7(E),10(19)-triene	vitamin D3 analogue	cancer
solverol; PRJ 1901	Phase I	(1R,3S,5Z)-4-methylene-5-[(2E)-[(1R,3aS,7aR)-octahydro-1-[(1R,5E)-7-hydroxy-1,7-dimethyl-5-octenyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol	vitamin D3 analogue; differentiation inducer	cancer; psoriasis

Table 25. Current Candidate Therapeutic Interventions for the Treatment of ALS

Product Name	Chemical Name	Action	Indication
EF 7412	N-3-[4-[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]-1-piperazinyl]phenyl]ethanesulfonamide	5HT antagonist; 5HT1A antagonist; glutamate release inhibitor	Neurodegeneration; depression; cancer
AMPA antagonists	Unspecified	AMPA antagonist; glutamate antagonist	Neurodegeneration; eye disease
SPD 502; NS 1209	2-[[[5-[4-[(dimethylamino)sulfonyl]phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy]-4-hydroxybutanoic acid monosodium salt	AMPA antagonist; glutamate antagonist	stroke; neurodegeneration
pirfenidone; MAR 01; AMR 69; DESKAR	5-methyl-1-phenyl-2(1H)-pyridinone	antifibrotic	skin disease; pulmonary fibrosis; neurodegeneration
dehydroascorbic acid	Unspecified	antioxidant	neurodegeneration; neurological
U 101033E	6,7,8,9-tetrahydro-9-[2-(4-morpholinyl)ethyl]-2,4-di-1-pyrrolidinyl-5H-pyrimido[4,5-b]indole dihydrochloride	antioxidant	stroke; neurodegeneration; brain ischemia
MDL 101002	3,4-dihydro-3,3-dimethylisoquinoline 2-oxide	antioxidant; free radical scavenger	stroke; neurodegeneration; septic shock
synthetic catalytic scavenger analogues; SCS analogues	Unspecified	antioxidant; free radical scavenger	stroke; trauma; atherosclerosis; neurodegeneration; asthma
neurodegenerative disease therapy	Unspecified	apoptosis inhibitor	neurodegeneration

neurodegeneration therapy	unspecified	apoptosis inhibitor	neurodegeneration; amyotrophic lateral sclerosis
apoptosis modulators	Unspecified	apoptosis inhibitor; apoptosis inducer	cancer; autoimmune disease; neurodegeneration
apoptosis inhibitors	Unspecified	apoptosis inhibitor; peptide	neurodegeneration
BAY Z 4406	Unspecified	calcium channel blocker	neurodegeneration; Alzheimer disease
cardiotrophin-1 secreting implant	Unspecified	Cardiotrophin-1 agonist	amyotrophic lateral sclerosis; neurodegeneration
caspase inhibitors	Unspecified	caspase inhibitor	neurodegeneration; myocardial infarction; rheumatoid arthritis; septic shock
CPP32 inhibitors, caspase 3 inhibitors,	unspecified	caspase inhibitor; apoptosis inhibitor	neurodegeneration
creb gene transcription modulators, CNS disorders	Unspecified	Creb gene transcription modulation	neurodegeneration; Alzheimer disease
Neurotransmitter transporter modulators	Unspecified	Excitatory amino acids transporter function	neurodegeneration
batyl alcohol; CPR 4001	Unspecified	free radical scavenger; ether lipid	skin disease; neurodegeneration
chimyl alcohol; CPR 4004	Unspecified	free radical scavenger; ether lipid	skin disease; neurodegeneration
free radical scavengers	Unspecified	free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
SLH 301	Unspecified	free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
growth and differentiation factor-1; GDF-1	Unspecified	GDF-1 agonist	neurodegeneration
LY 379268	(1R,4R,5S,6R)-4-amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid	glutamate agonist; mGluR agonist; analgesic	neurodegeneration; pain

Excitatory amino acid antagonists	unspecified	glutamate antagonist; excitatory amino acid antagonist; NMDA antagonist	epilepsy; neurodegeneration
SIB 1757	Unspecified	glutamate antagonist; mGluR antagonist; analgesic	pain; neurological; neurodegeneration
SIB 1893	Unspecified	glutamate antagonist; mGluR antagonist; analgesic	pain; neurological; neurodegeneration
2-PMPA; GPI 5000	Unspecified	glutamate release inhibitor	stroke; neurodegeneration
NZ 093	Unspecified	IGF-1	brain ischemia; trauma; stroke; neurodegeneration
insulin-like growth factor-1; IGF-1	Unspecified	IGF-1 agonist	brain ischemia; trauma; stroke; neurodegeneration
insulin-like growth factor binding protein ligand inhibitors	Unspecified	IGFBP ligand inhibitors	stroke; neurodegeneration
ICE inhibitors	Unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor	neurodegeneration
Neurodegenerative disease therapy	Unspecified	Immunomodulation, peptide mediated	neurodegeneration
MKK4 modulators	Unspecified	MAP kinase inhibitor; signal transduction inhibitor, NSAID	inflammation; neurodegeneration
Melatonin analogue	Unspecified	Melatonin agonist	neurodegeneration
Neurodegenerative disease therapy	Unspecified	monoclonal antibody; immunomodulation	neurodegeneration; Alzheimer disease
neural progenitor regulatory factor	Unspecified	Neural progenitor regulation, growth factor; peptide; neurotrophic factor	multiple sclerosis; trauma; neurodegeneration
Neuroimmunophilin ligands	Unspecified	Neuroimmunophilins, growth factor; neurotrophic factor	neurodegeneration
Neuroimmunophilins	Unspecified	neurotrophic factor	neurodegeneration
nerve growth factor secreting implant	Unspecified	NGF agonist	neurodegeneration; neuropathy
nerve growth factor mimetics	Unspecified	NGF mimetics	neurodegeneration

CP 101606	[S-(R*,R*)]-4-hydroxy-alpha-(4-hydroxyphenyl)-beta-methyl-4-phenyl-1-piperidineethanol	NMDA antagonist; glutamate antagonist	stroke; trauma; neurodegeneration
Remacemide; FPL 12924; PR 934423; FPL 12924AA; PR 934423A; FPL 14144; PR 1032644; FPL 14145, PR 1032646	(+,-)-2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide	NMDA antagonist; glutamate antagonist	epilepsy; Parkinson disease; neurodegeneration
Telomerase activators	Unspecified	NSAID	neurodegeneration; atherosclerosis; arthritis
Neurotropin-4/5 secreting implant; NT-4/5 implant	Unspecified	NT-4/5 agonist	neurodegeneration; neuropathy; amyotrophic lateral sclerosis; eye disease
Synthetic opioid alkaloids	Unspecified	Opioid agonists	neurodegeneration
prion inhibiting peptides	Unspecified	Prion inhibition	neurodegeneration
taltirelin; TA 0910; CEREDIST	(S)-N-[(hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-L-prolinamide	Protirelin analogue	neurodegeneration
telomere modulators	Unspecified	Telomere modulation	neurodegeneration; atherosclerosis; arthritis
NZ 097	Unspecified	TGF- β agonist	brain ischemia; trauma; stroke; neurodegeneration
Transforming growth factor beta; TGFbeta	Unspecified	TGF- β agonist	brain ischemia; trauma; stroke; neurodegeneration
CEP 3265; CB 1093	5-[[1-(2-ethoxy-6-ethyl-6-hydroxy-1-methyl-3-octynyl)octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-1,3-cyclohexanediol	transcription activator	neurodegeneration; Alzheimer disease

Table 26. Current Candidate Therapeutic Interventions for the Treatment of Anxiety

Product Name	Chemical Name	Action	Indication
CGS 12066	4-(4-methyl-1-piperazinyl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline	5HT agonist	anxiety
umespirone; KC 7218; KC 9172	3-butyl-7-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-9,9-dimethyl-3,7-diazabicyclo[3.3.1]nonane-2,4,6,8-tetrone	5HT agonist	anxiety
CP 110330	N,N-dimethyl-5-[4-[(phenylamino)methyl]-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
CP 119333	N,N-dimethyl-5-[4-(phenylmethyl)-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
alnespirone; S 20499	(+)-8-[4-[(3,4-dihydro-5-methoxy-2H-1-benzopyran-3-yl)propylamino]butyl]-8-azaspiro[4.5]decane-7,9-dione	5HT agonist; 5HT1A agonist	anxiety
EMD 67478		5HT agonist; 5HT1A agonist	anxiety
F 12439		5HT agonist; 5HT1A agonist	depression; anxiety
flesinoxan; DU 29373	(+)-N-[2-[4-[2,3-dihydro-2-(hydroxymethyl)-1,4-benzodioxin-5-yl]-1-piperazinyl]ethyl]-4-fluorobenzamide	5HT agonist; 5HT1A agonist	anxiety; depression
gepirone; gepirone hydrochloride; MJ 13805; BMY 13805; BMY 138051	4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione	5HT agonist; 5HT1A agonist	anxiety; depression

ipsapirone; BAY q 7821; TVX q 7821	2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide	SHT agonist; 5HT1A agonist	depression; anxiety
lesopitron; E 4424	2-[4-[4-(4-chloro-1H-pyrazol-1-yl)butyl]-1-piperazinyl]pyrimidine dihydrochloride	SHT agonist; 5HT1A agonist	anxiety
LY 228729	4-(dipropylamino)-1,3,4,5-tetrahydrobenz[cd]indole-6-carboxamide	SHT agonist; 5HT1A agonist	anxiety; depression
MKC 242	(S)-N-[3-(1,3-benzodioxol-5-yloxy)propyl]-2,3-dihydro-1,4-benzodioxin-2-methanamine, hydrochloride	SHT agonist; 5HT1A agonist	anxiety
S 14506	4-fluoro-N-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]benzamide hydrochloride	SHT agonist; 5HT1A agonist	anxiety
S 14671	N-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-2-thiophenecarboxamide	SHT agonist; 5HT1A agonist	anxiety; depression
SUN 8399	2,3,4,5-tetrahydro-4-(4-(4-(2-pyrimidinyl)piperazinyl)butyl)-1,4-benzoxazepine-3,5-dione hydrochloride	SHT agonist; 5HT1A agonist	anxiety; emesis
Tandospirone; metanopirone; SM 3997; SEDIEL	3alpha,4beta,7beta,7aaalpha-hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4,7-methano-1H-isoindole-1,3(2H)-dione	SHT agonist; 5HT1A agonist	anxiety
U 92016A		SHT agonist; 5HT1A agonist	anxiety; depression

U 93385; U 93385E	(3aR-cis)-2,3,3a,4,5,9b-hexahydro-3-propyl-1H-benz[e]indole-9-carboxamide	SHT agonist; 5HT1A agonist	anxiety; depression
SL 870765		SHT agonist; 5HT1A agonist; 5HT antagonist; 5HT1D antagonist	anxiety; depression
adatanserin; adatanserin hydrochloride; WY 50324; WAY SEB 324; SEB 324	N-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1(3,7)]decaantagonist; 5HT2ne-1-carboxamide	SHT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
FG 5865	2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide monohydrochloride	SHT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
FG 5893; FG 5974	(2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester)	SHT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
S 213571; S 21357-1	3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-6-[4-[4-(2-methoxyphenyl)-1-piperazinyl]-butyl]-2(3H)-benzothiazolone trihydrochloride	SHT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety
sunepitron; CP 93393; CP 93393-1	(7S-trans)-1-[[octahydro-2-(2-pyrimidinyl)-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-2,5-pyrrolidinedione	SHT agonist; 5HT1A agonist; alpha adrenergic antagonist; alpha2 adrenergic agonist	depression; anxiety
SB 236057		SHT agonist; 5HT1B agonist	anxiety
LY 293284	(R)-1-[4-(dipropylamino)-1,3,4,5-tetrahydrobenz[cd]indol-6-yl]ethanone	SHT agonist; 5HT1D agonist	anxiety

ICI 190622	4-amino-1-(3-pentynyl)-N-2-propenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide	5HT antagonism	anxiety
SHT1B antagonists		5HT antagonist	depression; anxiety
EMY 7378	8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride	5HT antagonist	anxiety
DU 123015		5HT antagonist	anxiety; depression
DU 125530		5HT antagonist	depression; anxiety; psychosis
ICI 170809	N,N,2-trimethyl-1-[(3-phenyl-2-quinoliny)thio]-2-propanamine monohydrochloride	5HT antagonist	anxiety
RS 42358; RS 42358197	(S)-2-(1-azabicyclo[2.2.2]oct-3-yl)-2,4,5,6-tetrahydro-1H-benz[de]isoquinolin-1-one monohydrochloride	5HT antagonist	anxiety; emesis
seganserin; R 56413	3-[2-[4-[bis(4-fluorophenyl)methylene]-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one	5HT antagonist	anxiety
serazapine; CGS 15040A	1,3,4,16b-tetrahydro-2-methyl-2H,10H-indolo[2,1-c]pyrazino[1,2-a][1,4]benzodiazepine-16-carboxylic acid methyl ester	5HT antagonist	anxiety

5-HT antagonist; pindobind	2-bromo-N-[4-[1-[[2-hydroxy-3-(1H-indol-4-yloxy)propyl]amino]-1-methylethyl]-1-methylcyclohexyl]acetamide	5HT antagonist; SHT1A antagonist	anxiety; depression
Anxiolytic	(S)-5,6,6a,7-tetrahydro-6,10-dimethyl-4H-dibenzo[de,g]quinolin-11-ol	5HT antagonist; SHT1A antagonist	anxiety
Binospirone; binospirone mesylate; MDL 73005EF	8-[2-[(2,3-dihydro-1,4-benzodioxan-2-yl)methyl]amino]ethyl-8-azaspiro[4.5]decan-7,9-dione	5HT antagonist; SHT1A antagonist	anxiety
F 8910RS		5HT antagonist; SHT1A antagonist	anxiety
Robalzotan; NAD 299	(3R)-3-(dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide (2R,3R)-2,3-dihydroxybutanedioate (1:1)	5HT antagonist; SHT1A antagonist	anxiety; depression
S 15535	1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)piperazine	5HT antagonist; SHT1A antagonist	anxiety; depression
SDZ 216525; SDZ 216-525	methyl 4-[4-(1,1,3-trioxo-2H-1,2-benzisothiazol-2-yl)butyl]-1-piperazinyl]-1H-indole-2-carboxylate	5HT antagonist; SHT1A antagonist	anxiety
UH 301	(+,-)-7-(dipropylamino)-4-fluoro-5,6,7,8-tetrahydro-1-naphthalenol	5HT antagonist; SHT1A antagonist	anxiety

WAY 100135	N-(1,1-dimethylethyl)-4-(2-methoxyphenyl)-alpha-phenyl-1-piperazinepropanamide	SHT antagonist; SHT1A antagonist	anxiety
WAY 100635	N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexane carboxamide trihydrochloride	SHT antagonist; SHT1A antagonist	anxiety
Buspirone hydrochloride; MJ 40221; MJ 9022; BESPAR; BUSPAR; NORMATON; TUTRAN; NAROL; ANSIENON; ANSITEN; TRANBUS; SIMPLESS	8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4,5]decane-7,9-dione hydrochloride	SHT antagonist; SHT1A antagonist; dopamine agonist	anxiety; depression; dermatitis
drug delivery system, transdermal buspirone; buspirone transdermal		SHT antagonist; SHT1A antagonist; dopamine agonist	anxiety; depression; attention deficit disorder
CR 1909		SHT antagonist; SHT2 antagonist	anxiety
Glemanserin; MDL 11939	(+,-)-alpha-phenyl-1-(2-phenylethyl)-4-piperidinemethanol	SHT antagonist; SHT2 antagonist	anxiety
ritanserin; R 55667	6-[2-[4-[bis(4-fluorophenyl)methylene]piperidino]ethyl]-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one	SHT antagonist; SHT2 antagonist	addiction; anxiety; schizophrenia
CGS 18102	trans-10-methoxy-4-propyl-1,3,4,4a,5,10b-hexahydro-2H-(1)benzopyrano(3,4-b)pyridine	SHT antagonist; SHT2 antagonist; SHT agonist; SHT1A agonist	anxiety

HT 90B	(-)-N-[2-[[[2,3-dihydro-8-methyl-1,4-benzodioxin-2-yl)methyl]amino]ethyl]tricyclo[3.3.1.13,7]decane-1-carboxamide	SHT antagonist; SHT2 antagonist; SHT agonist; 5HT1A agonist	anxiety; depression
Amesergide; amerserzide; LY 237733	8beta-N-cyclohexyl-6-methyl-1-(1-methylethyl)ergoline-8-carboxamide	SHT antagonist; SHT2 antagonist; SHT1C antagonist	sexual dysfunction; depression; anxiety
Deramciclane; EGIS 3886; EGYT 3886	(1R-exo)-N,N-dimethyl-2-[(1,7,7-trimethyl-2-phenylbicyclo[2.2.1]hept-2-yl)oxy]-ethanamine	SHT antagonist; SHT2 antagonist; SHT1C antagonist	anxiety
Ziprasidone; ziprasidone hydrochloride; CP 88059; CP 880591; CP 8805901; ZELDOX	5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one	SHT antagonist; SHT2 antagonist; SHT1C antagonist; dopamine antagonist; dopamine D2 antagonist; 5HT1A agonist; SHT agonist	schizophrenia; anxiety
EGIS 8465		SHT antagonist; SHT2C antagonist	anxiety
ORG 37415		SHT antagonist; SHT2C antagonist	depression; anxiety
SB 200646A	N-(1-methyl-1H-indol-5-yl)-N'-(3-pyridinyl)urea monohydrochloride	SHT antagonist; SHT2C antagonist	anxiety
SB 228357	N-[3-fluoro-5-(3-pyridinyl)phenyl]-2,3-dihydro-5-methoxy-6-(trifluoromethyl)-1H-indole-1-carboxamide	SHT antagonist; SHT2C antagonist	anxiety; depression
ADR 851	(S)-4-amino-5-chloro-2,3-dihydro-N-(2-pyrrolidinylmethyl)-7-benzofurancarboxamide monohydrochloride	SHT antagonist; SHT3 antagonist	anxiety; emesis

Antidepressant		SHT antagonist; SHT3 antagonist	depression; anxiety
itasetron; DAU 6215; DAU 6215CL; DA 6215; U 98079; U 98079A	endo-2,3-dihydro-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2-oxo-1H-benzimidazole-1-carboxamide	SHT antagonist; SHT3 antagonist	emesis; anxiety
ricasetron; BRL 46470; BRL 46470A	endo-2,3-dihydro-3,3-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indole-1-carboxamide	SHT antagonist; SHT3 antagonist	anxiety; schizophrenia; emesis
tropisetron; ICS 205930; NAVOBAN	1H-indole-3-carboxylic acid endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester	SHT antagonist; SHT3 antagonist	emesis; anxiety
VA 21B7	2-[(4-piperonyl)-1-piperazinyl]-3-indolecarboxaldehyde	SHT antagonist; SHT3 antagonist	anxiety
WAY 100289; WY 100289	(endo)-N-[(8-aza-8-methylbicyclo[3.2.1]octan-3-yl)amino]carbonyl]-2-(cyclopropylmethoxy)benzamide	SHT antagonist; SHT3 antagonist	anxiety
WAY 100579; SEC 579	endo-1-cyclohexyl-1,4-dihydro-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-4-oxo-3-quinolinecarboxamide (Z)-2-butenedioate	SHT antagonist; SHT3 antagonist	anxiety
zacopride; zacopride hydrochloride; ZAP; AHR 11190B; AHR 11190; MD 78027	4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy-benzamide	SHT antagonist; SHT3 antagonist	anxiety; emesis

zatosetron; LY 277359	endo-5-chloro-2,3-dihydro-2,2-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-7-benzofurancarboxamide	5HT antagonist; 5HT3 antagonist	emesis; anxiety
SB 204070	8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-carboxylic acid (1-butyl-4-piperidinyl)methyl ester	5HT antagonist; 5HT4 antagonist	anxiety; irritable bowel syndrome
SC 56184		5HT antagonist; 5HT4 antagonist	anxiety
THE JL3; JL 3	10-(4-methyl-1-piperazinyl)-pyrido[4,3-b][1,4]benzothiazepine	5HT antagonist; dopamine antagonist	anxiety; depression
fluvoxamine; fluvoxamine maleate; DU 23000; MK 264; SME 3110; FEVARIN; FLOXYFRAL; LUVOX; DUMYROX; DUMIROX; FLAVOXYL; FAVERIN; DEPROMEL	5-methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone (E)-O-(2-aminoethyl)oxime	5HT reuptake inhibitor	depression; anxiety; obsessive compulsive disorder
paroxetine hydrochloride; FR 7051; BRL 29060; BRL 29060A; SI 211103; SEROXAT; AROPAX; PAXIL; TAGONIS; FROSINOR; DEROXAT; SEREUPIN; MOTIVAN	(3S-trans)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine	5HT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety

sertraline; CP 51974; CP 519741; CP 5197401; LUSTRAL; ZOLOFT; ALTRULINE; TATIG; GLADEM	(1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthaleneamine	5HT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety; sexual dysfunction; obesity
venlafaxine; WY 45030; EFFEXOR; EFEXOR; EFFEXOR XR; EFFEXOR XL	(+,-)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol	5HT reuptake inhibitor; noradrenalin reuptake inhibitor; dopamine reuptake inhibitor	depression; anxiety
ST 1112	2-acetyl-5-(4-methoxyphenyl)-3-oxo-1,2,4-triazine	5HT1/5HT2 ligand	anxiety
L 0068; F 11440	4-methyl-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2,4-triazine-3,5(2H,4H)-dione	SHT1A agonist; 5HT agonist	anxiety; depression
OPC 14523	1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4-dihydro-5-methoxy-2(1H)-quinolinone	SHT1A agonist; sigma agonist; 5HT agonist	depression; anxiety; obsessive compulsive disorder
F 92502CN	Unspecified	5HT1A ligand	anxiety
EGIS 9933	2-(2-[N-(3-trifluoromethyl-benzyl)-N-piperazinyl]ethyl)mercapto-4,6-diamino-5-(2-methoxy-benzyl)-pyrimidine hydrochloride	SHT2C antagonist; SHT antagonist	anxiety
SB 243213	2,3-dihydro-5-methyl-N-[(6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-6-(trifluoromethyl)-1H-indole-1-carboxamide	SHT2C antagonist; SHT antagonist	depression; anxiety

zalospirone; WY 47846	(3aalpha,4beta,4aalpha,6aalpha,7beta,7aalpha)-3a,4,4a,6a,7,7a-hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4,7-etheno-1H-cyclobut[f]isoindole-1,3(2H)-dione	5HT3 antagonist	anxiety; depression
ceronapril; ceranapril; SQ 29852	(S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phospinyloxy]-1-oxohexyl]-L-proline	ACE inhibitor	cognitive defect; hypertension; anxiety
drug delivery system, adenosine; adenosine drug delivery system; adenosine prodrug	adenosine 5'-(1,4-dihydrotrigonellinate)-2',3'-O-bis-benzoate	adenosine agonist	anxiety; depression
atipamezole; MPV 1248; ANTISEDAN	4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist	sexual dysfunction; alcoholism; depression; hypotension; diabetes; anxiety
SNAP 5114	1-[2-[tris(4-methoxyphenyl)methoxy]ethyl]-3-piperidinecarboxylic acid	amine uptake inhibitor	epilepsy; anxiety; insomnia
gabapentin; CI 945; GO 3450; GOE 2450; NEURONTIN	1-(aminomethyl)cyclohexaneacetic acid	analgesic	epilepsy; anxiety; pain; neuropathy; psychosis; depression
losartan; losartan potassium; DUP 753; MK 954; DUP 89; E 3340; AVASTAR; COZAAR; LOORTAN; NULOTAN	2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol	angiotensin II antagonist	hypertension; anxiety; stroke; heart failure; myocardial infarction
AIT 084		antispasmodic	anxiety
alpidem; SL 80034200; ANANXYL	6-chloro-2-(4-chlorophenyl)-N,N-dipropylimidazo[1,2-a]pyridine-3-acetamide (imidazopyridine)	Anxiolytic activity with unspecified mechanism of action	anxiety

Anxiolytic	Ketoisoxalidine derivative	Anxiolytic activity with unspecified mechanism of action	anxiety
AP 521	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
BMS 181100	alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine-butanol	Anxiolytic activity with unspecified mechanism of action	anxiety
BMS 184111	Unspecified	Anxiolytic activity with unspecified mechanism of action	Anxiety
CEB 1128	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CEB 1342	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CEB 1459	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CGS 13767	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CL 870704	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CNS 3	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
Co 2-6749; Co 26749	Synthetic epalons	Anxiolytic activity with unspecified mechanism of action	anxiety
transmucosal etomidate	Etomidate derivative	Anxiolytic activity with unspecified mechanism of action	anxiety
transdermal buspirone;	Buspirone	Anxiolytic activity with unspecified mechanism of action	anxiety
duloxafone; dicozafone; F 1933	2-[bis(2-hydroxyethyl)amino]-N-[4-chloro-2-(chlorobenzoyl)phenyl]-N-methylacetamide	Anxiolytic activity with unspecified mechanism of action	anxiety

enciprazine; D 13112; WY 48624	(+,-)-4-(2-methoxyphenyl)-alpha-[(3,4,5-trimethoxyphenoxy)methyl]-1-piperazineethanol	Anxiolytic activity with unspecified mechanism of action	anxiety
etizolam; Y 7131; DEPAS; PASADEN	4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	Anxiolytic activity with unspecified mechanism of action	anxiety
F 2692	3-amino-6-methyl-1-[3-(trifluoromethyl)phenyl]-4(1H)-pyridazinone	Anxiolytic activity with unspecified mechanism of action	anxiety
mexidol	2-ethyl-6-methyl-3-hydroxypyridine succinate	Anxiolytic activity with unspecified mechanism of action	anxiety; cognitive defect
rilapine	(Z)-2-chloro-10-(4-methyl-1-piperazinyl)-5H-dibenzo[a,d]cycloheptene-delta5,alfa-acetonitrile	Anxiolytic activity with unspecified mechanism of action	anxiety
SC 48274; BTG 1501	3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-2,6-piperidinedione hydrochloride	Anxiolytic activity with unspecified mechanism of action	anxiety
sul托pride; sul托pride hydrochloride; LIN 1418; DAN 2163; BARNETIL	N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide	Anxiolytic activity with unspecified mechanism of action	anxiety
suricline; RP 31264; RP 006; SURIL	4-methyl-1-piperazinecarboxylic acid ester with 6-(7-chloro-1,8-naphthyridin-2-yl)-2,3,6,7-tetrahydro-7-oxy-5H-1,4-dithiino[2,3-c]pyrrol-5-yl	Anxiolytic activity with unspecified mechanism of action	anxiety

TAS 401	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
NNC 138119	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine	Benzodiazepine	epilepsy; anxiety
AD 8152		benzodiazepine	anxiety
adiazolam; adiazolam mesylate; adiazolam mesilate; U 41123F; U 41123; DERACYN	8-chloro-N,N-dimethyl-6-phenyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine-1-methanamine	benzodiazepine	anxiety; depression
AHR 14749	5-chloro-N,N-dimethyl-2-(4-methylphenyl)-3H-imidazo[4,5-b]pyridine-3-acetamide	benzodiazepine	anxiety
CGS 20625	5,6,7,8,9,10-hexahydro-2-(4-methoxyphenyl)-cyclohepta[b]pyrazolo[3,4-d]pyridin-3(2H)-one	benzodiazepine	anxiety
clobazam; HR 376; H 4723; LM 2717; NH 15; FRISIUM; CLIDIZAN; GRIFOCLOBAM; URBADAM; FRISIN; URBANYL; URBANIL; MYSTAN	7-chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4-(3H,5H)-dione	benzodiazepine	anxiety; epilepsy
drug delivery system, intranasal benzodiazepines; benzodiazepine intranasal delivery system		benzodiazepine	anxiety; insomnia

drug delivery system, transdermal alprazolam; alprazolam transdermal		benzodiazepine	anxiety
drug delivery system, transdermal alprazolam; alprazolam transdermal		benzodiazepine	anxiety
EGIS 5278	3-amino-4-ethylthio- 7-chloro-quinolone hydrochloride	benzodiazepine	anxiety
EGIS 8858	5-[2-(4- fluorophenyl)ethenyl] -8-methyl-9H-1,3- dioxolo[4,5- h][2,3]benzodiazepin e	benzodiazepine	anxiety
girisopam; EGIS 5810; GYKI 51189	1-(m-chlorophenyl)- 7,8-dimethoxy-4- methyl-5H-2,3- benzodiazepine	benzodiazepine	anxiety
midazolam; Ro 213981/001; Ro 213981/003; HYPNOVEL; VERSED; DORMICUM	8-chloro-6-(2- fluorophenyl)-1- methyl-4H- imidazo[1,5- a][1,4]benzodiazepine	benzodiazepine	anxiety; epilepsy
nerisopam; EGIS 6775; GYKI 52232	4-(7,8-dimethoxy-4- methyl-5H-2,3- benzodiazepin-1-yl)- benzenamine	benzodiazepine	anxiety
panadiplon; U 78875; FG 10571	3-(5-cyclopropyl- 1,2,4-oxadiazol-3-yl)- 5-(1-methylethyl)- imidazo[1,5a]- quinoxalin-4(5H)-one	benzodiazepine	anxiety
RU 32759	[6-ethyl-5-methyl-7- (methylthio)imidazo[1,2-a]pyrimidin-2- y]phenylmethanone	benzodiazepine	anxiety

tofisopam; EGYT 341; MER 19; MER 1961; GRANDAXIN; SERIEL; ISOTAN	1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine	benzodiazepine	anxiety; skin disease
abecarnil; ZK 112119; FG 7516; NNC 157516; SH 524; LADOTEC	4-(methoxymethyl)-6-(phenylmethoxy)-9H-pyrido[3,4-b]indole-3-carboxylic acid, 1-methylethyl ester	benzodiazepine partial agonist	anxiety
FG 8119	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-methyl-6H-imidazo[1,5-a][1,4]benzodiazepin-6-one	benzodiazepine partial agonist	anxiety
FG 8205; L 663581	7-chloro-4,5-dihydro-5-methyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-6H-imidazo[1,5-a][1,4]benzodiazepin-6-one	benzodiazepine partial agonist	epilepsy; anxiety
ICI D7569		benzodiazepine partial agonist	anxiety
imidazenil; FGIN 2073; FID 02023; Ro 231412	6-(2-bromophenyl)-8-fluoro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxamide	benzodiazepine partial agonist	anxiety
Ro 198022	(R)-1-((10-chloro-4-oxo-3-phenyl-4H-benzo(a)quinolizin-1-yl)carbonyl)-2-pyrrolidine-methanol	benzodiazepine partial agonist	anxiety
saripidem; SL 850274	N-[[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]methyl]-N-methylbutyramide	benzodiazepine partial agonist	anxiety

Y 23684	2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one 7-oxide	benzodiazepine partial agonist	anxiety
SHT4 human neuroreceptor; neuroreceptor, 5HT4		biotechnology	irritable bowel syndrome; cognitive defect; anxiety; arrhythmia; stroke; urinary incontinence; migraine; research tool
Cholecystokinin B antagonist		cholecystokinin antagonist; cholecystokinin B antagonist	schizophrenia; anxiety
CR 2622	[R-(R*,S*)]-4-[[5-(8-azaspiro[4.5]dec-8-yl)-4-[(3,5-dichlorobenzoyl)amino]-1,5-dioxopentyl]amino]-5-(1-naphthalenylamino)-5-oxo-pentanoic acid	cholecystokinin antagonist; cholecystokinin B antagonist	anxiety
GV 150013	(R)-N-phenyl-N'-[2,3,4,5-tetrahydro-2,4-dioxo-1-phenyl-5-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-1H-1,5-benzodiazepin-3-yl]urea	cholecystokinin antagonist; cholecystokinin B antagonist	anxiety
LY 288513		cholecystokinin antagonist; cholecystokinin B antagonist	schizophrenia; anxiety
CR 2345	N-[1-(8-azaspiro[4.5]dec-8-ylcarbonyl)-4-(4-methyl-1-piperazinyl)-4-oxobutyl]-3,5-dichlorobenzamide monohydrochloride	cholecystokinin antagonist; cholecystokinin B antagonist; gastrin antagonist	anxiety; gastrointestinal ulcer; bacterial infection

CR 2945		cholecystokinin antagonist; cholecystokinin B antagonist; gastrin antagonist	gastrointestinal ulcer; anxiety
L 740093	(R)-N-[5-(3-azabicyclo[3.2.2]nona-3-yl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)urea monohydrochloride	cholecystokinin B antagonist; cholecystokinin antagonist	anxiety
PD 134308; CI 988	[R-(R*,R*)]-4-[[2-[[3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[(tricyclo[3.3.1.1sup.3,7]dec-2-yl)oxy]carbonyl]amino]propyl]amino]-1-phenylethyl]amino]-4-oxobutanoic acid compound with 1-deoxy-1-(methylamino)-D-glucitol (1:1)	cholecystokinin B antagonist; cholecystokinin antagonist	anxiety
PD 135158	[1S-[1alfa,2beta[S*(S*)],4alfa]]-4-[[2-[[3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)oxy]carbonyl]amino]propyl]amino]-1-phenylethyl]amino]-4-oxobutanoic acid cmpd with meglumine (1:1)	cholecystokinin B antagonist; cholecystokinin antagonist	anxiety

PD 145942	[2-[(hexahydro-1H-azepin-1-yl)amino]-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxoethyl]carbamic acid tricyclo[3.3.1.13,7]dec-2-yl ester	cholecystokinin B antagonist; cholecystokinin antagonist	anxiety
AXC 2219		CRF antagonist	depression; anxiety
AXC 4007		CRF antagonist	depression; anxiety
CRA 1000	INDEX NAME NOT YET ASSIGNED	CRF antagonist	depression; anxiety
CRA 1001		CRF antagonist	depression; anxiety
CRF antagonist		CRF antagonist	depression; anxiety
CRF antagonists		CRF antagonist	depression; anxiety
CRF2 antagonists		CRF antagonist	depression; anxiety
NBI 27914	5-chloro-N-(cyclopropylmethyl)-2-methyl-N-propyl-N'-(2,4,6-trichlorophenyl)-4,6-pyrimidinediamine	CRF antagonist	anxiety
NBI 30545	3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propylpyrazolo[1,5-a]pyrimidin-7-amine	CRF antagonist	anxiety; depression
NBI 30775; R 121919		CRF antagonist	anxiety; depression; addiction
NGD 981; NGD 98-1		CRF antagonist	depression; anxiety
PD 171729	butyl-[3[(2,4-dichloro-phenyl)-2,5-dimethyl-pyrazolo(1,5-a)pyrimidin-7-yl]-ethyl-amine	CRF antagonist	anxiety; depression
corticotropin releasing factor analogue	Unspecified	CRF ligand	anxiety; depression

DMP 695	N-(2-chloro-4,6-dimethylphenyl)-1-[2-methoxy-1-(methoxymethyl)ethyl]-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine monomethanesulfonate	CRH antagonist	anxiety; depression
SA 627	N-(2-bromo-4,6-dimethoxyphenyl)-N-ethyl-4-methyl-6-(4-morpholinyl)-1,3,5-triazin-2-amine	CRH antagonist	depression; anxiety
SC 241		CRH antagonist	anxiety; depression
RP 60503	4-(acetylamino)butanoic acid 2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl ester	Cyclic GMP modulation	anxiety
CCD 2034		GABA agonist	anxiety
GABA agonist, XR 368 series	(2aR*,5aR,7E,11E,14aS*,14bS*,14cS*)-2a,5a,6,9,10,13,14,14a,14b,14c-decahydro-4-hydroxy-5a,9,9,12-tetramethyl-1,5-dioxacyclopenta[cd]cycloundec[f]inden-3(2H)-one	GABA agonist	anxiety; epilepsy
RWJ 38293	1,2,3,5-tetrahydro-3-oxo-N-4-pyridinylpyrido[1,2-a]benzimidazole-4-carboxamide	GABA agonist	anxiety
U 91571	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-dimethylimidazo[1,5-a]quinoxaline-5(4H)-carboxamide	GABA antagonist	anxiety
U 94625		GABA antagonist	anxiety

ocinaplon; CL 273547	2-pyridinyl[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	GABA modulation	anxiety
pazinaclone; DN 2327; A 77000	8-[[2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl]acetyl]-1,4-dioxa-8-azaspiro[4.5]decane	GABA modulation	anxiety
Anxiolytics		GABA modulator	anxiety
AWD 131138; AWD 131-138	1-(4-chlorophenyl)-1,5-dihydro-4-(4-morpholinyl)-2H-imidazol-2-one	GABA modulator	epilepsy; anxiety
NGD 911; CP 409092		GABA modulator	anxiety
NGD 912; NGD 91-2		GABA modulator	anxiety
NGD 913; NGD 91-3		GABA modulator	anxiety
NS 2552		GABA modulator	anxiety; epilepsy
NS 2608		GABA modulator	epilepsy; anxiety
NS 2710; ME 3127		GABA modulator	anxiety
pagoclone; IP 456; RP 62955; (+)-RP 59037	(+)-2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl-2-oxohexyl)-1H-isoindol-1-one	GABA modulator	anxiety
RWJ 53050		GABA partial agonist	anxiety
U 101017; PNU 101017	cis-7-chloro-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]imidazo[1,5-a]quinoline-3-carboxylic acid 1,1-dimethylethyl ester	GABA partial agonist	anxiety
RP 59037	2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl-2-oxohexyl)-1H-isoindol-1-one	GABA partial agonist; benzodiazepine partial agonist	anxiety
SNAP 5258	Unspecified	GAT1 transporter	epilepsy; anxiety; insomnia
SNAP 5294	Unspecified	GAT2 transporter	epilepsy; anxiety; insomnia

ACPC; cycloleucine; cycloleucin; NSC 1026; WR 14997	1-amino-1-cyclopentanecarboxylic acid	glutamate antagonist; NMDA antagonist	coronary artery disease; anxiety; depression; stroke; epilepsy; addiction
HA 966	3-amino-1-hydroxy-2-pyrrolidone	glutamate antagonist; NMDA antagonist	anxiety
LY 354740	(1alpha,2beta,5alpha,6alpha)-2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid	glutamate release inhibitor	anxiety; nicotine withdrawal
hBGT1 transporter modulator	Unspecified	HBGT1 transporter modulator	epilepsy; anxiety; insomnia
GT 5140		histamine agonist; histamine H3 agonist	insomnia; anxiety
Methylhistamine, R-alpha; BP 2.94		histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
SCH 49648	(2S-trans)-4-(2-methyl-3-pyrrolidinyl)-1H-imidazole	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
SCH 50971	(3R-trans)-4-(4-methyl-3-pyrrolidinyl)-1H-imidazole	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
CNS disorder modifiers	Unspecified	Ion channel modification	anxiety; schizophrenia; depression
Befloxitone; MD 370503	(R)-5-(methoxymethyl)-3-(p-((R)-4,4,4-trifluoro-3-hydroxybutoxy)phenyl)-2-oxazolidinone	MAO A inhibitor; MAO inhibitor	depression; anxiety; nicotine withdrawal
BW 1370U87	1-ethylphenoxythiin 10,10-dioxide	MAO A inhibitor; MAO inhibitor	depression; anxiety
Co 6-0549; Co 60549		neuroactive steroid	anxiety
MEN 10376		neurokinin antagonist; bronchodilator; neurokinin 2 antagonist	asthma; anxiety
CGP 60829		neurokinin antagonist; neurokinin 1 antagonist	anxiety

GR 100679	N-(cyclohexylcarbonyl)glycyl-L-alanyl-D-tryptophyl-N,N-dimethyl-L-phenylalaninamide	neurokinin antagonist; neurokinin 2 antagonist	anxiety
MEN 10207		neurokinin antagonist; neurokinin 2 antagonist	anxiety
osanetant; SR 142801	(R)-N-[1-[3-[1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl]propyl-4-phenyl-4-piperidinyl]-N-methylacetamide monohydrochloride	neurokinin antagonist; neurokinin 3 antagonist	schizophrenia; anxiety
Neuropeptide Y antagonists		neuropeptide Y antagonist; analgesic	obesity; cardiovascular disease; anxiety; pain
MDL 105519	(E)-3-(2-carboxy-2-phenylethethyl)-4,6-dichloro-1H-indole-2-carboxylic acid	NMDA antagonist; glutamate antagonist	anxiety; epilepsy
oxytocin antagonist		oxytocin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
SNAP 1156		peptide	anxiety; hypertension; obesity; addiction
LU 28179	1'-[4-[1-(4-fluorophenyl)-1H-indol-3-yl]butyl]spiro[isobenzofuran-1(3H),4'-piperidine]	Sigma ligand	anxiety
CGP 49823	(2R-trans)-1-(3,5-dimethylbenzoyl)-2-(phenylmethyl)-N-(4-quinolinylmethyl)-4-piperidinamine	substance P antagonist	anxiety; asthma
MK 869		substance P antagonist	depression; anxiety; schizophrenia; emesis

vasopressin antagonist		vasopressin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
------------------------	--	----------------------------------	---

Table 27. Current Candidate Therapeutic Interventions for the Treatment of Dementia

Product Name	Chemical Name	Action	Indication
SR 57746; SR 57746A	1,2,3,6-tetrahydro-1-[2-(1-naphthalenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]pyridine	5HT agonist; 5HT1A agonist; growth factor modulator	Alzheimer disease; neuropathy
AP 159	N-cyclohexyl-1,2,3,4-tetrahydro-[1]benzothieno[2,3c]pyridine-3-carboxamide monohydrochloride	5HT antagonist; SHT1A antagonist	cognitive defect
SL 880338		5HT antagonist; SHT1A antagonist	cognitive defect
GYKI 46903	(1R-endo)-6-(4-fluorophenyl)-1-azabicyclo[3.3.1]non-6-en-4-ol propanoate hydrochloride	5HT antagonist; SHT3 antagonist	cognitive defect
Ondansetron; GR 38032; GR 38032F; SN 307; ZOFRAN; ZOPHREN; ZOFRON	1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one	5HT antagonist; SHT3 antagonist	emesis; cognitive defect
FG 7080	trans-(-)-4-(4-fluorophenyl)-3-[(4-methoxyphenoxy)methyl]piperidine hydrochloride	5HT reuptake inhibitor	cognitive defect
Fluoxetine, (R)-; (R)-fluoxetine	(R)-N-methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine	5HT reuptake inhibitor	migraine; cognitive defect; depression

Indeloxazine; ideloxazine; YM 08054; CI 874; ELEN; NOIN	(+,-)-2-[(indel-7- yloxy)methyl]morpho- line	5HT reuptake inhibitor	cognitive defect
NS 2347		5HT reuptake inhibitor; dopamine reuptake inhibitor	depression; cognitive defect
SM 3163	3-((1,5- diphenylpentyl)oxy)- N,N-dimethyl-1- propanamine citrate	5HT reuptake inhibitor; vasodilator	cognitive defect; cerebrovascular disease
FK 960	N-(4-acetyl-1- piperazinyl)-4- fluorobenzamide	5HT, somatostatin	Alzheimer disease
SL 650102; SL 65.0102	(-)-8-amino-7-chloro- N-(1,4- diazabicyclo[2.2.2]oc- t-2-ylmethyl)-2,3- dihydro-1,4- benzodioxin-5- carboxamide dihydrochloride	5HT4 agonist; 5HT agonist	Alzheimer disease
5HT4 human neuroreceptor		5HT4 human neuroreceptor	irritable bowel syndrome; cognitive defect; anxiety; arrhythmia; stroke; urinary incontinence; migraine; research tool
Ceronapril; ceranapril; SQ 29852	(S)-1-[6-amino-2- [[hydroxy(4- phenylbutyl)phospiny- l]oxy]-1-oxohexyl]- L-proline	ACE inhibitor	cognitive defect; hypertension; anxiety
Alzheimer's disease therapy	1-[3,4- (methylenedioxy)ben- zoyl]-3-[2-(1-benzyl- 4- piperidinyl)ethyl]thio- urea	Acetylcholinesterase inhibitor	Alzheimer disease
NBI 117	Extracellular portion of activin receptor (soluble)	Activin soluble portion of receptor	Alzheimer disease
AD7C-NTP modulators, Alzheimer disease		AD7C-NTP modulation	Alzheimer disease

KF 15372	8-(3-dicyclopropylmethyl)-1,3-dipropylxanthine	adenosine antagonist	cognitive defect
KFM 19	3,7-dihydro-8-(3-oxocyclopentyl)-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	Alzheimer disease
MDL 102234	(R)-3,7-dihydro-8-(1-phenylpropyl)-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	cognitive defect
MDL 102503	(R)-3,7-dihydro-8-(1-methyl-2-phenylethyl)-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	cognitive defect
midaxifylline; IRFI 117	8-(1-aminocyclopentyl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	cognitive defect; depression; kidney disease
apaxifylline; BIIP 20XX; U 98950; BIIP 20	(S)-3,7-dihydro-8-(3-oxocyclopentyl)-1,3-dipropyl 1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist; xanthine	cognitive defect
MAb, adrenomedullin	Unspecified	adrenomedullin monoclonal antibody	cancer; diabetes; Alzheimer disease; diagnosis
Alzheimer's disease therapy		Alpha 2 macroglobulin inhibitor	Alzheimer disease
RU 49041; RU 49067	(3alpha)-(+,-)-11-methyl-20,21-dinoreburnamenine	alpha adrenergic agonist; alpha2 adrenergic partial agonist	cognitive defect
RU 52583	(3alpha)-11-methyl-20,21-dinoreburnamenine	alpha adrenergic agonist; alpha2 adrenergic partial agonist	cognitive defect
NS 1201		AMPA antagonist; glutamate antagonist	cognitive defect
NS 377	7-ethyl-1,6,7,8-tetrahydro-5-phenylbenzo[2,1-b:3,4-c']dipyrrole-2,3-dione 3-oxime	AMPA antagonist; glutamate antagonist	cognitive defect

NS 420	4-[2,3,6,7,8,9-hexahydro-3-(hydroxyimino)-8-methyl-2-oxo-1H-pyrrolo[3,2-h]isoquinolin-5-yl]-N,N-dimethylbenzenesulfonamide	AMPA antagonist; glutamate antagonist	cognitive defect
S 18986; S 18986-1	(S)-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide	AMPA antagonist; glutamate antagonist	cognitive defect
CX 691	Unspecified	AMPA glutaminergic receptor ligand	Alzheimer disease; schizophrenia
amyloid aggregation inhibitors	Unspecified	amyloid aggregation inhibitors	Alzheimer disease
antiamyloid	Unspecified	Amyloid antagonists	Alzheimer disease
GT 4001	Unspecified	Amyloid b destruction	Alzheimer disease
GT 4002	Unspecified	Amyloid b destruction	Alzheimer disease
GT 4003	Unspecified	Amyloid b destruction	Alzheimer disease
GT 4011	Unspecified	Amyloid b destruction	Alzheimer disease
GT 5011	Unspecified	Amyloid b destruction	Alzheimer disease
PTI 00703	Cats claw extract	Amyloid b protein deposition inhibitor	Alzheimer disease
amyloid enzyme inhibitors,	Unspecified	amyloid enzyme inhibitors	Alzheimer disease
amyloid inhibiting peptides	Unspecified	amyloid inhibiting peptides	Alzheimer disease
amyloid neurotoxicity antagonists,	Unspecified	amyloid neurotoxicity antagonists,	Alzheimer disease
CX 423	Unspecified	Amyloid neurotoxicity antagonist	Alzheimer disease
amyloid production inhibitors,	Unspecified	amyloid production inhibitors,	Alzheimer disease
amyloid production inhibitors,	Unspecified	amyloid production inhibitors,	Alzheimer disease; diabetes

FID 072021	3-atropanyl 2-(4-chlorophenoxy)butyrate maleate	analgesic	pain; cognitive defect
galanin modulators	Unspecified	galanin modulators analgesic	obesity; diabetes; cognitive defect; pain
galanin1 antagonists	Unspecified	galanin1 antagonists analgesic	obesity; pain; cognitive defect
metabotropic glutamate receptor modulators	Unspecified	metabotropic glutamate receptor modulators analgesic	pain; cognitive defect; schizophrenia; epilepsy
anatoxin analogue, prasterone; dehydroepiandrosterone; DHEA; GL 701; NBI 106; PB 007; ASTENILE; DEANDROS; DIANDRON	(3beta)-3-hydroxyandrost-5-en-17-one	androgen; vaccine adjuvant; hormone replacement therapy; corticosteroid	systemic lupus erythematosus; hormone deficiency; Alzheimer disease; reperfusion injury; ischemia
nootropic,	2-(4-allyl-1-piperazinyl)-4-pentyloxyquinazoline	antihypoxic	cognitive defect
RU 35929	(+,-)-5-ethoxy-1-(phenylsulfonyl)-2-pyrrolidinone	antihypoxic	cognitive defect
tenilsetam; tenimal; PAS 997; CAS 997; HR 029	(+/-)-3-(2-thienyl)-2-piperazinone	antihypoxic	cognitive defect
RGH 5279	(3alpha)-eburnamenine-14-carboxylic acid 2-(acetoxy)ethyl ester monohydrochloride	anti-ischemic	cognitive defect; brain ischemia
CPG 607	Unspecified	antioxidant	cognitive defect
Neurodegenerative disease therapy,	Unspecified	antioxidant	stroke; Alzheimer disease
antioxidant,	Unspecified	antioxidant; free radical scavenger	Alzheimer disease
VANTOX	Unspecified	antioxidant; NSAID	asthma; Parkinson disease; Alzheimer disease; stroke

antisense oligonucleotides, amyloid precursor/beta amyloid proteins; antisense oligonucleotides, Alzheimer's disease	Unspecified	antisense; oligonucleotide amyloid precursor/beta amyloid	Alzheimer disease
antisense oligonucleotide, APO-E4; antisense oligonucleotide, Alzheimer's disease	Unspecified	antisense; oligonucleotide APO-E4;	Alzheimer disease
Alzheimer's disease therapy	Unspecified	ApoE	Alzheimer disease
RU 34332	3-(cyclopropylcarbonyl)-7-fluoro-4,5-dihydro-5-methyl-6H-imidazo[1,5-a][1,4]benzodiazepine-6-one	benzodiazepine	cognitive defect
S 8510	1,6,7,9-tetrahydro-2-(3-isoxazolyl)imidazo[4,5-d]pyrano[4,3-b]pyridine phosphate (1:1)	benzodiazepine inverse agonist	cognitive defect; Alzheimer disease
SX 3933	5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1,6-naphthyridin-2(1H)-one monohydrochloride	benzodiazepine inverse agonist	cognitive defect; Alzheimer disease
RU 33965	3-(cyclopropylcarbonyl)-4,5-dihydro-5-methyl-6H-imidazo[1,5-a][1,4]benzodiazepine-6-one	benzodiazepine partial agonist	cognitive defect
terbequinil; SR 25776	1,4-dihydro-1-(methoxymethyl)-4-oxo-N-propyl-3-quinolinecarboxamide	benzodiazepine partial agonist	cognitive defect

nimodipine; BAY e 9736; BAY N 5248; BAY N 5427; NIMOTOP; NIMOTAP; NIVAS; TROPOCER; EUGERIAL; NIMODILAT; CEBROFORT; KENESIL; GENOVOX	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester	calcium antagonist	migraine; cognitive defect; Alzheimer disease; brain ischemia
RGH 2716; TDN 345	8-[4,4-bis(4-fluorophenyl)butyl]-3-(1,1-dimethylethyl)-4-methylene-1-oxa-3,8-diazaspiro[4.5]decan-2-one	calcium antagonist	cognitive defect
voltage-dependent calcium channel antagonists, VDCC antagonists	Unspecified	calcium antagonist	Alzheimer disease; neurological
sabeluzole; R 58735; JK 601	(+,-)-4-(2-benzothiazolylmethyl amino)-alfa-[(4-fluorophenoxy)methyl]-1-piperidineethanol	calcium antagonist; antihypoxic	Alzheimer disease
Tamolarizine; tamolaridine hydrochloride; NC 1100; ZC 110	(+,-)-alfa-(3,4-dimethoxyphenyl)-2-(4-diphenylmethyl)-1-piperazineethanol	calcium antagonist; vasodilator	cognitive defect; cerebrovascular disease
BAY Z 4406	Unspecified	calcium channel blocker	neurodegeneration; Alzheimer disease
NS 649	1-(2,5-dimethoxyphenyl)-5-(trifluoromethyl)-1H-benzimidazol-2-amine	calcium channel blocker	cognitive defect
elziverine; Ro 224839	1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-4-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]isoquinoline	calmodulin antagonist; vasodilator	peripheral vascular disease; cognitive defect

drug delivery system, CDS sinnabidol; sinnabidol CDS	Unspecified	cannabinoid; glutamate antagonist; NMDA antagonist	cognitive defect; glaucoma
SK 067	Unspecified	Cerebral metabolic agent	cognitive defect
SNK 882	2-oxo-N-[(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methyl]-1-pyrrolidin acetamide, monohydrochloride	Cerebral metabolic agent	cognitive defect
vinconate; vincantenate; vintenate; OM 853; OC 340; OC 34; BRENAL	(+,-)-methyl 3-ethyl-2,3,3a,4-tetrahydro-1H-indolo[3,2,1-de][1,5]naphthyridine-6-carboxylate	Cerebral metabolite enhancer	cognitive defect
SUT 8701	N-[(1,1-dimethylethoxy)carbonyl]-O-(dimethylphosinyl)-L-tyrosyl-L-norleucylglycyl-L-tryptophyl-L-norleucyl-L-alfa-aspartyl-L-phenylalaninamide	cholecystokinin antagonist	Alzheimer disease
sibopirdine; DUP 921; X 9121; EXP 9121; EXP921	5,5-bis(4-pyridinylmethyl)-5H-cyclopenta-[2,1-b:3,4-b']dipyridine	Choline release stimulator	cognitive defect
choline alphoscerate; choline glycerophosphate; GLIATILIN; DELECIT; BREZAL	L-alpha-glycerylphosphorylcholine	Choline releasing agent	cognitive defect
MKC 231	2-oxo-N-(5,6,7,8-tetrahydro-2,3-dimethylfuro[2,3-b]quinolin-4-yl)-1-pyrrolidineacetamide	Choline uptake stimulation	cognitive defect; Alzheimer disease

bifemelane; bifemelane hydrochloride; MCI 2016; E 0687; CELEPORT; ALNERT; NEUROCINE; SURTONIL; CORDINAL	N-methyl-4-[2- (phenylmethyl)pheno xy]-1-butanamine	Cholinergic agent	cognitive defect
ABT 089	(R)-2-methyl-3-(2- pyrrolidinylmethoxy) pyridine	Cholinergic channel modifier	Alzheimer disease
stacofylline; S 9977; S 99772; SE 9977	N,N-diethyl-4-[3- (2,3,6,7-tetrahydrio- 1,3,7-trimethyl-2,6- dioxo-1H-purin-8- yl)propyl]-1- piperazinecarboxamid e monohydrochloride	Cholinergic stimulation, 5HT uptake stimulation	Alzheimer disease
NS 2330	Unspecified	Cholinergic, adrenergic, noradrenergic	cognitive defect
choline derivatives,	Choline derivatives	Cholinomimetic	cognitive defect
HOE 065	[2S- [1[R*(R*)],2alpha,3a beta,6beta]-1-[2- [[1-(ethoxycarbonyl)- 3- phenylpropyl]amino]- 1- oxopropyl]octahydroc yclopenta[b]pyrrole- 2-carboxylic acid (Z)- 2-butenedioate	Cholinomimetic	cognitive defect
acetyl-L-carnitine; acetylcarnitine, L-; ALC; ST 200; TA 803; NICETILE; BRANIGAN; ALCAR; NEUROACTIL; BRANIGEN	acetyl-L-carnitine	Cholinomimetic, stimulation of neuron growth and repair	Alzheimer disease; stroke; diabetes; neuropathy
Alzheimer's therapy,	Unspecified	Complement activation by b- amyloid	Alzheimer disease

complement activation inhibitors	Unspecified	complement activation inhibitors	Alzheimer disease
Alzheimer's disease therapy,	Unspecified	Complex IV cytochrome oxidase function	Alzheimer disease
ebiratide; ACTH (4-9) analogue; corticotropin (4-9) analogue; HOE 427	4-(methylsulfonyl)-L-2-aminobutanoyl-L-alpha-glutamyl-L-histidyl-L-phenylalanyl-D-lysyl-N-alpha-(8-aminoctyl)-L-phenylalaninamide	corticotropin analogue	Alzheimer disease
GR 253035	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic	pain; Alzheimer disease
rofecoxib; MK 966; VIOXX	4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; rheumatoid arthritis; osteoarthritis; pain; Alzheimer disease
creb gene transcription modulators, CNS disorders,	Unspecified	creb gene transcription modulators	neurodegeneration; Alzheimer disease
CRF1 partial agonist	Unspecified	CRF1 partial agonist	Alzheimer disease; Crohn disease
differentiation-inducing factor; DIF	Unspecified	differentiation-inducing factor; DIF; growth factor; neurotrophic factor	cognitive defect
Alzheimer's disease therapy,	Unspecified	Disease specific protein targets	Alzheimer disease
Alzheimer's disease therapy,	Unspecified	Disease specific protein targets	Alzheimer disease
Alzheimer's disease therapy	Unspecified	Disease specific protein targets	Alzheimer disease
Alzheimer's therapy,	Unspecified	Disease specific protein targets	Alzheimer disease
NDD 094; SDZ NDD094	Unspecified	Disease specific targets	Alzheimer disease
alaptide; VUFB 15754	8-methyl-6,9-diazaspiro[4.5]decane-7,10-dione	dopamine agonist; cicatrizant; peptide	Alzheimer disease; skin ulcer; gastrointestinal ulcer
dihydrexidine; IP 202	trans-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine-10,11-diol	dopamine agonist; dopamine D1 agonist	Parkinson disease; Alzheimer disease

voxergolide; RU 41656	(8beta)-(+,-)-6-methyl-8-[(methylthio)methyl]-9-oxaergoline	dopamine agonist; dopamine D2 agonist	cognitive defect
estrogens,	Estrogens	estrogen	Alzheimer disease
estrogens,	Estrogens	estrogen	neuropathy; Alzheimer disease
ABPI 124	Unspecified	estrogen agonist	Alzheimer disease
17alpha estradiol	estra-1,3,5(10)-triene-3,17alpha-diol	estrogen; hormone replacement therapy	hormone deficiency; cognitive defect
estrogen,	Estrogen	estrogen; neuroactive steroid	Alzheimer disease
estrogen + medroxyprogesterone acetate; PREMPRO; PREMPHASE; PREMARIN MPA; PREMIQUE; PREMIQUE CYCLE	estrogen + medroxyprogesterone acetate	estrogen; progestogen; hormone replacement therapy	hormone deficiency; Alzheimer disease
excitatory amino acid antagonists,	Unspecified	excitatory amino acid antagonist	epilepsy; Alzheimer disease; stroke
carboxylated buckminsterfullerenes; carboxyfullerenes	Carboxylated buckminsterfullerenes; carboxyfullerenes	free radical scavenger; apoptosis inhibitor	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
nefiracetam; feniracetam; DM 9384; DMPPA; TRANSLON	N-(2,6-dimethylphenyl)-2-oxo-1-pyrrolidineacetamide	GABA agonist	cognitive defect
ZK 95962; ZK 45962	ethyl 5-isopropoxy-4-methoxymethyl-beta-carboline-3-carboxylate	GABA agonist	epilepsy; cognitive defect
CGP 36742	(3-aminopropyl)butylphosphinic acid	GABA antagonist	epilepsy; Alzheimer disease
cognition enhancer,	Unspecified	GABA inverse agonist	Alzheimer disease
NGD 971; NGD 97-1	Unspecified	GABA inverse agonist	cognitive defect
suritozole; MDL 26479	2,4-dimethyl-5-(3-fluorophenyl)-3H-1,2,4-triazole-3-thione	GABA inverse agonist	depression; cognitive defect

valproate sodium; sodium valproate; NIK 240; SENITA; SELENICA	2-propylpentanoic acid sodium salt	GABA release enhancer	Alzheimer disease; epilepsy
siagosome; AGF 2	[R-[R*,S*-(E)]]-N-[1-[[[O-[1',2'- anhydro]-N-acetyl- alpha-neuraminosyl- (2->3)-O-[O-beta-D- galactopyanosyl-(1- >3)-2-(acetylamino)- 2-deoxy-beta-D- galactopyranosyl-(1- >4)-O-beta-D- galactopyranosyl-(1- >4)-beta-D- glucopyranosyl]oxy] methyl]-2-hydroxy-3- heptadecenyl]octadec anamide	ganglioside	cognitive defect; stroke
Dimethylhomospermi ne; DMHSPM	Dimethylhomospermi ne	gastrokinetic; polyamine analogue	gastrointestinal motility disease; Alzheimer disease
Alzheimer disease therapy,	Unspecified	gene	Alzheimer disease
Alzheimer's disease therapy,	Unspecified	Gene transcription based drugs	Alzheimer disease
ALT 766	Unspecified	Glucose derived cross-link breaker	diabetes; cardiovascular disease; Alzheimer disease
riluzole; PK 26124; RP 54274; RILUTEK	6-(trifluoromethoxy)- 2-benzothiazolamine	glutamate antagonist	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
sinnabidol; HU 211; PA 50211; DEXANABINOL	(6aS-trans)-3-(1,1- dimethylheptyl)- 6a,7,10,10a- tetrahydro-1- hydroxy-6,6- dimethyl-6H- dibenzo[b,d]pyran-9- methanol	glutamate antagonist; cannabinoid; NMDA antagonist; free radical scavenger	cognitive defect; stroke; trauma; myocardial infarction; glaucoma

LY 341495	[1S-[1alpha(R*),2beta]]-alpha-amino-alpha-(2-carboxycyclopropyl)-9H-xanthene-9-propanoic acid	glutamate antagonist; mGluR antagonist	psychosis; cognitive defect
PD 129653; SC 46643	(+)-alpha-amino-4-(phosphonomethyl)benzeneacetic acid	glutamate antagonist; NMDA antagonist	cognitive defect
PD 130527	3-(phosphonomethyl)phenylalanine	glutamate antagonist; NMDA antagonist	cognitive defect
dimiracetam; ISF 4185	dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione	Glutaminergic, cholinergic pathways, inhibition of hippocampal serotonergic activity	cognitive defect
glycine transporter modulator,	Unspecified	glycine antagonist	epilepsy; cognitive defect
gene therapy, nerve growth factor	Unspecified	growth factor	Alzheimer disease
BU 4514N	Unspecified	growth factor	cognitive defect
CX 438	Unspecified	growth factor	Alzheimer disease
nerve growth factor inducer, NGF inducer,	Unspecified	growth factor	Alzheimer disease
drug delivery system, polymer pellet nerve growth factor; NGF polymer pellet	NGF polymer pellet	growth factor;	Alzheimer disease
neurodegenerative disease therapy,	Unspecified	growth factor; growth factor modulator	cognitive defect; Alzheimer disease; neuropathy
GPI 1046	1-(3,3-dimethyl-1,2-dioxopentyl)-L-proline 3-(3-pyridinyl)propyl ester	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
neurotrophin agonist,	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; neuropathy
NIL-A	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy

drug delivery system, neurotrophin-3 secreting implant; NT-3 implant	NT-3	growth factor; neurotrophic factor; biotechnology	Alzheimer disease; Parkinson disease; neuropathy
ciproxifan; compound 359; BP 2359	Cyclopropyl[4-[3-(1H-imidazol-4-yl)propoxyl]phenyl]ethanone	histamine antagonist; histamine H3 antagonist	Alzheimer disease; schizophrenia; cognitive defect
compound 421	Unspecified	histamine antagonist; histamine H3 antagonist	Alzheimer disease; schizophrenia; cognitive defect
GR 175737	Unspecified	histamine antagonist; histamine H3 antagonist	Alzheimer disease; cognitive defect
GT 2016	1-(5-cyclohexyl-1-oxpentyl)-4-(1H-imidazol-4-yl)piperidine	histamine antagonist; histamine H3 antagonist	cognitive defect; stroke; attention deficit disorder
GT 2227	1-[1H-imidazol-4-yl]-6-cyclohexyl-cis-hex-3-ene	histamine antagonist; histamine H3 antagonist	cognitive defect; attention deficit disorder
GT 2331	4-[(1R,2R)-2-(5,5-dimethyl-1-hexynyl)cyclopropyl]-1H-imidazole	histamine antagonist; histamine H3 antagonist	cognitive defect; attention deficit disorder; Alzheimer disease
thioperamide; MR 12842	N-cyclohexyl-4-(1H-imidazol-4-yl)-1-piperidinecarbothioamide	histamine antagonist; histamine H3 antagonist	cognitive defect
drug delivery system, thyrotropin releasing hormone; TRH-SR; HILTONIN SR	Unspecified	hormone	cognitive defect
ICE inhibitors,	Unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	endotoxic shock; rheumatoid arthritis; Alzheimer disease
AIT 083	Unspecified	immunostimulant	cognitive defect

CEP 1347; KT 7515	[9S-(9alpha,10beta,12alpha)-5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo [1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, methyl ester	Kinase inhibitor, jnk inhibitor	Alzheimer disease
m-NBA	2-amino-3-(3-nitrobenzoyl)propanoic acid	kynurenine 3 hydroxylase inhibitor	epilepsy; Parkinson disease; Alzheimer disease
Maillard reaction inhibitors	Unspecified	Maillard reaction ; blocks glycated proteins	atherosclerosis; Alzheimer disease
drug delivery system, transdermal selegiline; selegiline transdermal	Selgiline	MAO B inhibitor; MAO inhibitor	Alzheimer disease; depression
lazabemide; Ro 196327; PAKIO; TEMPIUM	N-(2-aminoethyl)-5-chloro-2-pyridine-carboxamide	MAO B inhibitor; MAO inhibitor	Parkinson disease; Alzheimer disease
LU 53439	3,4-dimethyl-7-(2-isopropyl-1,3,4-thiadiazol-5-yl)-methoxy-coumarin	MAO B inhibitor; MAO inhibitor	Parkinson disease; cognitive defect
rasagiline; rasagiline mesylate; TVP 1012; TV 1012	(R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine	MAO inhibitor; MAO B inhibitor	Parkinson disease; Alzheimer disease
SL 251188	Unspecified	MAO inhibitor; MAO B inhibitor	Alzheimer disease; nicotine withdrawal
neurodegenerative disease therapy	Unspecified	monoclonal antibody; biotechnology	neurodegeneration; Alzheimer disease
BY 1949	3-methoxy-11-methyl-dibenz(b,f)(1,4)oxazepine-8-carboxylic acid	Na ⁺ , K ⁺ ATPase activation	cerebrovascular disease; cognitive defect
SR 57667	Unspecified	Neurodegeneration protection agent	Alzheimer disease; Parkinson disease

memory enhancer,	Unspecified	Neuron enhancement at hippocampus	cognitive defect
neurophilins	Neurophilins	Neurophilin receptor ligand	Alzheimer disease; Parkinson disease; neuropathy
lubeluzole; R 87926; PROSYNAP	(S)-4-(2-benzothiazolylmethyl amino)-alpha-[(3,4-difluorophenoxy)methyl]-1-piperidineethanol	Neuroprotectant	stroke; Alzheimer disease
CX 417	Unspecified	Neurotransmitter receptro modulator	Alzheimer disease
DMP 543	10,10-bis[(2-fluoro-4-pyridinyl)methyl]-9(10H)-anthracenone	Neurotransmitter release	Alzheimer disease
leteprinim; leteprinim potassium; AIT 082; NEOTROFIN	4-[[3-(1,6-dihydro-6-oxo-9H-purin-9-yl)-1-oxopropyl]amino]benzoic acid	Neurotrophic factor production stimulation	cognitive defect; Alzheimer disease
CEP 427	Unspecified	neurotrophic factor; growth factor	Alzheimer disease
K 252a derivative	[(9S-(9alpha,10beta,12alpha)-a)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester	neurotrophic factor; growth factor	neuropathy; Alzheimer disease
NS 506	Unspecified	neurotrophic factor; growth factor	cognitive defect
NS 521	Unspecified	neurotrophic factor; growth factor	Alzheimer disease; neuropathy; cancer; diabetes

ST 857	[R-(R*,S*)]-2-(acetoxy)-4-[[4-[(aminoiminomethyl)amino]-1-carboxybutyl]amino]-N,N,N-trimethyl-4-oxo-1-butanaminium chloride	neurotrophic factor; growth factor	cognitive defect
eurystatin A; Bu 4164EA	[3S-[3R*,7R*,10R*(E)]]-6-methyl-N-[7-methyl-3-(2-methylpropyl)-2,5,6,9-tetraoxo-1,4,8-triazacyclotridec-10-yl]-2-heptenamide	neutral endopeptidase inhibitor	Alzheimer disease
eurystatin B; Bu 4164EB	[3S-[3R*,7R*,10R*(E)]]-6-methyl-N-[7-methyl-3-(2-methylpropyl)-2,5,6,9-tetraoxo-1,4,8-triazacyclotidec-10-yl]-2-octenamide	neutral endopeptidase inhibitor	Alzheimer disease
Y 29794	[2-[[8-(dimethylamino)octyl]thio]-6-(1-methylethyl)-3-pyridinyl]-2-thienylmethanone	neutral endopeptidase inhibitor	cognitive defect; Alzheimer disease
neurodegeneration therapy	Unspecified	Nicotinic compounds	Alzheimer disease; Parkinson disease
memantine; D 145; NMI 131; AKATINOL	3,5-dimethyl-1-adamantanamine	NMDA antagonist; analgesic; glutamate antagonist	cognitive defect; pain; glaucoma; neuropathy
CR 2249	(S)-4-amino-5-[(4,4-dimethylcyclohexyl)amino]-5-oxopentanoic acid	NMDA modulator	Alzheimer disease
GVS 111	1-(phenylacetyl)-L-prolylglycine ethyl ester	NMDA modulator	cognitive defect

adafenoxate; WON 150	4-chlorophenoxyacetic acid 2-(1-adamantylamino)ethyl ester	Nootropic agent	cognitive defect
ALE 26015	Unspecified	Nootropic agent	cognitive defect; Alzheimer disease
aloracetam; CAS 493	N-[2-(3-formyl-2,5-dimethylpyrrol-1-yl)ethyl]acetamide	Nootropic agent	cognitive defect
Alzheimer's disease therapy,	Unspecified	Nootropic agent	Alzheimer disease
AWD 5239	9,10-dihydrolysergic acid bis-(beta-acetoxyethyl)amide monutartrate	Nootropic agent	cognitive defect
bacoside A	3-[(O-alfa-L-arabinosyl-beta-D-glucosyl)oxy]-19,20-dihydroxydammar-24-en-16-one	Nootropic agent	cognitive defect
bacoside A + bacoside B	Unspecified	Nootropic agent	cognitive defect
bacoside B	3-[(O-L-arabinosyl-D-glucosyl)oxy]-19,20-dihydroxydammar-24-en-16-one	Nootropic agent	cognitive defect
BDP	(11beta,16beta)-9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione	Nootropic agent	Alzheimer disease
BMY 21502; BMS 181168	1-[[1-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone	Nootropic agent	cognitive defect
BR 16A	Unspecified	Nootropic agent	cognitive defect
CGP 34735	Unspecified	Nootropic agent	cognitive defect
CGP 50068A	Unspecified	Nootropic agent	cognitive defect

CL 275838	4,5-dihydro-4-((4-(phenylmethyl)-1-piperazinyl)acetyl)-7-(3-(trifluoromethyl)phenyl)pyrazolo(1,5-a)pyrimidine-3-carbonitrile	Nootropic agent	cognitive defect
CX 516; AMPALEX	1-(6-quinoxalinylcarbonyl)piperidine	Nootropic agent	Alzheimer disease; schizophrenia
cycloserine-D; cycloserine; SC 49088	4-amino-3-isoxazolidinone	Nootropic agent	Alzheimer disease
dablotine; S 12024; S 120242	(S)-1,2,3,4-tetrahydro-1-methyl-8-(2-morpholinylmethoxy)quinoline monomethanesulfonate	Nootropic agent	Alzheimer disease
exifone; ADLONE	2,3,3',4,4',5'-hexahydroxybenzophenone	Nootropic agent	cognitive defect
fasoracetam; NS 105; LAM 105	(R)-1-[(5-oxo-2-pyrrolidinyl)carbonyl]piperidine	Nootropic agent	cerebrovascular disease; cognitive defect
FR 121196	1-acetyl-4-[[4-fluorophenyl)sulfonyl]amino]piperazine	Nootropic agent	cognitive defect; sexual dysfunction
gedocarnil; SH 530; ZK 113315	5-(4-chlorophenoxy)-4-(methoxymethyl)-9H-pyrido[3,4-b]indole-3-carboxylic acid 1-methylethyl ester	Nootropic agent	cognitive defect
idebenone; CV 2619; AVAN; LUCEBANOL; GENICERAL; MNESIS; DARUMA; NEMOCEBRAL; KEDANON; ARZKAT; DAYSTROM	2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione	Nootropic agent	cognitive defect

IDRA 21	7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide	Nootropic agent	cognitive defect
KI 711	Sialic acid derivative	Nootropic agent	Alzheimer disease
KW 6055	N-[3-nitro-4-(2-pyridinylmethyl)phenyl]butanamide	Nootropic agent	cognitive defect
mexidol	2-ethyl-6-methyl-3-hydroxypyridine succinate	Nootropic agent	anxiety; cognitive defect
oxiracetam; ISF 2522; CT 848; CGP 21690; NEUROMET; NEURACTIV; SENEX	4-hydroxy-2-oxo-1-pyrrolidineacetamide	Nootropic agent	cognitive defect
P 128	Unspecified	Nootropic agent	cognitive defect
P 58	Unspecified	Nootropic agent	Alzheimer disease; cognitive defect
P 867493	Unspecified	Nootropic agent	cognitive defect
P 878184	Unspecified	Nootropic agent	cognitive defect
PPRT 424	Ginko biloba extract	Nootropic agent	cognitive defect
pramiracetam; amacetam; CI 879; CNS 1879; ECTAPRAM; NEUPRAMIR; REMEM	N-[2-[bis-(1-methylethyl)amino]ethyl]-2-oxo-1-pyrrolidineacetamide	Nootropic agent	Alzheimer disease
prisotinol; prisotinal; CGS 5649B	(+,-)-6-[2-(isopropylamino)propyl]-3-pyridinol	Nootropic agent	cognitive defect
RU 47067	5-(1-methylethoxy)-1-3-(trifluoromethyl)phenylsulfonyl-2-pyrrolidinone	Nootropic agent	cognitive defect
SC 110	Unspecified	Nootropic agent	Alzheimer disease
SEE 405	Unspecified	Nootropic agent	Alzheimer disease
South American frog toxins	Histrionicotoxin	Nootropic agent	Alzheimer disease
UCB 11056	Unspecified	Nootropic agent	Alzheimer disease
UCB 29427	Unspecified	Nootropic agent	cognitive defect
UCB 29536	Unspecified	Nootropic agent	cognitive defect

Z 4105	N-(3-carboxypropyl)-3-methylisoxazole-5-carboxamide	Nootropic agent	cognitive defect
T 588	(R)-1-alfa-[[2-(diethylamino)ethoxy]methyl]benzo[b]thiophene-5-methanol hydrochloride	Nootropic agent, neurodegeneration protection	cognitive defect
VA 045	(3alpha,16alpha)-eburnamenine-14-carboxylic acid 2-(nitrooxy)ethylester, apovincaminic acid derivative	Nootropic agent, neuroprotective agent	cognitive defect
nebracetam; WEB 1881; WEB 1881FU; MEMOLOG	4-aminomethyl-1-benzylpyrrolidin-2-one hemifumarate	Nootropic agent, unknown mechanism	Alzheimer disease
DQ-CER	des-Gln2-[Leu5,Nle8]-cerulein	Nootropic agent	cognitive defect
MCI 225	4-(2-fluorophenyl)-2-methyl-6-(piperazin-1-yl)-3a,7a-dihydrothieno[2,3-d]pyrimidine	Noradrenergic, serotonergic reuptake inhibitors	cognitive defect; depression
notch signalling pathway modulators	Unspecified	notch signalling pathway modulators	stroke; cognitive defect; cancer
CPH 82; REUMACON; COMIHOG	Unspecified	NSAID	inflammation; Alzheimer disease
HCT 1026	Unspecified	NSAID; nitric oxide donor	urinary incontinence; Alzheimer disease; osteoporosis
quadazocine; WIN 444413; WIN 44441	(-)-(2R,6S,11S)-1-cyclopentyl-5-(1,2,3,4,5,6-hexahydro-8-hydroxy-3,6,11-tromethyl-2,6-methano-3-benzazocin-11-yl)-3-pentanone	opiate antagonist; kappa antagonist	cognitive defect
MAb, OX 26-nerve growth factor conjugate; MAb, OX 26-NGF conjugate; OX 26-NGF	Unspecified	OX 26-nerve growth factor conjugate monoclonal antibody	cognitive defect

ACTH (4-10); SEMAX	Unspecified	peptide	cognitive defect; trauma; stroke
Alzheimer disease therapy,	Unspecified	peptide	Alzheimer disease
beta-sheet breaker,	Unspecified	peptide	Alzheimer disease
Transglutaminase inhibitor	Unspecified	peptide; transglutaminase inhibitor	psoriasis; Alzheimer disease
KS 505a	2,3,4,4a,4b,5,6,6a,6b, 7,8,8a,8b,9,10,10a,16, 16a,16b,17,18,18a,18 b,19,2 0,20a,20b,21,22,22a, triacontahydro- 8a,10a- bis(hydroxymethyl)- 14-(4-methoxy-1,4- dioxobutyl)1,4,4a,6,6 a,16b,18b,20b- octamethyl-2-((2-O - methyl-beta-D- glucopyranuronosyl)o- xy)-1H- benzo(9,10)picen- o(3,4-a)xanthen- 1,15-dicarboxylic acid	phosphodiesterase inhibitor	cognitive defect
Rolipram; ZK 62711; ME 3167; ADEO	4-[3- (cyclopentyloxy)-4- methoxyphenyl]-2- pyrrolidinone	phosphodiesterase inhibitor	cognitive defect; multiple sclerosis
Propentofylline; HWA 285; HEXTOL; BRAINORM; VIVIQ	3-methyl-1-(5-oxo- hexyl)-7- propylxanthine	phosphodiesterase inhibitor; xanthine	Alzheimer disease
Diethylnorspermine; DENSPM; CI 1006; DE 333	N1,N11- diethylnorspermine	polyamine analogue	cancer; psoriasis; Alzheimer disease
Dipropylnorspermine; DPNSPM	Dipropylnorspermine	polyamine analogue	diarrhea; Alzheimer disease
linear polyamine analogue	linear polyamine analogue	polyamine analogue	cancer; Alzheimer disease
Polymerization inhibitor	Unspecified	polymerization inhibitor	Alzheimer disease

Clausenamide	(3R,4S,5S)-rel-3-hydroxy-5-[(R)-hydroxyphenylmethyl]-1-methyl-4-phenyl-2-pyrrolidinone	potassium channel blocker	cognitive defect
Potassium channel modulators,	Unspecified	potassium channel modulator	cognitive defect; attention deficit disorder; depression; asthma; diabetes
Alzheimer's disease therapy	Unspecified	Presenilins	Alzheimer disease
JTP 3399	Unspecified	prolyl endopeptidase inhibitor	cognitive defect
JTP 4819	[S-(R*,R*)]-2-[[2-(hydroxyacetyl)-1-pyrrolidinyl]carbonyl]-N-(phenylmethyl)-1-pyrrolidinecarboxamide	prolyl endopeptidase inhibitor	Alzheimer disease; cognitive defect
ONO 1603	(S)-N-[(4-chlorophenyl)methyl]-2-formyl-gamma-oxo-1-pyrrolidinebutanamide	prolyl endopeptidase inhibitor	Alzheimer disease
S 17092	Unspecified	prolyl endopeptidase inhibitor	Alzheimer disease; cognitive defect
Z 321	(4R)-3-(2-indanyl-2-ylacetyl)-4-(1-pyrrolidinylcarbonyl)-1,3-thiazolidine	prolyl endopeptidase inhibitor	cerebrovascular disease; cognitive defect; Alzheimer disease
CEP 431	Unspecified	proteinase inhibitor	Alzheimer disease
proteinase inhibitors,	Unspecified	proteinase inhibitor	cognitive defect
SIB T1980	Unspecified	proteinase inhibitor	Alzheimer disease
azetirelin; YM 14673	(S)-N-[(4-oxo-2-azetidinyl)carbonyl]-L-histidyl-L-prolinamide	protirelin analogue	cognitive defect
JTP 2942	(1S-cis)-N-[(2-methyl-4-oxocyclopentyl)carbonyl]-L-histidyl-L-prolinamide	protirelin analogue	cognitive defect

posatirelin; RGH 2202	(S)-N-[(6-oxo-2-piperidinyl)carbonyl]-L-leucyl-L-prolinamide	protirelin analogue	cognitive defect; obesity
Alzheimer's disease therapy,	Unspecified	Serum amyloid p component	Alzheimer disease
igmesine; igmacine; JO 1784	(+)-N-(1,4-diphenyl-3-butenyl)-N-methylcyclopropane methanamine	sigma agonist	depression; cognitive defect; diarrhea
SA 4503	1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride	sigma agonist	Alzheimer disease; depression; cognitive defect; stroke
octreotide; octreotide acetate; SMS; SMS 201995; SMS 201995ac; SMS 995; SANDOSTATIN; SANDOSTATINE; SANDOSTATINA; LONGASTATINA; SAMILSTATINA	[R-(R*,R*)]-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2-7)-disulfide	somatostatin analogue; analgesic	Alzheimer disease; cancer; viral infection; psoriasis; diarrhea; diabetes; pain; acromegaly
NX D2858; NXD 2858	Unspecified	Spherons, inhibition of spherons into plaques	Alzheimer disease
screening technology, ADAP	Unspecified	target based screening	drug design technology; Alzheimer disease
drug delivery system, thyroid stimulating hormone;	Unspecified	thyroid stimulating hormone delivery system	cognitive defect
thalidomide; NSC 66847	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	HIV infection; Crohn disease; multiple sclerosis; Alzheimer disease; transplant rejection

CEP 3265; CB 1093	5-[[1-(2-ethoxy-6-ethyl-6-hydroxy-1-methyl-3-octynyl)octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-1,3-cyclohexanediol	transcription activator	neurodegeneration; Alzheimer disease
ademetionine; FO 1561; GUMBARAL; DONAMET; TRANSMETIL; CERITAN; ERGEN; TWIN; SAMY R	(3S)-5'-(3-amino-3-carboxypropyl)methylsulfonio]-5'-deoxyadenosine hydroxide inner salt	transmethylator; NSAID	inflammation; cognitive defect; cholestasis
AIT 034; AIT 34	1,6-dihydro-6-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]9H-purine-9-propanamide	Unknown	cognitive defect
BTG 1640	Heterocyclic compound	unknown	cognitive defect; Alzheimer disease
cebaracetam; ZY 15119	(+,-)-4-[(4-(p-chlorophenyl)-2-oxo-1-pyrrolidinyl)acetyl]-2-piperazinone	Unknown	cognitive defect
fatty acids, microalgal	Unspecified	Unknown	hyperlipidemia; Parkinson disease; Alzheimer disease; eye disease
NBI 107	Unspecified	vaccine adjuvant; immunostimulant; neuroactive steroid	infectious disease; Alzheimer disease
NBI 108	Unspecified	vaccine adjuvant; immunostimulant; neuroactive steroid	Alzheimer disease; infectious disease; multiple sclerosis
pregnenolone; NBI 113	Unspecified	vaccine adjuvant; immunostimulant; neuroactive steroid	infectious disease; Alzheimer disease

vinpocetine; AY 27255; CAVINTON; CERACTON; AIRPACIL; MEDICHILL; NAIKINOL TEISAN; NAIKINOL IWAKI	(3alpha,16alpha)-eburnamenine-14-carboxylic acid ethyl ester	vasodilator	peripheral vascular disease; cognitive defect
vasoactive intestinal peptide analogue; [stearyl norleucine17]VIP; [St-Nle17]VIP	Unspecified	VIP agonist	Alzheimer disease

Table 28. Current Candidate Therapeutic Interventions for the Treatment of Depression

Product Name	Chemical Name	Action	Indication
CP 110330	N,N-dimethyl-5-[4-[(phenylamino)methyl]-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
CP 119333	N,N-dimethyl-5-[4-(phenylmethyl)-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
F 12439		5HT agonist; 5HT1A agonist	depression; anxiety
Flesinoxan; DU 29373	(+)-N-[2-[4-[2,3-dihydro-2-(hydroxymethyl)-1,4-benzodioxin-5-yl]-1-piperazinyl]ethyl]-4-fluorobenzamide	5HT agonist; 5HT1A agonist	anxiety; depression
Gepirone; gepirone hydrochloride; MJ 13805; BMY 13805; BMY 138051	4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione	5HT agonist; 5HT1A agonist	anxiety; depression
Ipsapirone; BAY q 7821; TVX q 7821	2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide	5HT agonist; 5HT1A agonist	depression; anxiety

LY 228729	4-(dipropylamino)-1,3,4,5-tetrahydrobenz[cd]indole-6-carboxamide	SHT agonist; 5HT1A agonist	anxiety; depression
ORG 13011		SHT agonist; 5HT1A agonist	depression
S 14671	N-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-2-thiophenecarboxamide	SHT agonist; 5HT1A agonist	anxiety; depression
U 92016A		SHT agonist; 5HT1A agonist	anxiety; depression
U 93385; U 93385E	(3aR-cis)-2,3,3a,4,5,9b-hexahydro-3-propyl-1H-benz[e]indole-9-carboxamide	SHT agonist; 5HT1A agonist	anxiety; depression
WY 48723	octahydro-3-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,5-methano-6,7,9-metheno-2H-pentaleno[1,2-a]azepin-2,4(3H,5H)-dione dihydrochloride	SHT agonist; 5HT1A agonist	depression
SL 870765		SHT agonist; 5HT1A agonist; 5HT antagonist; 5HT1D antagonist	anxiety; depression
Adatanserin; adatanserin hydrochloride; WY 50324; WAY SEB 324; SEB 324	N-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1(3,7)]deca-1-carboxamide	SHT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
FG 5865	2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide monohydrochloride	SHT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
FG 5893; FG 5974	(2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester)	SHT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression

AF 2968	(S)-[R-(R*,R*)]-2,3-2-[3-[4-(3-chlorophenyl)-2-methyl-1-piperazinyl]propyl]-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one dihydroxybutanedioate (1:1)	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2A antagonist; 5HT2C antagonist	depression
Sunepitron; CP 93393; CP 93393-1	(7S-trans)-1-[[octahydro-2-(2-pyrimidinyl)-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-2,5-pyrrolidinedione	5HT agonist; 5HT1A agonist; alpha adrenergic antagonist; alpha2 adrenergic agonist	depression; anxiety
Aromatic triflates,		SHT agonist; SHT1D agonist	depression; migraine
GMC 2020		SHT agonist; SHT1D agonist	depression; migraine
GMC 2021	trifluoromethanesulfonic acid 3-[2-(dimethylamino)ethyl]-1H-indol-5-yl ester (1:1) ethanedioate	SHT agonist; SHT1D agonist	depression; migraine
ORG 12962		SHT agonist; 5HT2C agonist	depression
ORG 37684		SHT agonist; 5HT2C agonist	depression
Ro 600175; Ro 60-0175	(alphaS)-6-chloro-5-fluoro-alpha-methyl-1H-indole-1-ethanamine (2E)-2-butenedioate (1:1)	SHT agonist; 5HT2C agonist	depression; obsessive-compulsive disorder
SR 57227; CM 57277	1-(6-chloro-2-pyridinyl)-4-piperidinamine	SHT agonist; 5HT3 agonist	depression
SHT1B antagonists,		SHT antagonist	depression; anxiety
BN 50156	3-(4-chlorophenyl)-alfa-[3-(dimethylamino)-1-propenyl]-1,3-dihydro-7-hydroxyfuro[3,4-c]pyridine-6-methanol	SHT antagonist	depression
DU 123015		SHT antagonist	anxiety; depression

DU 125530		SHT antagonist	depression; anxiety; psychosis
Moxyfetin		SHT antagonist	depression
SB 245570		SHT antagonist	depression
5-HT antagonist, pindobind	2-bromo-N-[4-[1-[[2-hydroxy-3-(1H-indol-4-yloxy)propyl]amino]-1-methylethyl]-1-methylcyclohexyl]acetamide	SHT antagonist; SHT1A antagonist	anxiety; depression
Robalzotan; NAD 299	(3R)-3-(dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide (2R,3R)-2,3-dihydroxybutanedioate (1:1)	SHT antagonist; SHT1A antagonist	anxiety; depression
S 14063	1-(2-benzothiazolyl)-N-[2-(2-methoxyphenoxy)ethyl]-4-piperidinemethamine dihydrochloride	SHT antagonist; SHT1A antagonist	depression
S 15535	1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)piperazine	SHT antagonist; SHT1A antagonist	anxiety; depression
Buspirone hydrochloride; MJ 40221; MJ 9022; BESPAR; BUSPAR; NORMATON; TUTRAN; NAROL; ANSIENON; ANSITEN; TRANBUS; SIMPLESS	8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4,5]decane-7,9-dione hydrochloride	SHT antagonist; SHT1A antagonist; dopamine agonist	anxiety; depression; dermatitis
Drug delivery system, transdermal buspirone; buspirone transdermal		SHT antagonist; SHT1A antagonist; dopamine agonist	anxiety; depression; attention deficit disorder

EF 7412	N-3-[4-[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]-1-piperazinyl]phenyl]ethanesulfonamide	SHT antagonist; SHT1A antagonist; glutamate release inhibitor	neurodegeneration; depression; cancer
L 694247	N-[4-[[5-[3-(2-aminoethyl)-1H-indol-5-yl]-1,2,4-oxadiazol-3-yl]methyl]phenyl]ethanesulfonamide	SHT antagonist; SHT1D antagonist	depression
GR 127935	N-(4-methoxy-3-(4-methyl-1-piperazinyl)phenyl-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-5-yl)-1H-indole-3-yl)ethylamine	SHT antagonist; SHT1Dbeta antagonist	depression
Flibanserin; BIMT 17	1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-2H-benzimidazol-2-one	SHT antagonist; SHT2 antagonist; SHT agonist; SHT1A agonist	depression
HT 90B	(-)-N-[2-[(2,3-dihydro-8-methyl-1,4-benzodioxin-2-yl)methyl]amino]ethyltricyclo[3.3.1.13,7]decane-1-carboxamide	SHT antagonist; SHT2 antagonist; SHT agonist; SHT1A agonist	anxiety; depression
Nefazodone; MJ 13754; MS 13754; BMY 13754; BMY 137541; SERZONE; DUTONIN; RESERIL; NEFADAR; NIFEREL; MENFAZONA; RULIVAN; DEPREFAX; SERZONIL	2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one	SHT antagonist; SHT2 antagonist; SHT reuptake inhibitor; alpha adrenergic antagonist; alpha1 adrenergic antagonist	depression

Amesergide; amerserzide; LY 237733	8beta-N-cyclohexyl-6-methyl-1-(1-methylethyl)ergoline-8-carboxamide	5HT antagonist; 5HT2 antagonist; 5HT1C antagonist	sexual dysfunction; depression; anxiety
Mirtazapine; mepirzepine; azamianserin; ORG 3770; REMERON; ZISPIN	1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine	5HT antagonist; 5HT2 antagonist; 5HT3 antagonist; alpha2 adrenergic antagonist; alpha adrenergic antagonist	depression
Olanzapine; LY 170053; ZYPREX; ZYPREXA; OLANZEPK	2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia; psychosis; depression
ORG 37415		5HT antagonist; 5HT2C antagonist	depression; anxiety
SB 228357	N-[3-fluoro-5-(3-pyridinyl)phenyl]-2,3-dihydro-5-methoxy-6-(trifluoromethyl)-1H-indole-1-carboxamide	5HT antagonist; 5HT2C antagonist	anxiety; depression
Antidepressant		5HT antagonist; 5HT3 antagonist	depression; anxiety
5HT7 receptor antagonists,		5HT antagonist; 5HT7 antagonist	depression; insomnia; schizophrenia
DR 4004		5HT antagonist; 5HT7 antagonist	depression; insomnia
THE JL3; JL 3	10-(4-methyl-1-piperazinyl)-pyrido[4,3-b][1,4]benzothiazepine	5HT antagonist; dopamine antagonist	anxiety; depression
BMS 181101; BMY 42569	5-fluoro-3-[3-[4-(1,4,5,6-tetrahydropyrimidin-4-yl)-2,3-dihydropyrazin-1-yl]propyl]-2,3-dihydro-1H-indole	5HT reuptake inhibitor	depression

Cericlamine; JO 1017(+,-); JO 1239(-); JO 1240(+)	(+,-)-3,4-dichloro-beta-(dimethylamino)-beta-methylbenzenepropanol	5HT reuptake inhibitor	depression
CGP 6085A	4-(5,6-dimethyl-2-benzofuranyl)piperidine hydrochloride	5HT reuptake inhibitor	depression
Citalopram; nitalopram; nitalapram; ZD 211; LU 10171; CIPRAMIL; SEROPRAM; CIPRAM; ELOPRAM; CELEXA	1-[3-(dimethylamino)propyl]-1-4-fluorophenyl)-5-isobenzofurancarbonitrile	5HT reuptake inhibitor	depression
Citalopram, (S); (+)-citalopram	(S)-1-[3-(dimethylamino)propyl]-1-4-fluorophenyl)-5-isobenzofurancarbonitrile	5HT reuptake inhibitor	depression
Dapoxetine; LY 210448	(S)-N,N-dimethyl-alpha-[2-(1-naphthalenylloxy)ethyl]benzenemethanamine	5HT reuptake inhibitor	depression
Depression therapy,		5HT reuptake inhibitor	depression
Dexfenfluramine; dexfenfluramine hydrochloride; S 5614; IP 001; ISOMERIDE; ADIFAX; ARDIX; ISOLIPAN; SIRAN; OBESINE; FLURIL; DISPONDAL; REDUX	(S)-N-ethyl-alpha-methyl-3-(trifluoromethyl)benzeneethanamine	5HT reuptake inhibitor	obesity; depression; nicotine withdrawal

Drug delivery system, controlled release GEOMATRIX paroxetine; paroxetine GEOMATRIX; PAXIL CR		5HT reuptake inhibitor	depression
FCE 25876	(E)-N-methyl-3-phenyl-3-(4-trifluoromethylphenoxy)-2-propen-1-amine	5HT reuptake inhibitor	depression
FI 4500		5HT reuptake inhibitor	depression
FI 4501		5HT reuptake inhibitor	depression
FI 4503		5HT reuptake inhibitor	depression
Fluoxetine, (R)-; (R)-fluoxetine	(R)-N-methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine	5HT reuptake inhibitor	migraine; cognitive defect; depression
Fluvoxamine; fluvoxamine maleate; DU 23000; MK 264; SME 3110; FEVARIN; FLOXYFRAL; LUVOX; DUMYROX; DUMIROX; FLAVOXYL; FAVERIN; DEPROMEL	5-methoxy-1-[4-(trifluoromethyl)phenyl]-1-pantanone (E)-O-(2-aminoethyl)oxime	5HT reuptake inhibitor	depression; anxiety; obsessive compulsive disorder
Litoxetine; SL 810385	4-(2-naphthalenylmethoxy)piperidine	5HT reuptake inhibitor	depression
LY 280253	Unspecified	5HT reuptake inhibitor	depression
LY 285974	Unspecified	5HT reuptake inhibitor	depression

Paroxetine hydrochloride; FR 7051; BRL 29060; BRL 29060A; SI 211103; SEROXAT; AROPAK; PAXIL; TAGONIS; FROGINOR; DEROXAT; SEREUPIN; MOTIVAN	(3S-trans)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine	5HT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety
Sertraline; CP 51974; CP 519741; CP 5197401; LUSTRAL; ZOLOFT; ALTRULINE; TATIG; GLADEM	(1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthaleneamine	5HT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety; sexual dysfunction; obesity
Tianeptine; S 1574; STABLON	7-[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide	5HT reuptake inhibitor	depression
EMD 68843	5-[4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl]benzofuran-2-carboxamide hydrochloride	5HT reuptake inhibitor; 5HT agonist; 5HT1A agonist	depression
YM 992; YM 35992	(S)-2-[[[7-fluoro-2,3-dihydro-1H-inden-4-yl)oxy]methyl]morpholine hydrochloride	5HT reuptake inhibitor; 5HT antagonist; 5HT2A antagonist	depression
A 80426	(R)-N-methyl-N-[(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)methyl]-6-benzofuranethanamine	5HT reuptake inhibitor; alpha adrenergic antagonist; alpha2 adrenergic antagonist	depression
Antidepressants		5HT reuptake inhibitor; alpha adrenergic antagonist; alpha2 adrenergic antagonist	depression

NS 2347		5HT reuptake inhibitor; dopamine reuptake inhibitor	depression; cognitive defect
NS 2389		5HT reuptake inhibitor; dopamine reuptake inhibitor; noradrenalin reuptake inhibitor	depression
Drug delivery system, OROS oral controlled release venlafaxine; venlafaxine OROS; EFFEXOR XL		SHT reuptake inhibitor; noradrenalin reuptake inhibitor	depression
Duloxetine; LY 248686	(S)-N-methyl-gamma-(1-naphthalenylxyloxy)-2-thiophenepropanamine	SHT reuptake inhibitor; noradrenalin reuptake inhibitor	depression; urinary incontinence
Venlafaxine; WY 45030; EFFEXOR; EFEXOR; EFFEXOR XR; EFFEXOR XL	(+,-)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol	SHT reuptake inhibitor; noradrenalin reuptake inhibitor; dopamine reuptake inhibitor	depression; anxiety
Ebalzotan; NAE 086	(R)-3,4-dihydro-N-(1-methylethyl)-3-[(1-methylethyl)propylamino]-2H-1-benzopyran-5-carboxamide	5HT1A agonist; 5HT agonist	depression
L 0068; F 11440	4-methyl-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2,4-triazine-3,5(2H,4H)-dione	5HT1A agonist; 5HT agonist	anxiety; depression
LY 274600	(S)-1,2,3,4-tetrahydro-8-(methylthio)-N,N-dipropyl-2-naphthalenamine hydrochloride	5HT1A agonist; 5HT agonist	sexual dysfunction; depression; irritable bowel syndrome
LY 274601	(R)-1,2,3,4-tetrahydro-8-(methylthio)-N,N-dipropyl-2-naphthalenamoine hydrochloride	5HT1A agonist; 5HT agonist	sexual dysfunction; depression; irritable bowel syndrome

OPC 14523	1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4-dihydro-5-methoxy-2(1H)-quinolinone	SHT1A agonist; sigma agonist; 5HT agonist	depression; anxiety; obsessive compulsive disorder
F 12682; F 14258	N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(2-phenylethyl)-1-piperazinecarboxamide	SHT1B/SHT1D inverse agonist	depression
GMC 5036	Mirtazepine analogue	SHT2, 5HT3 antagonist; alpha 2 adrenergic antagonist; histaminergic antagonism;	depression
Levoprotiiline; levo-oxaprotiline; oxaprotiline, R-(-) enantiomer; CGP 12103A; CONSONAR	(R)-alpha-[(methylamino)methyl]-9,10-ethanoanthracene-9(10H)-ethanol	SHT2A, SHT2C SHT1A agonist alpha adrenergic agonist; SHT1D and histaminergic antagonist	depression
SB 243213	2,3-dihydro-5-methyl-N-[(6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-6-(trifluoromethyl)-1H-indole-1-carboxamide	SHT2C antagonist; 5HT antagonist	depression; anxiety
Zalospirone; WY 47846	(3aalpha,4beta,4aalpha,6aalpha,7beta,7aalpha)-3a,4,4a,6a,7,7a-hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4,7-etheno-1H-cyclobut[f]isoindole-1,3(2H)-dione	5HT3 antagonist	anxiety; depression
Drug delivery system; adenosine; adenosine drug delivery system; adenosine prodrug	adenosine 5'-(1,4-dihydrotrigonellinate)-2',3'-O-bis-benzoate	adenosine agonist	anxiety; depression

Midaxifylline; IRFI 117	8-(1-aminocyclopentyl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	cognitive defect; depression; kidney disease
MCI 225	4-(2-fluorophenyl)-2-methyl-6-(piperazin-1-yl)-3a,7a-dihydrothieno[2,3-d]pyrimidine	Adrenergic and serotonergic reuptake inhibitor	cognitive defect; depression
Adrafinil; adrafinil; CRL 40028; OLMIFON	2-[(diphenylmethyl)sulfonyl]N-hydroxyacetamide	alpha adrenergic agonist	neurological depression
Modafinil; CRL 40476; CEP 1538; MODIODAL; PROVIGIL; ALERTEC; MODASOMIL	2-[(diphenylmethyl)sulfonyl]acetamide	alpha adrenergic agonist	neurological depression
SDZ NVI085	(-)-(4aR,10aR)-3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-methylthio-2H-naphth[2,3,b]-1,4-oxazine	alpha adrenergic agonist; alpha1 adrenergic agonist	neurological depression; depression
Imiloxan; RS 21361	2-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-1-ethyl-1H-imidazole	alpha adrenergic antagonist	depression
ORG 6906		alpha adrenergic antagonist	depression
Setiptiline; teciptiline; MO 8282; ORG 8282; TECIPUL	2,3,4,9-tetrahydro-2-methyl-1H-dibenzo[3,4:6,7]cyclohepta[1,2-c]pyridine	alpha adrenergic antagonist	depression
Atipamezole; MPV 1248; ANTISEDAN	4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist	sexual dysfunction; alcoholism; depression; hypotension; diabetes; anxiety

CH 38083	[8aS-(8aalpha,11alpha,12aalpha,13aalpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizin-11-ol hydrochloride	alpha adrenergic antagonist; alpha2 adrenergic antagonist	depression
MK 912; L 657743	(2S-trans)-1,3,4,5',6,6',7,12b-octahydro-1',3'-dimethylspiro[2H-benzofuro[2,3-a]quinolizine-2,4'(1'H)-pyrimidin]-2'(3'H)-one monohydrochloride	alpha adrenergic antagonist; alpha2 adrenergic antagonist	depression
Idazoxan; RX 781094; RX 781094 A	2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist; antiproliferative agent	Parkinson disease; depression; cardiovascular disease; retinopathy
A 75200	(R*,R*)-(+,-)-3-phenyl-1-[(6,7,8,9-tetrahydronaphtho[1,2-d]-1,3-dioxol-6-yl)methyl]pyrrolidine	alpha adrenergic antagonist; alpha2 adrenergic antagonist; noradrenalin reuptake inhibitor	depression
Napitane; ABT 200; A 75200	(R*,R*)-(+,-)-3-phenyl-1-[(6,7,8,9-tetrahydronaphtho[1,2-d]-1,3-dioxol-6-yl)methyl]pyrrolidine	alpha adrenergic antagonist; alpha2 adrenergic antagonist; noradrenalin reuptake inhibitor	depression
ORG 9768		alpha adrenergic antagonist; alpha2 adrenergic antagonist; noradrenalin reuptake inhibitor	depression
Reboxetine; FCE 20124; FCE 21684; EDRONAX; PROLIFT	(R*,S*)-2-[(2-ethoxyphenoxy)phenylmethyl]morpholine	alpha adrenergic antagonist; alpha2 adrenergic antagonist; noradrenalin reuptake inhibitor	depression
AMPA receptor modulators,		AMPA receptor modulators	schizophrenia; depression

Dehydroepiandrosterone analogues; DHEA analogues,		androgen	atherosclerosis; depression
Drug delivery system, dehydroepiandrosterone; dehydroepiandrosterone delivery system; drug delivery system, DHEA		androgen	atherosclerosis; depression
Adinazolam; adinazolam mesylate; adinazolam mesilate; U 41123F; U 41123; DERACYN	8-chloro-N,N-dimethyl-6-phenyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine-1-methanamine	benzodiazepine	anxiety; depression
Flumazenil; flumazepil; flumenazil; Ro 151788; ANEXATE; MAZICON; LANEXAT; ROMAZICON	8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester	benzodiazepine antagonist	neurological depression; liver disease
Flerobuterol	alpha-[(1,1,dimethylethyl)amino]methyl]-2-fluorobenzenemethanol	beta adrenergic agonist	depression
SR 56811; SR 58611A; SR 58611; ME 3411	[R-(R*,S*)]-[[7-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]acetic acid ethyl ester hydrochloride	beta adrenergic agonist; beta3 adrenergic agonist	irritable bowel syndrome; obesity; depression
KP 840	diethyl 1,4-dihydro 2,6-dimethyl-4-(3-ethynyl phenyl)-3,5-pyridine-dicarboxylic acid	calcium antagonist	ischemia; depression
Topiramate; KW 6485; McN 4853; RWJ 17021; TOPAMAX	2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate	carbonate dehydratase inhibitor; sodium channel blocker; AMPA antagonist; GABA agonist; glutamate antagonist	epilepsy; psychosis; depression

CMI 477	(1S-exo)-2-(6-chloro-3-pyridinyl)-7-azabicyclo[2.2.1]heptane	cholinergic agonist; nicotinic agonist; analgesic	obesity; depression; Alzheimer disease; nicotine withdrawal
Corticotropin releasing factor analogue		CRF analogue	anxiety; depression
AXC 2219		CRF antagonist	depression; anxiety
AXC 4007		CRF antagonist	depression; anxiety
CRA 1000	INDEX NAME NOT YET ASSIGNED	CRF antagonist	depression; anxiety
CRA 1001		CRF antagonist	depression; anxiety
CRF antagonist,		CRF antagonist	depression; anxiety
CRF antagonists		CRF antagonist	depression; anxiety
CRF receptor antagonist; corticotropin releasing factor antagonist		CRF antagonist	depression
CRF2 antagonists,		CRF antagonist	depression; anxiety
NBI 103		CRF antagonist	depression; eating disorder
NBI 104		CRF antagonist	depression; stroke
NBI 30545	3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propylpyrazolo[1,5-a]pyrimidin-7-amine	CRF antagonist	anxiety; depression
NBI 30775; R 121919		CRF antagonist	anxiety; depression; addiction
NGD 981; NGD 98-1		CRF antagonist	depression; anxiety
PD 171729	butyl-[3[(2,4-dichloro-phenyl)-2,5-dimethyl-pyrazolo(1,5-a)pyrimidin-7-yl]-ethyl-amine	CRF antagonist	anxiety; depression
Pivagabine; PG 2; TONERG	4-[(2,2-dimethyl-1-oxopropyl)amino]butanoic acid	CRF modulation	depression

DMP 695	N-(2-chloro-4,6-dimethylphenyl)-1-[2-methoxy-1-(methoxymethyl)ethyl]-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine monomethanesulfonate	CRH antagonist	anxiety; depression
SA 627	N-(2-bromo-4,6-dimethoxyphenyl)-N-ethyl-4-methyl-6-(4-morpholinyl)-1,3,5-triazin-2-amine	CRH antagonist	depression; anxiety
SC 241		CRH antagonist	anxiety; depression
Etrabamine; JL 14839	4,5,6,7-tetrahydro-N-methyl-6-benzothiazolamine	dopamine agonist	depression
MR 708	N-acetyl-DL-phenylalanine with tricyclo[3.3.1.13,7]decan-1-amine (1:1)	dopamine agonist	depression
Roxindole; EMD 62100; EMD 49980; EMD 62080	3-(4-(3,6-dihydro-4-phenyl-1(2H)-pyridyl)butyl)indol-5-ol	dopamine agonist; 5HT reuptake inhibitor	depression
Amisulpride; aminosulpride; AST; DAN 2163; SOCIAN; SOLIAN; ENORDEN; DENIBAN; SULAMID	4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy benzamide	dopamine agonist; dopamine antagonist	schizophrenia; depression
Pergolide; pergolide mesylate; LY 141B; LY 127809; PERMAX; CELANCE; PHARKEN; PARKOTIL	(8beta)-8-[(methylthio)methyl]-6-propylergoline	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	Parkinson disease; depression

Pramipexole; pramipexole dihydrochloride; SND 919; U 98528E; SND919CL2Y; PNU 98528E; SIFROL; MIRAPEX; DAQUIRAN; MIRAPEXIN; FIROL	(S)-2-amino-4,5,6,7- tetrahydro-6- (propylamino)- benzothiazole	dopamine agonist; dopamine D2 agonist; dopamine D3 agonist	Parkinson disease; schizophrenia; depression
GYKI 52895	4-(8-methyl-9H-1,3- dioxolo[4,5- h][2,3]benzodiazepin- 5-yl)-benzodiazepine	dopamine reuptake inhibitor	depression
HOE 249	(+)-2-[(3- chlorophenyl)-1H- imidazol-1- ylmethyl]tricyclo[3.3. 1.1(3,7)]decan-2-ol	dopamine reuptake inhibitor	depression
NS 2200		dopamine reuptake inhibitor	Parkinson disease; depression; addiction
OPC 14117	N-(2,3-dihydro-7- hydroxy-2,2,4,6- tetramethyl-1H- inden-1-yl)-4-(3- methoxyphenyl)-1- piperazineacetamide	free radical scavenger	neurological depression
GABA-based depression therapy,		GABA agonist	depression
CGP 35348	(3- aminopropyl)(diethoxy- methyl)phosphinic acid	GABA antagonist	depression
Suritazole; MDL 26479	2,4-dimethyl-5-(3- fluorophenyl)-3H- 1,2,4-triazole-3- thione	GABA inverse agonist	depression; cognitive defect
Valproate semisodium; divalproex sodium; semisodium valproate; AB 50711; DEPAKOTE; EPIVAL; VALCOTE	2-propylpentanoic acid sodium salt (2:1)	GABA receptor	epilepsy; migraine; schizophrenia; depression

Gabapentin; CI 945; GO 3450; GOE 2450; NEURONTIN	1-(aminomethyl)cyclohexaneacetic acid	GABA release; analgesic	epilepsy; anxiety; pain; neuropathy; psychosis; depression
ACPC; cycloleucine; cycloleucin; NSC 1026; WR 14997	1-aminocyclopentanecarboxylic acid	glutamate antagonist; NMDA antagonist	coronary artery disease; anxiety; depression; stroke; epilepsy; addiction
BN 50043	N-allyl N-isopropyl (p-chlorophenyl-4-piperidino)-2-acetamide hydrochloride	Imipramine binding site	depression
L 671776	3',4',4'a,5',6',7',8',8'a-octahydro-4,6'-dihydroxy-6-(hydroxymethyl)-2',5',5',8'a-tetramethylspiro[benzofuran-2(3H),1'(2'H)-naphthalene]-5-carboxaldehyde	inositol monophosphatase inhibitor	depression
Befloxatone; MD 370503	(R)-5-(methoxymethyl)-3-(p-((R)-4,4,4-trifluoro-3-hydroxybutoxy)phenyl)-2-oxazolidinone	MAO A inhibitor; MAO inhibitor	depression; anxiety; nicotine withdrawal
Brofaromine; CGP 11305A; CONSONAR	4-(7-bromo-5-methoxy-2-benzofuranyl)piperidine	MAO A inhibitor; MAO inhibitor	depression
BW 1370U87	1-ethylphenoxathiin 10,10-dioxide	MAO A inhibitor; MAO inhibitor	depression; anxiety
CS 8359; RS 8359	(+,-)-4-[(6,7-dihydro-7-hydroxy-5H-cyclopentapyrimidin-4-yl)amino]benzonitrile	MAO A inhibitor; MAO inhibitor	depression
E 2011	[R-(R*,S*)]-gamma-hydroxy-6-[5-(methoxymethyl)-2-oxo-3-oxazolidinyl]-2-benzothiazolebutanenitrile	MAO A inhibitor; MAO inhibitor	depression

Esuprone; LU 43839	ethanesulfonic acid 3,4-dimethyl-2-oxo-2H-1-benzopyran-7-yl ester	MAO A inhibitor; MAO inhibitor	depression
Moclobemide; Ro 111163; Ro 111163/000; AURORIX; MANERIX; ACULIX; MOCLAMINE	4-chloro-N-[2-(4-morpholinyl)ethyl]benzamide	MAO A inhibitor; MAO inhibitor	depression
Pirlindole; pyrasidol; pyrazidol; pyrazidole; LIFRIL; PYRAZIDOL; EUTHYM	2,3,3a,4,5,6-hexahydro-8-methyl-1H-pyrazino[3,2,1-jk]carbazole	MAO A inhibitor; MAO inhibitor	depression
Drug delivery system, controlled release selegiline; selegiline		MAO B inhibitor; MAO inhibitor	depression
Drug delivery system, transdermal selegiline; selegiline transdermal		MAO B inhibitor; MAO inhibitor	Alzheimer disease; depression
MDL 72145	(E)-(beta-fluoromethylene)-3,4-dimethoxybenzeneethanamine hydrochloride	MAO B inhibitor; MAO inhibitor	depression; Parkinson disease
KP 157		MAO inhibitor; MAO A inhibitor	depression
KP 9		MAO inhibitor; MAO A inhibitor	depression
T 794	(R)-3-[6-(cyclopropylmethoxy)-2-naphthalenyl]-5-(methoxymethyl)-2-oxazolidinone	MAO inhibitor; MAO A inhibitor	depression
SL 650477; SL 65.0477	[R-(R*,R*)]-5-(methoxymethyl)-3-[6-(4,4,4-trifluoro-3-hydroxybutoxy)-3-benzofuranyl]-2-oxazolidinone	MAO inhibitor; MAO A inhibitor; MAO B inhibitor; oxazolidinone	depression; Parkinson disease
Agomelatine; S 20098	N-[2-(7-methoxy-1-naphthalenyl)ethyl]acetamide	melatonin agonist	depression; insomnia

Melatonin modulators; melatonin analogues		Melatonin analogues	depression; infertility
Neuropeptide Y antagonists		neuropeptide Y antagonist; neuropeptide Y2 antagonist	hypotension; obesity; depression
RB 101	N-[2-[[[2-amino-4-(methylthio)butyl]dithio]methyl]-1-oxo-3-phenylpropyl]-L-phenylalanine phenylmethyl ester	neutral endopeptidase inhibitor	addiction; depression
EGYT 4201	ethanesulfonic acid compd. with 5-chloro-2-(2-imino-3-thiazolidinyl)benzamine (2:1)	Nonmomoaminergic action	depression
COR 3224	4,5-dihydro-5-((4-phenyl-1-piperazinyl)methyl)-2-oxazolamine	Nontricyclic action	depression
Minaprine; minaprine hydrochloride; minaprina; CB 30038; 30038 CB; AGR 1240; CANTOR; KANTOR; ALCAS; NORTIMIC; BRANTUR; ISOPULSAN	4-[2-[(4-methyl-6-phenyl-3-pyridazinyl)amino]ethyl]morpholine	Nontricyclic action	depression
Amfebutamone; bupropion hydrochloride; bupropion; bupropin; BW 323U; WELLBUTRIN; ZYBAN	(+,-)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone	noradrenalin reuptake inhibitor	depression; nicotine withdrawal; obesity
Beloxyepin; ORG 4428	cis-2,10-dimethyl-1,2,3,4,4a,13b-hexahydrodibenz-[2,3:6,7]oxepino [4,5-c]pyridin-4a-ol	noradrenalin reuptake inhibitor	depression

Dexnafenodone; LU 43706	(S)-2-[2-(dimethylamino)ethyl]-3,4-dihydro-2-phenyl-1(2H)-naphthalenone	noradrenalin reuptake inhibitor	depression
Hydroxynortriptyline	(E)-10-11-dihydro-5-[3-(methylamino)propylidene]-5H-dibenzo-[a,d]cyclohepten-10-ol	noradrenalin reuptake inhibitor	depression
Drug delivery system, sustained release milnacipran; milnacipran sustained release		noradrenalin reuptake inhibitor; 5HT reuptake inhibitor	depression
Milnacipran; midalcipran; midacipran; F 2207; TN 912; DALCIPRAN; IXEL	cis-(+,-)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide	noradrenalin reuptake inhibitor; 5HT reuptake inhibitor	depression
1555; 1555U88; BW 1555U88	[2S-(2alpha,3alpha,5alpha)]-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol hydrochloride	noradrenalin reuptake inhibitor; dopamine reuptake inhibitor	attention deficit disorder; nicotine withdrawal; depression; psychosis
Nalinefene; nalmetrene; JF 1; INCYSTENE; ARTHENE; FENARC; CERVENE; REVEX	17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol	opiate antagonist; NSAID	intoxication; alcoholism; pruritis; obesity; neurological depression; rheumatoid arthritis; cystitis; trauma
Oxytocin antagonist		oxytocin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
NS 1546		potassium channel modulator	depression
Potassium channel modulators		potassium channel modulator	cognitive defect; attention deficit disorder; depression; asthma; diabetes

Igmesine; igmacine; JO 1784	(+)-N-(1,4-diphenyl-3-butenyl)-N-methylcyclopropane methanamine	sigma agonist	depression; cognitive defect; diarrhea
SA 4503	1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride	sigma agonist	Alzheimer disease; depression; cognitive defect; stroke
GW 273293		sodium channel blocker	epilepsy; depression
Lamotrigine; BW 430C; LAMICTAL	6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine	sodium channel blocker	epilepsy; psychosis; depression
MK 869		substance P antagonist	depression; anxiety; schizophrenia; emesis
Sifaprazine; FI 4303	1-(2-(phenylmethyl)phenyl)-4-methylpiperazine hydrochloride	Tricyclic antidepressant activity	depression
Antidepressant	N'-[5-[(2-chlorophenyl)methylene]-4,5-dihydro-6-methyl-3-pyridazinyl]-N,N-dimethyl-1,2-ethanediamine	Unknown	depression
Antidepressant, PPRT 152	St. John's Wort herbal remedy extract	Unknown	depression
ATX 70	(SP-4-2)-[[N,N'-[[7,12-bis[1-(decyloxy)ethyl]-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-diyl-kappaN21,kappaN22, kappaN23,kappaN24]bis(1-oxo-3,1-propanediyl)]bis[L-aspartato]](6-)]gallate (3-) trihydrogen	Unknown	depression; cancer
Bipenamol; BW 647U	2-[2-(aminomethyl)phenyl]thio]benzenemethanol	Unknown	depression

BW 403U76		Unknown	depression
CGP 25454		Unknown	depression
CS 2232		Unknown	depression
Delfaprazine; FI 4310	1-(alpha2-phenyl-2,5-xylyl)-piperazine	Unknown	depression
Depression therapy		Unknown	depression
E 5505		Unknown	depression
ORG 12437		Unknown	depression
ORG 20091	5-chloro-4-(1,2,5,6-tetrahydro-1-methyl-3-pyridinyl)-2-thiazolamine (Z)-2-butenedioate (2:1)	Unknown	depression
YKP 10A		Unknown	depression
DGAVP; ORG 5667	8-L-arginine-9-deglycinamide devasopressin	Vasopressin	depression
Vasopressin antagonist,		vasopressin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure

Table 29. Current Candidate Therapeutic Interventions for the Treatment of Epilepsy

Product Name	Chemical Name	Action	Indication
MMPQ; SRC 820; SRC 820R	2-methyl-3-(3-methyl-2-pyridinyl)-4(3H)-quinazolinone	5HT neuromodulation	epilepsy
Adenosine regulating agents, epilepsy	Unspecified	adenosine regulating agent	epilepsy
Adenosine utilization inhibitors, epilepsy	Unspecified	adenosine regulating agent	epilepsy
GP 3269; GP 13269	7-(5-deoxy-beta-D-ribofuranosyl)-N-(4-fluorophenyl)-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine	adenosine regulating agent	epilepsy
SNAP 5114	1-[2-[tris(4-methoxyphenyl)methoxy]ethyl]-3-piperidinecarboxylic acid	amine uptake inhibitor	epilepsy; anxiety; insomnia

LY 215490	(3alpha,4alpha,6beta,8alpha)-decahydro-6-[2-(1H-tetrazol-5-yl)ethyl]-3-isoquinolinecarboxylic acid	AMPA antagonist; glutamate antagonist	epilepsy
LY 293558	[3S-(3alpha,4alpha,6beta,8alpha)]-decahydro-6-[2-(1H-tetrazol-5-yl)ethyl]-3-isoquinolinecarboxylic acid	AMPA antagonist; glutamate antagonist	heart ischemia; epilepsy
SYM 2189	Unspecified	AMPA antagonist; glutamate antagonist	stroke; epilepsy
SYM 2206	8-(4-aminophenyl)-5-methyl-N-propyl-1,3-dioxolo[4,5-g]phthalazine-6(5H)-carboxamide	AMPA antagonist; glutamate antagonist	stroke; epilepsy
Pregabalin; CI 1008; PD 144723	(S)-3-(aminomethyl)-5-methyl-hexanoic acid	analgesic	epilepsy; pain
mu-conopeptides	Unspecified	analgesic; peptide; sodium channel blocker	pain; epilepsy
ADD 196022	4-[(4-chlorophenyl)amino]-6-methyl-2-oxo-3-cyclohexene-1-carboxylic acid methyl ester	Antiepileptic agent with unspecified mechanism of action	epilepsy
ADD 55051	4-chlorobenzenesulfonamide	Antiepileptic agent with unspecified mechanism of action	epilepsy
AHN 649	(9alpha,13alpha,14alpha)-17-methyl-morphinan-3-amine	Antiepileptic agent with unspecified mechanism of action	epilepsy; neuropathy
Ameltolide; LY 201116; ADD 75073	4-amino-N-(2,6-dimethylphenyl)benzamide	Antiepileptic agent with unspecified mechanism of action	epilepsy
Anticonvulsant	(R)-7-[1-(4-chlorophenoxy)ethyl]-[1,2,4]triazolo[1,5-a]pyrimidine	Antiepileptic agent with unspecified mechanism of action	epilepsy

Anticonvulsants	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Antiepileptic	4-phenoxy-2-(4-propyl-1-piperazinyl)quinazoline	Antiepileptic agent with unspecified mechanism of action	epilepsy
Antiepileptic	(S)-2-amino-4,5-dihydro-5-(2-methylpropyl)-4-oxo-1H-imidazole-1-carboxylic acid phenylmethyl ester	Antiepileptic agent with unspecified mechanism of action	epilepsy
Antiepileptics	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
B 974	N-(alpha,alpha,alpha-trifluoro-m-tolyl)piperazino-2-acetamido-4-methylthiazole	Antiepileptic agent with unspecified mechanism of action	epilepsy
Benzoidazoxan	6,7-benzoidazoxan	Antiepileptic agent with unspecified mechanism of action	epilepsy
Carabersat; SB 204269; SB 204269EO	(3R-trans)-N-(6-acetyl-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-4-fluorobenzamide	Antiepileptic agent with unspecified mechanism of action	epilepsy
CGS 18416	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
CHF 2993	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
CHF 3381	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
D 20443	[2-amino-4-[[[4-fluorophenyl)methyl]amino]phenyl]carbamic acid ethyl ester dihydrochloride	Antiepileptic agent with unspecified mechanism of action	epilepsy

D 2624	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Endixaprine; SR 41378	1-[6-(2,4-dichlorophenyl)-3-pyridazinyl]-4-piperidinol	Antiepileptic agent with unspecified mechanism of action	epilepsy
F 721	5-[4-(trifluoromethyl)phenyl]-3-(diethylamino)-2,2-dimethylpropyl 2-furancarboxylic acid ester hydrochloride	Antiepileptic agent with unspecified mechanism of action	epilepsy
FCE 23819	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Harkoseride; ADD 234037	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Lodaxaprine; CM 40907	1-(6-(2-chlorophenyl)-3-pyridazinyl)-4-piperidinol	Antiepileptic agent with unspecified mechanism of action	epilepsy
Loreclezole; R 72063	(Z)-1-[2-chloro-2-(2,4-dichlorophenyl)ethenyl]-1H-1,2,4-triazole	Antiepileptic agent with unspecified mechanism of action	epilepsy
LY 193453	Amelotide derivative	Antiepileptic agent with unspecified mechanism of action	epilepsy
LY 228721	Bentamide amelotide derivative	Antiepileptic agent with unspecified mechanism of action	epilepsy
LY 274959	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
MS 16056	1-(3-phenyl-5-isoxazolyl)-3-(1-imidazolyl)-methylindole hydrochloride	Antiepileptic agent with unspecified mechanism of action	epilepsy
NPS 1776	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy

Oxcarbazepine; CGP 47680; KIN 493; GP 47680; TRILEPTAL; TOXECAR	10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide	Antiepileptic agent with unspecified mechanism of action	epilepsy; diabetes; neuropathy
Ro 70213	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
RWJ 37868	2-(4-chlorobenzoyl)-4-[(1-piperidinyl)acetyl]-1,3,5-trimethylpyrrole	Antiepileptic agent with unspecified mechanism of action	epilepsy
RX 751067	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
SL 900571	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Soretolide; D 2916	2,6-dimethyl-N-(5-methyl-3-isoxazolyl)benzamide; aryl-isoxazole carboxamide derivative	Antiepileptic agent with unspecified mechanism of action	epilepsy
Stiripentol; BCX 2600	4,4-dimethyl-1-[(3,4-methylenedioxy)phenyl]-1-penten-3-ol	Antiepileptic agent with unspecified mechanism of action	epilepsy
TV 141	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
TV 1901	Unspecified	Antiepileptic agent with unspecified mechanism of action	Epilepsy
Clobazam; HR 376; H 4723; LM 2717; NH 15; FRISIUM; CLIDIZAN; GRIFOCLOBAM; URBADAM; FRISIN; URBANYL; URBANIL; MYSTAN	7-chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4-(3H,5H)-dione	benzodiazepine	anxiety; epilepsy
GYKI 52466	1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine	benzodiazepine	epilepsy

Midazolam; Ro 213981/001; Ro 213981/003; HYPNOVEL; VERSED; DORMICUM	8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine	benzodiazepine	anxiety; epilepsy
Ro 417812	Unspecified	benzodiazepine	epilepsy
Ro 428773	Unspecified	benzodiazepine	epilepsy
FG 8205; L 663581	7-chloro-4,5-dihydro-5-methyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-6H-imidazo[1,5-a][1,4]benzodiazepin-6-one	benzodiazepine partial agonist	epilepsy; anxiety
CNS 1067	Unspecified	calcium antagonist	epilepsy
U 54494A	cis-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzamide monohydrochloride	calcium antagonist	epilepsy
NPS 846	Unspecified	calcium antagonist; analgesic	stroke; epilepsy; pain
Flunarizine; R 14950; FLUZINA; SIBELIUM; ZINASEN; SESNARBO; RIZENA; SINAZINE; HEADACHE; FLORIRATO; DIESPRUDEL	Unspecified	calcium antagonist; vasodilator	peripheral vascular disease; cerebrovascular disease; migraine; epilepsy
CNS 2103	Unspecified	calcium antagonist; venom	epilepsy
CPC 8027	Unspecified	calcium channel blocker	stroke; epilepsy
CPC 8029	Unspecified	calcium channel blocker	stroke; epilepsy
NS 696	Unspecified	calcium channel blocker	epilepsy
drug delivery system, conopeptides	Unspecified	calcium channel blocker; sodium channel blocker; potassium channel blocker; analgesic	epilepsy; Parkinson disease; stroke; pain; brain ischemia

DP 16	Acylglycerol derivative of BAPTA	Calcium chelation	epilepsy; stroke; heart ischemia
AO 78	Tetronic acid derivative, unspecified	Calcium ion modulator	epilepsy
Topiramate; KW 6485; McN 4853; RWJ 17021; TOPAMAX	2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate	carbonate dehydratase inhibitor; sodium channel blocker; AMPA antagonist; GABA agonist; glutamate antagonist	epilepsy; psychosis; depression
Losigamone; AO 33	5-[(2-chlorophenyl)hydroxymethyl)-4-methoxy-2(5H)-furanone; tetronic acid derivative	Chloride ion influx by GABA sensitive mechanism at a site distant from GABA	epilepsy
Levetiracetam; etiracetam, (S); UCB L059 (S); SIB S1 (S); UCB L060 (R); UCB 6474 (no stereo, etiracetam)	(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide	cholinergic agonist	epilepsy
Dopamine D4 receptor ligands	Unspecified	dopamine antagonist; dopamine D4 antagonist	attention deficit disorder; epilepsy; addiction
ADD 17014	4-[1-(4-chlorophenyl)-4,5-dihydro-1H-1,2,3-triazol-5-yl]pyridine	excitatory amino acid antagonist	epilepsy
Excitatory amino acid antagonists	Unspecified	excitatory amino acid antagonist	epilepsy; Alzheimer disease; stroke
NPC 18123	Unspecified	excitatory amino acid antagonist; glutamate antagonist	epilepsy; stroke
Dezinamide; AN 051; AHR 11748; ADD 94057	3-[(3-trifluoromethyl)phenoxy]-1-azetidinecarboxamide (desmethyl metabolite of fluzinamide)	Fluzinamide derivative	epilepsy
1-decylpyrrolidinone	1-decanoyl-2-pyrrolidinone	GABA agonist	epilepsy
1-dodecylpyrrolidinone	1-dodecanoyl-2-pyrrolidinone	GABA agonist	epilepsy

GABA agonist, XR 368 series	(2aR*,5aR,7E,11E,14aS*,14bS*,14cS*)-2a,5a,6,9,10,13,14,14a,14b,14c-decahydro-4-hydroxy-5a,9,9,12-tetramethyl-1,5-dioxacyclopenta[cd]cycloundec[flinden-3(2H)-one	GABA agonist	anxiety; epilepsy
Ganaxolone; CCD 1042	(3alpha,5alpha)-3-hydroxy-3-methyl-pregnan-20-one	GABA agonist	epilepsy; migraine
MDL 27192	5-(4-chlorophenyl)-4-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one	GABA agonist	epilepsy
PD 144550	(R)-3-(aminomethyl)-5-methylhexanoic acid	GABA agonist	epilepsy
R 7621	N1-(3-trifluoromethylphenyl)N2-nicotinoylpiperazine hydrochloride	GABA agonist	epilepsy
Vigabatrin; gamma vinyl GABA; GVG; RMI 71754; MDL 71754; RMI 71890; RMI 71894; SABRIL; SABRILEX	4-amino-5-hexenoic acid	GABA agonist	epilepsy; addiction
ZK 95962; ZK 45962	ethyl 5-isopropoxy-4-methoxymethyl-beta-carboline-3-carboxylate	GABA agonist	epilepsy; cognitive defect
Milacemide; CP 15525; CP 1552S	2-(pentylamino)acetamide	GABA agonist; MAO B inhibitor; MAO inhibitor	epilepsy; Parkinson disease
CGP 36742	(3-aminopropyl)butylphosphinic acid	GABA antagonist	epilepsy; Alzheimer disease
Rufinamide; CGP 33101; RUF 331	1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide	GABA antagonist	epilepsy

Gabapentin; CI 945; GO 3450; GOE 2450; NEURONTIN	1-(aminomethyl)cyclohexaneacetic acid	GABA modulation	epilepsy; anxiety; pain; neuropathy; psychosis; depression
NNC 138119	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine; benzodiazepine derivative	GABA modulation	epilepsy; anxiety
AWD 131138; AWD 131-138	1-(4-chlorophenyl)-1,5-dihydro-4-(4-morpholinyl)-2H-imidazol-2-one	GABA modulator	epilepsy; anxiety
Co 21068	(3alpha,5beta)-3-[(4-acetylphenyl)ethynyl]-21-(3-carboxy-1-oxopropoxy)-3-hydroxypregn-20-one sodium salt	GABA modulator	epilepsy
NNC 140189	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-5-(4-methyl-1-piperazinyl)-imidazo[1,5-a]quinazoline	GABA modulator	epilepsy
NS 2552	Unspecified	GABA modulator	anxiety; epilepsy
NS 2608	Unspecified	GABA modulator	epilepsy; anxiety
NS 2664	Unspecified	GABA modulator	epilepsy
Retigabine; D 23129; GKE 841	2-amino-4-[(4-fluorophenyl)methyl]amino]phenyl]carbamic acid ethyl ester	GABA modulator; potassium channel activator	epilepsy
Co 21970	(3alpha,5alpha)-3-hydroxy-3-(trifluoromethyl)-pregnan-20-one	GABA partial agonist; neuroactive steroid	epilepsy
Valproate magnesium; magnesium valproate; DEPAMAG; VALPAMAG	2-propylpentanoic acid magnesium salt	GABA release	epilepsy

Valproate semisodium; divalproex sodium; semisodium valproate; ABBOTT 50711; DEPAKOTE; EPIVAL; VALCOTE	2-propylpentanoic acid sodium salt (2:1)	GABA release	epilepsy; migraine; schizophrenia; depression
Valproate sodium; sodium valproate; NIK 240; SENITA; SELENICA	2-propylpentanoic acid sodium salt	GABA release	Alzheimer disease; epilepsy
CI 966	1-[2-[bis[4-(trifluoromethyl)phenyl]methoxy]ethyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid	GABA uptake inhibitor	epilepsy
NNC 711	1,2,5,6-tetrahydro-1-[2-[(diphenylmethylene)amino]oxy]ethyl]-3-pyridinecarboxylic acid monohydrochloride	GABA uptake inhibitor	epilepsy
Tiagabine; tiagabine hydrochloride; NO 050328; A 70569; NO 328; NNC 050328; NNC 328; NN 301; ABT 569; GABITRIL; TIABIX	(R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid	GABA uptake inhibitor	epilepsy
3-isobutyl GABA	3-(aminoethyl)-5-methylhexanoic acid	GAD modulation, L-glutamic acid decarboxylase	Epilepsy
SNAP 5294	Unspecified	GAT1 transporter	epilepsy; anxiety; insomnia
SNAP 5258	Unspecified	GAT3 transporter	epilepsy; anxiety; insomnia
NNC 079202; FG 9202	1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo(f)quinoxaline-7-sulfon amide	glutamate antagonist	epilepsy; stroke

Talampanel; LY 300164	(R)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine	glutamate antagonist; AMPA antagonist	epilepsy; amyotrophic lateral sclerosis
Excitatory amino acid antagonists	Unspecified	glutamate antagonist; excitatory amino acid antagonist; NMDA antagonist	epilepsy; neurodegeneration
CNS 2	Unspecified	glutamate antagonist; mGluR antagonist	epilepsy
NPS 2390	Unspecified	glutamate antagonist; mGluR antagonist	pain; epilepsy
ACPC; cycloleucine; cycloleucin; NSC 1026; WR 14997	1-aminocyclopentanecarboxylic acid	glutamate antagonist; NMDA antagonist	coronary artery disease; anxiety; depression; stroke; epilepsy; addiction
Dizocilpine; dizocilpine maleate; MK 801	(+)-10,11-dihydro-5-methyl-5H-dibenzo[a,d]cyclohepten-5,10-imine	glutamate antagonist; NMDA antagonist	epilepsy; stroke; neuropathy
drug delivery system, felbamate; felbamate drug delivery system	unspecified	glutamate antagonist; NMDA antagonist	epilepsy
Felbamate; W-554; ADD 03055; FELBATOL; FELBAMYL; TALOXA	2-phenyl-1,3-propanediol dicarbamate	glutamate antagonist; NMDA antagonist	epilepsy
GPI 3000; NPC 17742	[1R-[1alpha(R*),2alpha]]-alpha-amino-2-(2-phosphonoethyl)cyclohexane propanoic acid	glutamate antagonist; NMDA antagonist	epilepsy; stroke; neuropathy
L 701324	7-chloro-4-hydroxy-3-(3-phenoxyphenyl)-2(1H)-quinolinone	glutamate antagonist; NMDA antagonist	epilepsy; stroke
MDL 27266	5-(4-chlorophenyl)-4-ethyl-2,4-dihydro-2-methyl-3H-1,2,4-triazol-3-one	glutamate antagonist; NMDA antagonist	epilepsy
RPR 118723	Unspecified	glutamate antagonist; NMDA antagonist	epilepsy

YKP 509	Unspecified	glutamate antagonist; NMDA antagonist	epilepsy
Metabotropic glutamate receptor modulators	Unspecified	Glutamate receptor modulation	pain; cognitive defect; schizophrenia; epilepsy
CNS 1145	N,N'-bisacenaphth-5-ylguanidine	glutamate release inhibitor	epilepsy
glycine transporter modulator	Unspecified	glycine antagonist	epilepsy; cognitive defect
MDL 100458	3-(benzoylmethylamino)-6-chloro-1H-indole-2-carboxylic acid	glycine antagonist	epilepsy
L 687414	(3R-cis)-3-amino-1-hydroxy-4-methyl-2-pyrrolidone	glycine partial agonist	epilepsy
hBGT1 transporter modulator	Unspecified	hBGT1 transporter modulator	epilepsy; anxiety; insomnia
AQ 0145	4-[1-[(adamant-3-yl)iminomethyl]piperidin-4-yl]imidazole	histamine antagonist; histamine H3 antagonist	epilepsy
m-NBA	2-amino-3-(3-nitrobenzoyl)propanoic acid	kynurenine 3 hydroxylase inhibitor	epilepsy; Parkinson disease; Alzheimer disease
FCE 26743	(S)-2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]propanamide	MAO B inhibitor; MAO inhibitor	epilepsy
Remacemide, (-); FPL 14145; PR 1032646; PR 1032-646	(-)-2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide	NMDA antagonist	epilepsy
NMDA antagonists	Unspecified	NMDA antagonist; analgesic; glutamate antagonist	epilepsy; pain; brain ischemia
ACEA 1011	Unspecified	NMDA antagonist; glutamate antagonist	ischemia; epilepsy
CGP 37849	(E)-(+,-)-2-amino-4-methyl-5-phosphono-3-pentenoic acid	NMDA antagonist; glutamate antagonist	epilepsy
CGP 39551	(E)-(+,-)-2-amino-4-methyl-5-phosphono-3-pentenoic acid 1-ethyl ester	NMDA antagonist; glutamate antagonist	epilepsy

CGP 40116	[R-(E)]-2-amino-4-methyl-5-phosphono-3-pentenoic acid	NMDA antagonist; glutamate antagonist	epilepsy; stroke
D-CPP	(R)-4-(3-phosphonopropyl)-2-piperazinecarboxylic acid	NMDA antagonist; glutamate antagonist	epilepsy
FR 115427	(+)-1-methyl-1-phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride	NMDA antagonist; glutamate antagonist	epilepsy
L 701252	Unspecified	NMDA antagonist; glutamate antagonist	epilepsy
L 703717	7-chloro-4-hydroxy-3-[3-(4-methoxyphenyl)methylphenyl]-2(1H)-quinolinone	NMDA antagonist; glutamate antagonist	epilepsy; stroke
L 708541	Unspecified	NMDA antagonist; glutamate antagonist	epilepsy; stroke
LY 233536	(3R-(3alpha,4alpha,6beta,8aalpha))-decahydro-6-(1H-tetrazol-5-ylmethyl)-3-isoquinolinecarboxylic acid	NMDA antagonist; glutamate antagonist	epilepsy
LY 235723	(2R-cis)-4-(1H-tetrazol-5-ylmethyl)-2-piperidinecarboxylic acid	NMDA antagonist; glutamate antagonist	epilepsy
LY 274614	(3alpha,4alpha,6beta,8aalpha)-decahydro-6-(phosphonomethyl)-3-isoquinolinecarboxylic acid	NMDA antagonist; glutamate antagonist	epilepsy; neuropathy
MDL 100453	4-oxo-5-phosphono-D-norvaline	NMDA antagonist; glutamate antagonist	epilepsy; neuropathy; stroke
MDL 104653	7-chloro-4-hydroxy-3-phenyl-2(1H)-quinolinone	NMDA antagonist; glutamate antagonist	epilepsy

MDL 105519	(E)-3-(2-carboxy-2-phenylethethyl)-4,6-dichloro-1H-indole-2-carboxylic acid	NMDA antagonist; glutamate antagonist	anxiety; epilepsy
MDL 29814	5,7 dichlorokynurenic acid	NMDA antagonist; glutamate antagonist	epilepsy
NMDA antagonist	Unspecified	NMDA antagonist; glutamate antagonist	epilepsy; stroke; neuropathy
NPS 1387	Unspecified	NMDA antagonist; glutamate antagonist	epilepsy
Remacemide; FPL 12924; PR 934423; FPL 12924AA; PR 934423A; FPL 14144; PR 1032644; FPL 14145, PR 1032646	(+,-)-2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide	NMDA antagonist; glutamate antagonist	epilepsy; Parkinson disease; neurodegeneration
RPR 104632; RPR 110754	2-[(3-bromophenyl)methyl]-6,8-dichloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-3-carboxylic acid 1,1-dioxide	NMDA antagonist; glutamate antagonist	epilepsy
ACEA 1416; NMCQX	5-nitro-6-methyl-7-chloro-2,3-quinoxalinedione	NMDA antagonist; glutamate antagonist; analgesic	epilepsy; pain; brain ischemia
Conantokins	Unspecified	NMDA antagonist; glutamate antagonist; peptide; analgesic	epilepsy; stroke; schizophrenia; pain; ischemia
ADCI; SGB 017; ADCI	10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine-5-carboxamide	NMDA antagonist; glutamate antagonist; sodium channel blocker	epilepsy; stroke
oxytocin antagonist	Unspecified	oxytocin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
Conantokin G	Unspecified	peptide; glutamate antagonist; NMDA antagonist	stroke; brain ischemia; epilepsy

Fosphenytoin; fosphenytoin sodium; prophenytoin; ACC 9653; CI 982; PD 135711-15B; CEREBYX; PRO-EPANUTIN	5,5-diphenyl-3-[(phosphonoxy)methyl]-2,4-imidazolidinedione	Phenytoin prodrug; fosphenytoin converted to phenytoin by endogenous phosphatases	epilepsy
proline transport inhibitors	Unspecified	Proline transporter inhibitor	epilepsy; stroke
JNK 3 inhibitors	Unspecified	signal transduction inhibitor	epilepsy
Zonisamide; fenisoxine; AD 810; CI 912; PD 110843; EXCEGRAN; EXEGRAN; ZONEGRAN	1,2-benzisoxazole-3-methansulfonamide	Sodium and calcium voltage sensitive channel blockade	epilepsy
534U87; BW 534U87	Unspecified	sodium channel blocker	epilepsy
AWD 140190	4-(4-bromophenyl)-3-(4-morpholinyl)-1H-pyrrole-2-carboxylic acid, methyl ester	sodium channel blocker	epilepsy
Co 102862	2-[[4-(4-fluorophenoxy)phenyl]methylene]hydrazinecarboxamide	sodium channel blocker	epilepsy
GW 273293	Unspecified	sodium channel blocker	epilepsy; depression
Lamotrigine; BW 430C; LAMICTAL	6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine	sodium channel blocker	epilepsy; psychosis; depression
PNU 151774E	(2S)-2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]propanamide monomethanesulfonate	sodium channel blocker; calcium channel blocker; MAO B inhibitor; MAO inhibitor	epilepsy; Parkinson disease; brain ischemia
taurine transporter modulator	Unspecified	Taurine transporter inhibitor	epilepsy; brain ischemia
MDL 27531	4-methyl-3-(methylsulphonyl)-5-phenyl-4H-1,2,4-triazole		epilepsy

A 76895; ABBOTT 76895	Unspecified	Valproic acid derivative	epilepsy
Anticonvulsants	Unspecified	Valproic acid derivative	epilepsy
Antiepileptics	Unspecified	Valproic acid derivative	epilepsy
CHF 1504	Unspecified	Valproic acid derivative	epilepsy
RAP-valproic acid; DP VPA	Unspecified	Valproic acid derivative	epilepsy
ABS 103; ABS-103R	Unspecified	Valproic acid derivative	epilepsy
CHF 1355	Unspecified	Valproic acid derivative	epilepsy
Vasopressin antagonist	Unspecified	vasopressin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure.

Table 30. Current Candidate Therapeutic Interventions for the Treatment of Huntington's Disease

Product Name	Chemical Name	Action	Indication
Neurodegenerative disease therapy	Unspecified	apoptosis inhibitor	Neurodegeneration
Brain-derived neurotrophic factor; BDNF;	BDNF, and derivatives	BDNF, growth factor; neurotrophic factor	amyotrophic lateral sclerosis; neuropathy
Dopamine release inhibitor	Unspecified	Calcium antagonist	schizophrenia
Cardiotrophin-1 secreting implant; cardiotrophin-1 secreting implant	Cardiotrophin-1 and derivatives	Cardiotrophin-1; growth factor	amyotrophic lateral sclerosis; neurodegeneration
Tacrine; THA; tetrahydroaminacrine; CI 970; COGNEX	1,2,3,4-tetrahydro-9-acridinamine	cholinesterase inhibitor	Alzheimer disease
AXOKINE	Ciliary neurotrophic factor derivative	CNTF, growth factor	amyotrophic lateral sclerosis; obesity; eye disease
Ciliary neurotrophic factor; CNTF; CNTF delivery system	CNTF and derivatives	CNTF, growth factor	amyotrophic lateral sclerosis; neuropathy

Estrogens	Estrogen and derivatives	estrogen	neuropathy; Alzheimer disease
SYM 2101	Unspecified	glutamate agonist; AMPA partial agonist	neurological
SYM 2250	Unspecified	glutamate agonist; AMPA partial agonist	neurological
SYM 2007	Unspecified	glutamate agonist; kainate partial agonist	neurological
SYM 2192	Unspecified	glutamate agonist; kainate partial agonist	neurological
SYM 1010	Unspecified	glutamate agonist; NMDA partial agonist	neurological
SYM 2315	Unspecified	glutamate agonist; NMDA partial agonist	neurological
Riluzole; PK 26124; RP 54274; RILUTEK	6-(trifluoromethoxy)-2-benzothiazolamine	glutamate antagonist	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
MAb, major histocompatibility complex I; F(ab')2, MHC I	Monoclonal antibody fragment	Immunomodulation	transplant rejection
Nerve growth factor secreting implant	NGF and derivatives	NGF, growth factor	Neurodegeneration; neuropathy
Remacemide; FPL 12924; PR 934423; FPL 12924AA; PR 934423A; FPL 14144; PR 1032644; FPL 14145, PR 1032646	(+,-)-2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide	NMDA antagonist; glutamate antagonist	epilepsy; Parkinson disease; neurodegeneration
Idebenone; CV 2619; AVAN; LUCEBANOL; GENICERAL; MNESIS; DARUMA; NEMOCEBRAL; KEDANON; ARZKAT; DAYSTROM	2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione	Nootropic agent	cognitive defect
Neurotrophin-3 secreting implant	NT-3 and derivatives	NT-3, growth factor	Alzheimer disease; Parkinson disease; neuropathy
Neurotrophin-4; NT-4	NT-4 and derivatives	NT-4, growth factor	neuropathy; diabetes

Nalmefene; nalmetrene; JF 1; INCYSTENE; ARTHENE; FENARC; CERVENE; REVEX	17- (cyclopropylmethyl)- 4,5alpha-epoxy-6- methylenemorphinan- 3,14-diol	opiate antagonist; NSAID	intoxication; alcoholism; pruritis; obesity; neurological depression; rheumatoid arthritis; cystitis; trauma
Synthetic opioid alkaloids	Unspecified	Opioid ligand	Neurodegeneration

Table 31. Current Candidate Therapeutic Interventions for the Treatment of Migraine

Product Name	Chemical Name	Action	Indication
ALX 0646	Unspecified	5HT agonist	migraine
CP 122288	(R)-N-methyl-3-[(1-methyl-2-pyrrolidinyl)methyl]-1H-indole-5-methanesulfonamide	5HT agonist	migraine
IS 159	Unspecified	5HT agonist	migraine
avitiptan; avitiptan fumarate; BMS 180048; BMS 18004802	3-[3-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]propyl]-N-methyl-1H-indole-5-methanesulfonamide	5HT agonist; 5HT1 agonist	migraine
BW 324C91	Unspecified	5HT agonist; 5HT1 agonist	migraine
CP 110330	N,N-dimethyl-5-[4-[(phenylamino)methyl]-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
CP 119333	N,N-dimethyl-5-[4-(phenylmethyl)-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
D 1997	2-quinolineethanamine	5HT agonist; 5HT1 agonist	migraine
GR 127607	Unspecified	5HT agonist; 5HT1 agonist	migraine
GR 40370	Unspecified	5HT agonist; 5HT1 agonist	migraine

Naratriptan; naratriptan hydrochloride; GR 85548; GR 85548A; GR 85548X; NARAMIG; AMERGE	N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide	5HT agonist; 5HT1 agonist	migraine
Sumatriptan; GR 43175; GR 43175X; GR 43175A; GR 43175C; SN 308; GW 102; IMIGRAN; IMITREX; SUMADOL; IMIJECT; ARCOIRAN	3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide	5HT agonist; 5HT1 agonist	migraine
tonabersat; SB 220453	(3S-cis)-N-(6-acetyl-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-3-chloro-4-fluorobenzamide	5HT agonist; 5HT1 agonist	migraine
CP 93129	1,4-dihydro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-5H-pyrido[3,2-b]pyridin-5-one	5HT agonist; 5HT1B agonist	migraine
Frovatriptan; VML 251; SB 209509; MIGUARD	(R)-2,3,4,9-tetrahydro-3-(methylamino)-1H-carbazole-6-carboxamide	5HT agonist; 5HT1B agonist; 5HT1D agonist	migraine
rizatriptan; rizatriptan benzoate; rizatriptan sulfate; MK 462; MAXALT	N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine	5HT agonist; 5HT1B agonist; 5HT1D agonist	migraine
Almotriptan; LAS 31416	1-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidine	5HT agonist; 5HT1D agonist	migraine

alniditan; R 91274; PASMIGREN; PASMIGRINE	(R)-N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine	5HT agonist; 5HT1D agonist	migraine
ALX 1323	Unspecified	5HT agonist; 5HT1D agonist	migraine
aromatic triflates,	Unspecified	5HT agonist; 5HT1D agonist	depression; migraine
eletriptan; UK 116044; RELPAX	(R)-3-[(1-methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-indole	5HT agonist; 5HT1D agonist	migraine
GMC 2020	Unspecified	5HT agonist; 5HT1D agonist	depression; migraine
GMC 2021	Trifluoromethanesulfonic acid 3-[2-(dimethylamino)ethyl]-1H-indol-5-yl ester (1:1) ethanedioate	5HT agonist; 5HT1D agonist	depression; migraine
L 741519	3-(1-methyl-4-piperidinyl)-5-(4H-1,2,4-triazol-4-yl)-1H-indole	5HT agonist; 5HT1D agonist	migraine
L 741604	N,N-dimethyl-5-(4H-1,2,4-triazol-4-yl)-1H-indole-3-ethanamine	5HT agonist; 5HT1D agonist	migraine
LAS 31727	Unspecified	5HT agonist; 5HT1D agonist	migraine
VS 395	3-[3-[4-(5,6-dimethoxy-4-pyrimidinyl)-1-piperazinyl]propyl]-N-methyl-1H-indole-5-methanesulfonamide	5HT agonist; 5HT1D agonist	migraine

F 11356; L 0076	1-[[3-(2-aminoethyl)-1H-indol-5-yl]oxy]acetyl]-4-(4-cyanophenyl)piperazine monohydrochloride	5HT agonist; 5HT1D agonist; 5HT1B agonist	migraine
Zolmitriptan; 311C90; BW 311C90; ZOMIG	(S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone	5HT agonist; 5HT1Dalpha agonist; 5HT1Dbeta agonist; 5HT1B agonist	migraine
LY 334370	4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide	5HT agonist; 5HT1F agonist	migraine
selective serotonin 1F receptor agonists,	Unspecified	5HT agonist; 5HT1F agonist	migraine
Sergolexole; LY281067	trans-4-methoxycyclohexyl 1-isopropyl-6-methylergoline-8beta-carboxylate	5HT antagonist; 5HT2 antagonist	migraine
tropoxin	O-(3,4,5-trimethoxybenzoyl)oxime-8-methyl-8-azabicyclo[3.2.1]octan-3-one monohydrochloride	5HT antagonist; 5HT2 antagonist	migraine
dotarizine; FI 6026	1-(diphenylmethyl)-4-[3-(2-phenyl-1,3-dioxolan-2-yl)propyl]piperazine	5HT antagonist; 5HT2 antagonist; 5HT1C antagonist; calcium antagonist	migraine
Bemesetron; MDL 72222	3,5-dichlorobenzoic acid, endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester	5HT antagonist; 5HT3 antagonist	emesis; migraine
LY 53857	(8beta)-6-methyl-1-(1-methylethyl)ergoline-8-carboxylic acid 2-hydroxy-1-methylpropyl ester,(Z)-2-butenedioate (1:1)	5HT antagonist; vasodilator	migraine

fluoxetine, (R)-; (R)-fluoxetine	(R)-N-methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine	SHT reuptake inhibitor	migraine; cognitive defect; depression
fluoxetine, (S)-; (S)-fluoxetine	(S)-N-methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine	SHT reuptake inhibitor	migraine
5HT4 human neuroreceptor; neuroreceptor, 5HT4	Unspecified	5HT4 human neuroreceptor;	Irritable bowel syndrome; cognitive defect; anxiety; arrhythmia; stroke; urinary incontinence; migraine; research tool
drug delivery system, transdermal lidocaine; PAINTROL TW; PAINTROL HM; PAINTROL TV	unspecified	analgesic	pain; migraine
CNS 5161	N'-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-(methylthio)phenyl]guanidine monohydrochloride	analgesic; NMDA antagonist; glutamate antagonist	pain; migraine; neuropathy
nebivolol; narbivolol; R 67555; R 65824; ME 3255; R 67138; R 67145; R 065824; NEBILET; LOBIVON	[2R*[R*[R*(S*)]]]-alpha,alpha'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol]	beta adrenergic antagonist; beta1 adrenergic antagonist; nitric oxide activator, vasodilator	hypertension; migraine; heart failure
drug delivery system, intranasal propranolol; propranolol intranasal; MIGRASTAT	Unspecified	beta adrenergic antagonist; beta2 adrenergic antagonist	migraine
Bradykinin antagonist/mu agonist,	Unspecified	bradykinin antagonist; mu agonist; opiate agonist; analgesic; NSAID	Inflammation; pain; migraine

calcitonin gene-related peptide (CGRP) receptor modulators,	Unspecified	Calcitonin gene related peptide modulation	migraine; diabetes
Nimodipine; BAY e 9736; BAY N 5248; BAY N 5427; NIMOTOP; NIMOTAP; NIVAS; TROPOCER; EUGERIAL; NIMODILAT; CEBROFORT; KENESIL; GENOVOX	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester	calcium antagonist	migraine; cognitive defect; Alzheimer disease; brain ischemia
Flunarizine; R 14950; FLUZINA; SIBELIUM; ZINASEN; SESNARBO; RIZENA; SINAZINE; HEADACHE; FLORIRATO; DIESPRUDEL	Unspecified	calcium antagonist; vasodilator	peripheral vascular disease; cerebrovascular disease; migraine; epilepsy
Lomerizine; KB 2796; TERRANAS TAB; MIGSIS	1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine	calcium antagonist; vasodilator	hypertension; migraine
BIBN 4096	Unspecified	CGRP antagonist	migraine
botulinum toxin type A; Clostridium botulinum toxin type A; OCULINUM; BOTOX	botulin A	cholinergic antagonist; muscle relaxant	muscle spasm; eye disease; migraine
Ganaxolone; CCD 1042	(3alpha,5alpha)-3-hydroxy-3-methyl-pregnan-20-one	GABA agonist	epilepsy; migraine
valproate semisodium; divalproex sodium; semisodium valproate; ABBOTT 50711; DEPAKOTE; EPIVAL; VALCOTE	2-propylpentanoic acid sodium salt (2:1)	GABA releasing agent	epilepsy; migraine; schizophrenia; depression

4991 W93	Unspecified	Inflammation inhibitor	migraine
FK 888	trans-4-hydroxy-1-[(1-methyl-1H-indol-3-yl)carbonyl]-L-propyl-N- methyl-3-(2-naphthalenyl)-N-(phenylmethyl)-L-alaninamide	neurokinin antagonist	asthma; migraine
lanepitant; LY 303870	(R)-N-[2-acetyl[(2-methoxyphenyl)methyl]amino]-1-(1H-indol-3-ylmethyl)ethyl]-[1,4'-bipiperidine]-1'-acetamide	neurokinin antagonist; analgesic; neurokinin 1 antagonist	asthma; pain; migraine
GR 205171	(2S-cis)-N-[(2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl)methyl]-2-phenyl-3-piperidinamine	neurokinin antagonist; neurokinin 1 antagonist	emesis; migraine
neutral endopeptidase; NEP	Unspecified	neutral endopeptidase; proteinase; metalloproteinase	cancer; migraine; inflammatory bowel disease; inflammation; asthma; respiratory disease
nitric oxide inhibitor, unspecified	nitric oxide inhibitor	nitric oxide inhibitor	migraine
diclofenac potassium; CGP 45840B; CATAFLAM; CATAFLAN; DICLOFEN; VOLTAREN	potassium (o-(2,6-dichloroanilino)-phenyl)acetate	NSAID	Inflammation; migraine; surgery
dapitan; RPR 100893	3aS-[2(R*),3aalpha,4beta,7aalpha]-octahydro-4-(2-methoxyphenyl)-2-[2-(2-methoxyphenyl)-1-oxopropyl]-7,7-diphenyl-1H-isoindol-4-ol	substance P antagonist; NSAID	asthma; inflammation; migraine

BMS 182246	Unspecified	Sumitriptan-like activity	migraine
ALX 0625	Unspecified	Unspecified	migraine
BMS 181885	3-[[3-[3-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]propyl]-1H-indol-5-yl]amino]-4-methyl-3-cyclobutene-1,2-dione	Unspecified	migraine
drug delivery system, solid liquid polymer, migraine therapy	Unspecified	Unspecified	migraine
migraine therapy	Unspecified	Unspecified	migraine
Parthenolide	Unspecified	Unspecified	migraine
SB 218842	Unspecified	Unspecified	migraine

Table 32. Current Candidate Therapeutic Interventions for the Treatment of Multiple Sclerosis

Product Name	Chemical Name	Action	Indication
RG 13577	(4-hydroxyphenoxy)acetic acid, polymer with formaldehyde monoammoniate	angiogenesis inhibitor; FGF antagonist	restenosis; multiple sclerosis
VLA4 integrin antagonist,	unspecified	cell adhesion inhibitor; integrin antagonist; VLA 4 antagonist; NSAID	asthma; rheumatoid arthritis; multiple sclerosis
drug delivery system, corticotropin; corticotropin delivery system; drug delivery system, ACTH	Unspecified	Corticotropin; hormone	multiple sclerosis
interferon agonists,	Unspecified	cytokine agonist; NSAID	cancer; viral infection; infectious disease; multiple sclerosis
gene therapy, cytokines,	Unspecified	cytokine; immunosuppressant	autoimmune disease; rheumatoid arthritis; diabetes; multiple sclerosis

Interleukin-10; IL-10; cytokine synthesis inhibitory factor; CSIF; SCH 52000; TENOVIL	interleukin 10 (human clone pH15C)	cytokine; vaccine adjuvant; immunosuppressant; NSAID	autoimmune disease; inflammatory bowel disease; rheumatoid arthritis; multiple sclerosis; psoriasis; HIV infection; viral infection
Spirogermanium; NSC 192965; SPIRO-32	8,8-diethyl-N,N-dimethyl-2-aza-8-germaspiro[4.5]decan-2-propanamine	DMARD; NSAID	malaria; multiple sclerosis; rheumatoid arthritis; cancer
SRI 62834	(+,-)- 2-[[hydroxy[[tetrahydro-2-[(octadecyloxy)methyl]-2-furanyl]methoxy]phosphinyl]oxy]-N,N,N-trimethyl-ethanamium, inner salt.	ether lipid	cancer; multiple sclerosis
Transforming growth factor beta 2; TGF beta2; FOVALIN; BetaKine	Unspecified	growth factor; cicatrizant	retinopathy; osteoporosis; skin ulcer; multiple sclerosis
GPI 1046	1-(3,3-dimethyl-1,2-dioxopentyl)-L-proline 3-(3-pyridinyl)propyl ester	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
NIL-A	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
neural progenitor regulatory factor	Unspecified	growth factor; peptide; neurotrophic factor	multiple sclerosis; trauma; neurodegeneration
AG 284	MHC molecule with myelin basic protein	Immunomodulation	multiple sclerosis
Multiple sclerosis therapy	Chimeric virus particles	Immunomodulation	multiple sclerosis
Oligodendroglial trophic factor; OTF	Peptide	Immunomodulation	multiple sclerosis
RecepTox-MBP	peptide; fusion toxin	Immunomodulation	multiple sclerosis

MAb, 23F2G; MAb, leukointegrin; Hu 23F2G; Leuk Arrest	23F2G; MAb, leukointegrin monoclonal antibody	Immunomodulation;	multiple sclerosis; cardiovascular disease; myocardial infarction; stroke
MAb, OX40-ricin A; immunotoxin OX40-ricin A	Immunotoxin monoclonal antibody;	Immunomodulation;	multiple sclerosis
MAb, alpha4beta1 integrin; AN 100226; ANTEGREN	Unspecified	Immunomodulation; monoclonal antibody	multiple sclerosis; Crohn disease; ulcerative colitis
MAb, M1	Unspecified	Immunomodulation; monoclonal antibody	trauma; multiple sclerosis
MAb, humanized, leukemia; MAb, IgG2B; LDP 03; BW 7U; CAMPATH; CAMPATH-1H	Unspecified	Immunomodulation; monoclonal antibody; NSAID	rheumatoid arthritis; cancer; multiple sclerosis; transplant rejection
ABR 215062	Unspecified	Immunomodulator	multiple sclerosis
Glatiramer acetate; copolymer 1; COP 1; COPAXONE	L-glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt)	Immunomodulator	multiple sclerosis
PA 1093	Herpes virus 6 protein derivative	Immunomodulator	multiple sclerosis
Roquinimex; LS 2616; FCF 89; LINOMIDE	1,2-dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide	immunostimulant	multiple sclerosis
AI 101	Unspecified	immunosuppressant	multiple sclerosis
AI 102	Unspecified	immunosuppressant	multiple sclerosis
Galaptin L-14-1; immunomodulatory lectin-1; IML-1	Unspecified	immunosuppressant	transplant rejection; multiple sclerosis
PEPTIMER	Unspecified	immunosuppressant	autoimmune disease; multiple sclerosis; rheumatoid arthritis; diabetes
AI 100; MYLORAL	Unspecified	immunosuppressant	multiple sclerosis

Gusperimus; gusperimus hydrochloride; deoxyspergualin, 15-; desoxyspergualin; DSG; NKT 01; NSC 356894; BMS 181173; BMY 42215-e; SPANIDIN; SUPANIDIN	(+,-)-7-[(aminoiminomethyl)amino]-N-[2-[[4-[(3-aminopropyl)amino]butyl]amino]-1-hydroxy-2-oxoethyl]heptanamid	immunosuppressant	transplant rejection; multiple sclerosis; cancer
MAb, gamma interferon, humanized; SMART anti-gamma interferon	Unspecified	immunosuppressant monoclonal antibody;	systemic lupus erythematosus; multiple sclerosis
Lymphocyte activation gene 3 protein; LAG 3 protein	Unspecified	immunosuppressant; biotechnology	transplant rejection; multiple sclerosis
MP 4	Unspecified	immunosuppressant; biotechnology; apoptosis inducer	multiple sclerosis
ATP 012; TP 12	Unspecified	immunosuppressant; biotechnology; peptide	multiple sclerosis
MAb, T cell antigen receptor; ATM 027; TM 27	Unspecified	immunosuppressant; monoclonal antibody;	multiple sclerosis
Priliximab; MAb, humanized CD4; cM-T412; CEN 000029; CENTARA	Immunoglobulin G1 (human-mouse monoclonal cm-T412 anti-human antigen CD 4), disulfide with human-mouse monoclonal cm-T412.kappa.-chain, dimer	immunosuppressant; monoclonal antibody; NSAID	multiple sclerosis; autoimmune disease; rheumatoid arthritis
Lenercept; tumor necrosis factor receptor fusion protein; TNF receptor fusion protein; Ro 452081; TENEFUSE	Unspecified	immunosuppressant; NSAID	rheumatoid arthritis; asthma; septic shock; multiple sclerosis

MAb, CD40 ligand; SC8; ANTOVA	Unspecified	immunosuppressant; NSAID	inflammation; systemic lupus erythematosus; multiple sclerosis
Autoimmune disease therapy,	Unspecified	immunosuppressant; NSAID	rheumatoid arthritis; multiple sclerosis; systemic lupus erythematosus
Cladribine; 2-CdA; NSC 105014F; RWJ 26251; LEUSTATIN; LEUSTAT; MYLINAX	2-chloro-2'-deoxyadenosine	immunosuppressant; nucleoside analogue; NSAID	cancer; multiple sclerosis; rheumatoid arthritis
ZAP inhibitors, Ariad	unspecified	immunosuppressant; protein kinase inhibitor; tyrosine kinase inhibitor; NSAID	transplant rejection; rheumatoid arthritis; inflammatory bowel disease; systemic lupus erythematosus; multiple sclerosis
alpha4beta1 integrin antagonist	Unspecified	integrin antagonist; cell adhesion inhibitor; alpha4 beta1 integrin antagonist	multiple sclerosis
VLA-4 antagonists, inflammatory diseases; BIO 1211	N-[[4-[[[(2-methylphenyl)amino] carbonyl]amino]phenyl]acetyl]-L-leucyl-L-alpha-aspartyl-L-valyl-L-proline	integrin antagonist; VLA 4 antagonist	asthma; multiple sclerosis
Interferon beta-1a; IFN beta; AVONEX	interferon beta-1a	interferon	viral infection; multiple sclerosis; cancer
Interferon beta-1a; interferon beta; IFN-beta; REBIF	Unspecified	interferon	cancer; viral infection; multiple sclerosis; inflammatory bowel disease
Interferon beta-1b; interferon beta-serine; SH 579; ZK 157046; BETASERON; BENESERON; BETAFERON	2-166-interferon beta 1 (human fibroblast reduced)	interferon	multiple sclerosis; cancer; viral infection
Interferon tau	Unspecified	interferon	multiple sclerosis

alpha interferon, natural; OMNIFERON	Unspecified	interferon	multiple sclerosis; viral infection
Interferon beta; FRONE	Unspecified	interferon	multiple sclerosis; cancer; eye disease
Solimastat; BB 3644	(2S,3R)-3-[(1S)-2,2-dimethyl-1-(2-pyridylcarbamoyl)propyl]carbamoyl]-2-methoxy-5-methylhexanohydroxamic acid	matrix metalloproteinase inhibitor; TNF inhibitor; proteinase inhibitor	multiple sclerosis; rheumatoid arthritis; inflammatory bowel disease; cancer
LG 21101	Unspecified	NSAID	inflammation; multiple sclerosis
NBI 116	Unspecified	NSAID	multiple sclerosis; rheumatoid arthritis
PKC-RACK interaction inhibitors, white blood cell migration inhibitors,	Unspecified	NSAID; PKC-RACK interaction inhibitors	arthritis; multiple sclerosis; asthma
Neurotactin-blockers	Unspecified	NSAID; white blood cell migration inhibitors,	inflammation; multiple sclerosis
Lexipafant; BB 882; DO 6; GR 167089; ZACUTEX	N-methyl-N[[4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonyl]-L-leucine ethyl ester	PAF antagonist	thrombosis; endotoxic shock; pancreatitis; eye disease; multiple sclerosis
Ginkgolide B; BN 52021	hexacyclic trilactone	PAF antagonist; platelet antiaggregant	thrombosis; dermatitis; asthma; multiple sclerosis; septic shock
CGP 77116	Unspecified	peptide	multiple sclerosis
Multiple sclerosis therapy	Unspecified	peptide	multiple sclerosis
Multiple sclerosis therapy	Unspecified	peptide	multiple sclerosis
Multiple sclerosis therapy	Unspecified	peptide	multiple sclerosis
NBI 114	Unspecified	peptide	multiple sclerosis
NBI 115	Unspecified	peptide	multiple sclerosis

NBI 5788; MSP 771	D-ala-L-lys-L-pro-L-val-L-val-L-his-L-leu-L-phe-L-ala-L-asn-L-ile-L-val-L-thr-L-pro-L-arg-L-thr-L-pro	peptide	multiple sclerosis
rD-mPGptide	Unspecified	peptide; immunosuppressant	transplant rejection; multiple sclerosis
TNF receptor antagonist; TNF receptor antagonist, rolipram; ZK 62711; ME 3167; ADEO	Unspecified	peptide; NSAID	rheumatoid arthritis; multiple sclerosis
SH 636	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	multiple sclerosis
drug delivery system, IPDAS fampridine; fampridine IPDAS	Unspecified	potassium channel blocker	multiple sclerosis; neuropathy
Fampridine; EL 970; AVITROL	4-pyridinamine	potassium channel blocker	multiple sclerosis
adapalene; CD 271; DIFFERINE; DIFFERIN	6-(4-methoxy-3-tricyclo[3.3.1.1(3,7)]dec-1-ylphenyl)-2-naphthalenecarboxylic acid	retinoid agonist; retinoid; RAR agonist; RARbeta agonist	acne; multiple sclerosis
drug delivery system, biodegradable micellar paclitaxel; paclitaxel micellar	Unspecified	Taxane; DMARD; NSAID; microtubule inhibitor	rheumatoid arthritis; multiple sclerosis
CC 1080	Unspecified	TNF inhibitor; NSAID	arthritis; cancer; multiple sclerosis
MNX 160	Unspecified	TNF inhibitor; NSAID	rheumatoid arthritis; diabetes; multiple sclerosis
Thalidomide; NSC 66847	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	HIV infection; Crohn disease; multiple sclerosis; Alzheimer disease; transplant rejection

Mitoxantrone; CL 232315; NSC 279836; NSC 301739; DHAQ; DHAD; NOVANTRONE; NOVATRON	1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione	Topoisomerase inhibitor	cancer; multiple sclerosis
TCR peptide, multiple sclerosis	Vaccine	vaccine	multiple sclerosis
vaccine, activated T cells; vaccine, multiple sclerosis	Vaccine	vaccine	multiple sclerosis
vaccine, multiple sclerosis; vaccine, Vbeta6.2/6.5 T cell receptor; AI 208; IR 208	Vaccine	vaccine	multiple sclerosis
NBI 108	Unspecified	vaccine adjuvant; immunostimulant; neuroactive steroid	Alzheimer disease; infectious disease; multiple sclerosis
VCAM antagonists	Unspecified	vascular cell adhesion molecule inhibitor; NSAID	atherosclerosis; rheumatoid arthritis; multiple sclerosis
TBC 609	Unspecified	vascular cell adhesion molecule inhibitor; NSAID; peptide	atherosclerosis; rheumatoid arthritis; multiple sclerosis
TBC 772	Unspecified	vascular cell adhesion molecule inhibitor; NSAID; peptide	atherosclerosis; rheumatoid arthritis; multiple sclerosis
ZD 7349	Unspecified	VLA 4 antagonist; integrin antagonist; NSAID; cell adhesion inhibitor	multiple sclerosis; arthritis

Table 33. Current Candidate Therapeutic Interventions for the Treatment of Pain

Product Name	Chemical Name	Action	Indication
anpirtoline	4-[(6-chloro-2-pyridyl)thio]piperidine	5HT agonist; 5HT1B agonist; analgesic	pain
5HT antagonists	Unspecified	5HT antagonist; SHT1A antagonist; analgesic	pain
SP 186	Unspecified	5HT reuptake inhibitor; analgesic	pain

AAL 13	2-[4-(3-chloropropyl)-1-piperazinyl]quinoline	5HT reuptake inhibitor; analgesic; NSAID	inflammation; pain
GR 79236	(1S-trans)-N-(2-hydroxycyclopentyl)adenosine	adenosine agonist; adenosine A1 agonist	pain; coronary artery disease
UP 20232	Unspecified	adenosine agonist; analgesic	pain; neuropathy
adenosine analogues	Unspecified	adenosine analogues	pain
analgesic adenosine regulating agents	Unspecified	adenosine regulating agent	pain
GP 1683	Unspecified	adenosine regulating agent; analgesic	pain
adrenergic alpha2 human neuroreceptors; neuroreceptors, adrenergic alpha2 human	Unspecified	adrenergic alpha2 human neuroreceptors	research tool; pain; hypertension; analgesic
S 18616	8-chloro-3,4-dihydrospiro[naphthalene-2(1H),4'(5'H)-oxazol]-2'-amine	alpha adrenergic agonist; alpha2 adrenergic agonist; analgesic	pain
SNAP 5143	Unspecified	alpha adrenergic agonist; alpha2 adrenergic agonist; analgesic	pain; glaucoma
RWJ 52807	Unspecified	alpha2 adrenergic agonist; alpha adrenergic agonist; analgesic	pain
ABT 594	(R)-2-chloro-5-(2-azetidinylmethoxy)pyridine	analgesic	pain
analben	Unspecified	analgesic	rheumatoid arthritis; pain
analgesic,	2-phenylimidazo[2,1-b]benzothiazole-3-propanoic acid 9,9-dioxide	analgesic	pain
analgesic,	9-phenyl-9H-thioxanthen-9-ol propanoate	analgesic	pain

analgesic	N-[4-(4-methyl-2-thiazolyl)-1-[2-(1H-pyrazol-1-yl)ethyl]-4-piperidinyl]N-phenylpropanamide	analgesic	pain; anesthesia
analgesic,	Unspecified	analgesic	pain
analgesic	(R)-3-amino-2,3,4,9-tetrahydrothiopyrano(2,3-b)indole	analgesic	pain
analgesic	(R)-3-methylamino-2,3,4,9-tetrahydrothiopyrano(2,3-b)indole	analgesic	pain
analgesic	(R)-3-dimethylamino-2,3,4,9-tetrahydrothiopyrano(2,3-b)indole	analgesic	pain
analgesic,	Unspecified	analgesic	pain
analgesic	5-(4-methylbenzoyl)-6-(methylthio)-1,2-dihydro-3H-pyrrolo(1,2-a)pyrrole-1-carboxylic acid	analgesic	pain
analgesics	Unspecified	analgesic	pain
Analgesics	Unspecified	analgesic	pain; neuropathy
BCH 1788	Unspecified	analgesic	pain
buprenorphine + naloxone; naloxone + buprenorphine	Unspecified	analgesic	pain
capsaicin; ZOTRIX; ZOTRIX HP; THERAGEN; THERAGEN HP; CAPSIDOL;	(E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide	analgesic	pain; neuropathy; diabetes
cizolirtine; E 4018	N,N-dimethyl-2-[(1-methyl-1H-pyrazol-5-yl)phenylmethoxy]ethanamine	analgesic	pain
D 20450	Unspecified	analgesic	pain
D 21151	1-phenoxyphthalazine	analgesic	pain
dexpamedolac; PEM 420; WAY PEM 420	(1S-cis)-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyran o[3,4-b]indole-1-acetic acid	analgesic	pain

dezocine; WY 16225; DALGAN	[5R-(5alfa,11alfa,13S*)]-13-amino-5,6,7,8,9,10,11,12-octahydro-5-methyl-11-methanobenzocyclodecen-3-ol	analgesic	pain
F 9004T	Unspecified	analgesic	pain
FID 072021	3-atropanyl 2-(4-chlorophenoxy)butyrate maleate	analgesic	pain; cognitive defect
filenadol; FI 2024	(R*,S*)-(+,-)-beta-1,3-benzodioxol-5-yl-alpha-methyl-4-morpholineethanol	analgesic	pain
flubichin	Unspecified	analgesic	pain
flupirtine; D 998; W 2964M; KATADOLON	[2-amino-6-[(4-fluorophenyl)methyl]amino]-3-pyridinyl]-, ethyl ester, carbamic acid	analgesic	pain; neurological
gapxavanyl; DA 5018; DA 50018; KR 25018	4-(2-aminoethoxy)-N-[3-(3,4-dimethylphenyl)propyl]-3-methoxybenzeneacetamide	analgesic	pain
GW 275919	Unspecified	analgesic	pain
JTC 801	Unspecified	analgesic	pain
KR 25018	4-(2-aminoethoxy)-N-[3-(3,4-dimethylphenyl)propyl]-3-methoxybenzeneacetamide	analgesic	pain
pain therapy	Unspecified	analgesic	pain
pain therapy	Unspecified	analgesic	pain
pemedolac; AY 30715	cis-(+,-)-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyran o[3,4-b]indole-1-acetic acid	analgesic	pain
peripheral nervous system therapy	Unspecified	analgesic	pain; urinary tract disorder

phenaridine; fenaridin	N-[2,5-dimethyl-1-(2-phenylethyl)-4-piperidinyl]-N-phenylpropanamide	analgesic	pain
pregabalin; CI 1008; PD 144723	(S)-3-(aminomethyl)-5-methyl-hexanoic acid	analgesic	epilepsy; pain
Ro 158081	Unspecified	analgesic	pain
ruzadolane; UP 2691	3-[[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]thio]-1,2,4-triazolo[4,3-a]pyridine	analgesic	pain
S 01	5,6-dihydro-9,10,14-trimethoxy-8H-1,3-dioxolo[4,5-h]isoindolo[1,2-b][3]benzazepine-8-one	analgesic	pain
S 14080	benzoyl-6 dihydro-2,3-benzothiazole	analgesic	pain
S 8117	Unspecified	analgesic	pain
sameridine; LPB 139	N-ethyl-1-hexyl-N-methyl-4-phenyl-4-piperidinecarboxamide	analgesic	local anesthesia; pain
SJ 2321	Unspecified	analgesic	pain
SYM 2081	(4R)-4-methyl-L-glutamic acid	analgesic	pain
tramadol analogues	Unspecified	analgesic	pain
UP 52204	Unspecified	analgesic	pain
V 2	Unspecified	analgesic	pain
NC 164	Unspecified	analgesic	pain
dynorphin A; dynorphin A (1-13)	Unspecified	analgesic; peptide	pain
bradykinin antagonists	Unspecified	bradykinin antagonist; analgesic; NSAID	pain; inflammation; septic shock
bradykinin antagonist/mu agonist, Cortech	Unspecified	bradykinin antagonist; mu agonist; opiate agonist; analgesic; NSAID	inflammation; pain; migraine

CP 0880; CP 880	N-[[3-[[1-oxo-3-[4-[(1-oxopropyl)phenylamino]-1-(2-phenylethyl)-3-piperidinyl]propyl]amino]phenyl]acetyl]-beta-alanyl-D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-(3R)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-N-cyclohexylglycyl-L-arginine	bradykinin antagonist; mu agonist; opiate agonist; analgesic; NSAID	inflammation; pain
FR 173657	(E)-3-[6-(acetylamino)-3-pyridinyl]-N-[2-[[2,4-dichloro-3-[(2-methyl-8-quinolinyl)oxy]methyl]phenyl]methylamino]-2-oxoethyl-2-propenamide	bradykinin antagonist; NSAID; analgesic	asthma; inflammation; pain
NPS 846	Unspecified	calcium antagonist; analgesic	stroke; epilepsy; pain
ziconotide; SNX 111; oméga-conotoxin CI 1009	OMEGA-conotoxin MVIIA	calcium antagonist; analgesic; peptide	stroke; pain; brain ischemia
AM 336	Unspecified	calcium channel blocker; analgesic	pain
calcium channel blockers,	Unspecified	calcium channel blocker; analgesic	pain
SNX 239	Unspecified	calcium channel blocker; analgesic	pain; neuropathy
drug delivery system, conopeptides	Unspecified	calcium channel blocker; sodium channel blocker; potassium channel blocker; analgesic	epilepsy; Parkinson disease; stroke; pain; brain ischemia
NE 21610	(Z)-N-[[4-(2-aminoethoxy)-3-methoxyphenyl]methyl]-9-octadecenamide	capsaicin analogue; analgesic	pain

L 365031	4-bromo-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)benzamide	cholecystokinin A antagonist; cholecystokinin antagonist	pain
L 156586	Unspecified	cholecystokinin antagonist	gastrointestinal ulcer; pain
L 156587	14,15-didehydro-14-deoxyvirginiamycin M1	cholecystokinin antagonist	gastrointestinal ulcer; pain
L 156588	14-deoxyvirginiamycin M1	cholecystokinin antagonist	gastrointestinal ulcer; pain
L 156906	Unspecified	cholecystokinin antagonist	gastrointestinal ulcer; pain
devazepide; L 364718; MK 329	(S)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-1H-indole-2-carboxamide	cholecystokinin antagonist; cholecystokinin A antagonist; analgesic	pain
L 365260	(R)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)urea	cholecystokinin B antagonist; cholecystokinin antagonist; analgesic	pain
vedaclidine; NNC 111053; LY 297802	(S)-3-[4-(butylthio)-1,2,5-thiadiazol-3-yl]-1-azabicyclo[2.2.2]octane	cholinergic agonist; muscarinic agonist; analgesic	pain
CMI 980	Unspecified	cholinergic agonist; nicotinic agonist; analgesic	pain
nicotinic agonists	Unspecified	cholinergic agonist; nicotinic agonist; analgesic	cognitive defect; pain; nicotine withdrawal
SIB T1887	Unspecified	cholinergic antagonist; nicotinic antagonist; analgesic	pain
RU 54808	Unspecified	COX inhibitor; 5 lipoxygenase inhibitor	pain

drug delivery system, transdermal ketorolac; ketorolac transdermal	Unspecified	COX inhibitor; analgesic	pain
ketorolac; ketorolac trometamol; BPPC; RS 37619; RS 3761900313; TORADOL; TARASYN; TORATEX; ACULAR; LIDIXOL; TORA DOL; TORA-DO; TONUM; KETRODOL	(+,-)-5-benzoyl-2,3-dihydro-1H-pyрrolizine-1-carboxylic acid	COX inhibitor; analgesic	pain
meloxicam; UH AC62; UH AC26XX; MOBIC; MOBICOX; MOBEC; MOVALIS; MOVATEC	4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide	COX inhibitor; analgesic; COX 2 inhibitor; NSAID	rheumatoid arthritis; inflammation; pain; osteoarthritis
AHR-10037	2-amino-3-(4-chlorobenzoyl)benzenacetamide	COX inhibitor; analgesic; NSAID	inflammation; pain
D 1367	Unspecified	COX inhibitor; analgesic; NSAID	pain; inflammation
T 614	N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]-methanesulfonamide	COX inhibitor; analgesic; NSAID; DMARD	inflammation; pain
GR 253035	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic	pain; Alzheimer disease
L 783003	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic	pain
parecoxib; SC 69124A	N-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]propanamide	COX inhibitor; COX 2 inhibitor; analgesic	pain
celecoxib; SC 58635; YM 177	4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis; pain; cancer

CT 3	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	pain; inflammation
JTE 522	4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluorobenzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
L 745337	N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1H-inden-5-yl]methanesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	pain; inflammation
L 752860	unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
MK 663	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
NS 398	N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
Rofecoxib; MK 966; VIOXX	4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; rheumatoid arthritis; osteoarthritis; pain; Alzheimer disease
Valdecoxib; SC 65872	4-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis; pain
COX 2 inhibitors,	Unspecified	COX inhibitor; COX 2 inhibitor; NSAID; analgesic	inflammation; osteoarthritis; pain
Lornoxicam; chlortenoxicam; Ro 139297; TS 110; CTX; SAFEM; XEFO; LORCAM	6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-2H-thieno[2,3-e]-1,2-thiazin e-3-carboxamide 1,1-dioxide	COX inhibitor; NSAID; analgesic	inflammation; pain
E 5090	(Z)-3-[4-(acetoxy)-5-ethyl-3-methoxy-1-naphthalenyl]-2-methyl-2-propenoic acid	cytokine inhibitor; analgesic; NSAID	inflammation; pain

TAN 67	trans-3-(1,3,4,5,12,12a-hexahydro-2-methylpyrido[3,4-b]acridin-4a(2H)-yl)phenol	delta agonist; opiate agonist; analgesic	pain
Prinomide; prinomide tromethamine; CGS 10787; CGS 10787B	alpha-cyano-1-methyl-beta-oxopyrrole-2-propionanilide with 2-amino-2-(hydroxymethyl)-1,3-propanediol	DMARD; analgesic; immunosuppressant; NSAID	inflammation; pain; rheumatoid arthritis
FR 64822	N-(3,6-dihydro-1(2H)-pyridinyl)-N'-4-pyridinylurea	dopamine agonist; dopamine D2 agonist; analgesic	pain
BW 443C	L-tyrosyl-D-arginylglycyl-4-nitro-L-phenylalanyl-L-prolinamide diacetate (salt)	enkephalinase inhibitor; analgesic	asthma; pain; cough
KK 3	[S-(R*,R*)]-alpha-amino-4-hydroxy-N-[4-[[1-(hydroxymethyl)-2-phenylethyl]amino]-4-oxobutyl]-N-methylbenzenepropanamide	enkephalinase inhibitor; analgesic	pain
ONO 9902	[1S-[1R*[R*(R*)]]]-4-[[2-[[1,3-dihydro-3-oxo-1-isobenzofuranyl)thio]methyl]-1-oxo-3-phenylpropyl]amino]-5-oxo-5-(phenylamino)pentanoic acid	enkephalinase inhibitor; analgesic	pain
Excitatory amino acid antagonist	Unspecified	excitatory amino acid antagonist; analgesic	pain
CGP 29030A	1-[2-(4-chlorophenyl)ethyl]-4-(3,5-dimethoxybenzoyl)-piperazine, monohydrochloride	GABA agonist; analgesic	pain

Gabapentin; CI 945; GO 3450; GOE 2450; NEURONTIN	1-(aminomethyl)cyclohexaneacetic acid	GABA release analgesic	epilepsy; anxiety; pain; neuropathy; psychosis; depression
galanin1 antagonists,	Unspecified	Galanin 1 antagonists	obesity; pain; cognitive defect
galanin modulators,	Unspecified	Galanin modulation analgesic	obesity; diabetes; cognitive defect; pain
Mipragoside; AGF 44	<chem>R*-[R*,S*-(E)]-N-[1-[[[O-[N-acetyl-1-(1-methylethyl)-alpha-neuraminosyl]-2-3)-O-[O-beta-D-galactopyranosyl-(1-3)-2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1-4)-O-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranosyl]oxy]methyl]-2-hydroxy-3-heptadecenyl]octadecanamide</chem>	ganglioside analogue; analgesic; NSAID	inflammation; pain
LY 379268	(1R,4R,5S,6R)-4-amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid	glutamate agonist; mGluR agonist; analgesic	neurodegeneration; pain
BW 524C79	Unspecified	glutamate antagonist; analgesic	pain
NPS 2390	Unspecified	glutamate antagonist; mGluR antagonist	pain; epilepsy
SIB 1757	Unspecified	glutamate antagonist; mGluR antagonist; analgesic	pain; neurological; neurodegeneration
SIB 1893	Unspecified	glutamate antagonist; mGluR antagonist; analgesic	pain; neurological; neurodegeneration
GV 196771; GV 196771A	E-4,6-dichloro-3-[(2-oxo-1-phenyl-3-pyrrolidinylidene)methyl]-1H-indole-2-carboxylic acid monosodium salt	glutamate antagonist; NMDA antagonist; analgesic	pain

CP 331; CP 6	1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 2-[[2-oxo-2-[[3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]ethyl]thio]ethyl ester	histamine antagonist; histamine H2 antagonist; analgesic; NSAID	inflammation; pain
Melanocortin receptor-1 modulators	Unspecified	melanocortin agonist; melanocortin MC1 agonist	asthma; pain; nephritis
Metabotropic glutamate receptor modulators	Unspecified	metabotropic glutamate receptor modulators analgesic	pain; cognitive defect; schizophrenia; epilepsy
remifentanil; GI 87084; GI 87084B; GI 87084X; ULTIVA	4-(methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-1-piperidinepropanoic acid methyl ester	mu agonist; opiate agonist; analgesic	pain
trefentanil; trefentanil hydrochloride; A 3665	N-(1-(2-(4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl)-4-phenyl-4-piperidinyl)-N-(2-fluorophenyl)propanamide monohydrochloride	mu agonist; opiate agonist; analgesic	pain
BCH 150	Unspecified	mu agonist; opiate agonist; peptide; analgesic	pain
mirfentanil; mirfentanil hydrochloride; A 3508	N-[1-(2-phenethyl)-4-piperidinyl]-N-pyrazinyl-2-furancarboxamide	mu antagonist; opiate antagonist; analgesic	anesthesia; pain
Narcotics	Unspecified	Narcotics analgesic	pain; addiction; intoxication
WIN 64821	(2alpha,2'beta,5beta,5'alpha)-2,5:2',5'-dide(epidithio)-3,3'-didemethyl-19,19'-dideoxy-19,19'-diphenylchaetocin	neurokinin antagonist; analgesic	pain

GR 82334	9-deglycine-10-[(5S)-6-oxo-L-alfa-(2-methylpropyl)-1,7-diazaspiro[4.4]nonane-7-acetic acid]-11-L-tryptophanamidephysalemin	neurokinin antagonist; analgesic; neurokinin 1 antagonist	pain
lanepitant; LY 303870	(R)-N-[2-acetyl][(2-methoxyphenyl)methyl]amino]-1-(1H-indol-3-ylmethyl)ethyl]-[1,4'-bipiperidine]-1'-acetamide	neurokinin antagonist; analgesic; neurokinin 1 antagonist	asthma; pain; migraine
L 733060	(2S-cis)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine	neurokinin antagonist; analgesic; neurokinin 1 antagonist; NSAID	inflammation; pain; asthma
CP 96345	(2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine	neurokinin antagonist; analgesic; neurokinin 1 antagonist; NSAID; substance P antagonist	inflammation; pruritis; pain
saredutant; SR 48968	(S)-N-[4-(4-acetylamino-4-phenyl-1-piperidinyl)-2-(3,4-dichlorophenyl)butyl]-N-methyl-benzamide	neurokinin antagonist; analgesic; neurokinin 2 antagonist	asthma; pain; urinary incontinence
neurokinin antagonists	Unspecified	neurokinin antagonist; analgesic; NSAID	pain; inflammation
CP 99994	(2S-cis)-N-[(2-methoxyphenyl)methyl]-2-phenyl-3-piperidinamine	neurokinin antagonist; neurokinin 1 antagonist; analgesic	asthma; pain
SR 144190	(R)-4-benzoyl-2-(3,4-difluorophenyl)-2-[2-[4-[(dimethylamino)carbonyl]amino]-4-phenyl-1-piperidinyl]ethyl]morpholine	neurokinin antagonist; neurokinin 2 antagonist; analgesic	asthma; urinary incontinence; asthma; pain

neuropeptide Y antagonists	Unspecified	neuropeptide Y antagonist; analgesic	obesity; cardiovascular disease; anxiety; pain
JMV 449	(S)-1-de-L-lysine-2-[N2-(2,6-diaminohexyl)-L-lysine]neuromedin N (pig spinal cord)	neurotensin analogue; analgesic	pain
nitroglycerin; glyceryl trinitrate; trinitrin; ANOGESIC	Unspecified	nitrate; cicatrizant; analgesic	skin ulcer; angina; pain
memantine; D 145; NMI 131; AKATINOL	3,5-dimethyl-1-adamantanamine	NMDA antagonist; analgesic; glutamate antagonist	cognitive defect; pain; glaucoma; neuropathy
NMDA antagonists	Unspecified	NMDA antagonist; analgesic; glutamate antagonist	epilepsy; pain; brain ischemia
CNS 5161	N'-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-(methylthio)phenyl]guanidine monohydrochloride	NMDA antagonist; glutamate antagonist	pain; migraine; neuropathy
ACEA 1328	5-nitro-6,7-dimethyl-2,3-quinoxalinedione	NMDA antagonist; glutamate antagonist; analgesic	pain
ACEA 1416; NMCQX	5-nitro-6-methyl-7-chloro-2,3-quinoxalinedione	NMDA antagonist; glutamate antagonist; analgesic	epilepsy; pain; brain ischemia
aptiganel; CNS 1102; CDD 2515A; CERESTAT	N-(3-ethylphenyl)-N-methyl-N'-1-naphthalenyl-guanidine	NMDA antagonist; glutamate antagonist; analgesic	stroke; neuropathy; trauma; Parkinson disease; pain
budipine; budipine hydrochloride; BY 701; PARKINSAN	1-(1,1-dimethylethyl)-4,4-diphenylpiperidine	NMDA antagonist; glutamate antagonist; analgesic	Parkinson disease; pain
NMDA antagonists,	Unspecified	NMDA antagonist; glutamate antagonist; analgesic	pain
conantokins	Unspecified	NMDA antagonist; glutamate antagonist; peptide; analgesic	epilepsy; stroke; schizophrenia; pain; ischemia
nociceptor blockers, NB 1	Unspecified	nociceptor blockers analgesic	pain
non-narcotic analgesic	Unspecified	non-narcotic analgesic analgesic	pain

2-halopyridine	Unspecified	NSAID	inflammation; pain; insomnia
Analgesic	3-methyl-5-oxobenzo(b)thieno(2,3-d)thiazolo(3,2-a)pyrimidine-2-carboxylic acid ethyl ester	NSAID	pain; inflammation; gastrointestinal ulcer
BN 50370	1,3-dihydro-3,6-dimethyl-7-hydroxy-furo(3,4)pyridine hydrochloride	NSAID	inflammation; pain
Diaveridine; EGIS 5645	5-[(3,4-dimethoxyphenyl)methyl]-2,4-pyrimidinediamine	NSAID	inflammation; pain
drug delivery system, hydrogel diclofenac; diclofenac hydrogel; DICLOFENAC HYCORE-R	Unspecified	NSAID	pain; inflammation
drug delivery system, OSAT diclofenac; diclofenac sustained release	Unspecified	NSAID	pain; inflammation
drug delivery system, OSAT ibuprofen; ibuprofen sustained release	Unspecified	NSAID	pain; rheumatoid arthritis; osteoarthritis; inflammation
drug delivery system, sustained release microsphere flurbiprofen; flurbiprofen, sustained release	Unspecified	NSAID	pain; inflammation
DTA	4'-methyl-[1,1':3',1"-terphenyl]-5'-acetic acid	NSAID	inflammation; pain
FA 401	1-(4-fluorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid carboxymethyl ester	NSAID	pain; inflammation

Flurbiprofen axetil; LFP 83; ROPION; LIPFEN	2-fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid, 1-(acetoxy)ethyl ester	NSAID	pain; inflammation
HU 239	(6aR-trans)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-carboxylic acid	NSAID	inflammation; pain
LA 351	5H-(1)-benzopyrano(2,3-b)pyridin-5-one	NSAID	inflammation; pain; asthma
M 5011; T 3788	alpha-2-[4-(3-methylthienyl)phenyl]propionic acid	NSAID	inflammation; pain
Proglumetacin; protacine; CR 604; IMPETIN; PROXIL; PROXATIL; AFLOXAN; TOLINDOL; BRUXEL; MIRIDACIN	1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 2-[4-[3-[[4-(benzoylamino)-5-(dipropylamino)-1,5-dioxopentyl]oxy]propyl]-1-piperazinyl]ethyl ester, (+,-)-	NSAID	inflammation; pain
RP 67580	(3aR-cis)-octahydro-2-[1-imino-2-(2-methoxyphenyl)ethyl]-7,7-diphenyl-4H-isoindol-4-one	NSAID	pain; inflammation
SC 107	Unspecified	NSAID	arthritis; pain
TZI 41078	Unspecified	NSAID	inflammation; pain
Aceclofenac; YT 919; AIRTAL; GERBIN; FALCOL; BRISTAFLAM; PRESERVEX; BIOFENAC; BARRACAN	2-[(2,6-dichlorophenyl)amino]benzeneacetic acid, carboxymethyl ester	NSAID; analgesic	pain; inflammation

Amtolmetin guacil; ST 679; MED 15; ARTROMED; EUFANS	N-[[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetyl]glycine 2-methoxyphenyl ester	NSAID; analgesic	arthritis; rheumatoid arthritis; inflammation; pain
bromfenac; bromfenac sodium; AHR 10282; DURACT	2-amino-3-(4-bromobenzoyl)benzenoacetic acid	NSAID; analgesic	inflammation; pain
CHF 2003	Unspecified	NSAID; analgesic	pain; inflammation
Dexketoprofen trometamol; LM 1158.TRIS; D 1158; ENANTYUM; QUIRALAM; KETESSE	(S)-3-benzoyl-alpha-methylbenzenoacetic acid cpd with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)	NSAID; analgesic	pain; inflammation
Esflurbiprofen; flurbiprofen, (S)-; (S)-flurbiprofen; BTS 24332	(S)-2-fluoro-alpha-methyl-4-biphenylacetic acid	NSAID; analgesic	pain
florifanine; FI 2522	2-(1-pyrrolidinyl)ethyl-N-[7-(trifluoromethyl)-4-quinolyl]anthranilate	NSAID; analgesic	inflammation; pain
flosulide; ZK 38997; CGP 28238; CGS 28238; SH 459	N-[6-(2,4-difluorophenoxy)-2,3-dihydro-1-oxo-1H-inden-5-yl]methanesulfonamide	NSAID; analgesic	inflammation; pain
FS 205397	6-ethoxy-2,3-dihydro-3,3-dimethyl-1H-indole methanesulfonate	NSAID; analgesic	pain
HAI 105	6,11-dihydro-2-methoxy-alpha-methyl-11-oxodibenzo[b,e]oxepin-3-acetic acid	NSAID; analgesic	pain; inflammation
HN 3392	N-(4-(4-methoxyphenyl)-5-phenylthiazolyl)	NSAID; analgesic	inflammation; pain
mofezolac; N 22; DISOPAIN	3,4-bis(4-methoxyphenyl)-5-isoxazoleacetic acid	NSAID; analgesic	inflammation; pain

Nabumetone; BRL 14777; RELIFEN; RELIFEX; LISTRAN; PRODAG; BALMOX; NABUMETON; RELAFEN	4-(6-methoxy-2-naphthyl)-2-butanone	NSAID; analgesic	pain; inflammation
olvanil; oluvanil; NE 19550	N-vanillyloleamide	NSAID; analgesic	pain; inflammation; viral infection
Pelubiprofen; CS 670; RS 2131	alpha-methyl-4-[(2-oxocyclohexyllidene)methyl]benzeneacetic acid	NSAID; analgesic	inflammation; pain
piroxicam betadex; piroxicam cyclodextrin; CHF 1194; BREXIN; BREXINE; BREXIDOL; CYCLADOL; BREXICAM; BREXINIL	4-hydroxy-2-methyl-N-(2-pyridinyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound with beta-cyclodextrin	NSAID; analgesic	pain; inflammation
Polyunsaturated fatty acids, PUFA	Unspecified	NSAID; analgesic	inflammation; pain
Tenosal; MR Y134	2-thiophenecarboxylic acid, ester with salicylic acid	NSAID; analgesic	pain
Tifurac; RS 82917; RS 82917030	7-[4-(methylthio)benzoyl]-5-benzofuranacetic acid	NSAID; analgesic	inflammation; pain
Tilnoprofen arbamel; Y 23023	(+/-)-alpha-2-methyl-SH-[1]benzopyran[2,3-b]pyridine-7-acetic acid, 2-(dimethylamino)-2-oxoethyl ester	NSAID; analgesic	inflammation; pain
HCT 3012	Unspecified	NSAID; nitric oxide donor	pain; inflammation
HCT 6015	Unspecified	NSAID; nitric oxide donor	pain

NCX 4016	2-(acetyloxy)benzoic acid, 2-[(nitrooxy)methyl]phenylester	NSAID; nitric oxide donor; platelet antiaggregant; analgesic	thrombosis; pain
HP 228	N-acetyl-Nleu-Gln-His-Phe-Arg-Trp-Gly-amide	NSAID; peptide; melanocortin agonist	pain; inflammation; asthma; cachexia
Samarium 153 Sm lexidronam; Sm 153-EDTMP; samarium 153-EDTMP; samarium EDTMP; CYT 424;	(OC-6-21)-[[[1,2-ethanediylbis[nitrilobis(methylene)]tetrakis[phosphonato]](8-)-N,N',OP,OP',OP",OP"]]-samarate(5)-153Sm	NSAID; radiotherapeutic	cancer; pain; rheumatoid arthritis
Analgesic, human serum albumin conjugated opioid peptide	Unspecified	opiate agonist	pain
AXC 3742	Unspecified	opiate agonist	pain
AXC 3943	Unspecified	opiate agonist	pain
drug delivery system, hydrogel pethidine; pethidine hydrogel	Unspecified	opiate agonist	pain
Oxycodone + ibuprofen; ibuprofen + oxycodone	Unspecified	opiate agonist	pain
ADL 21294	Unspecified	opiate agonist; analgesic	pain; corneal abrasion
Analgesic	Unspecified	opiate agonist; analgesic	pain
Brifentanil; A 3331	(+,-)-cis-N-[1-[2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-3-methyl-4-piperidyl]-2'-fluoro-2-methoxyacetanilide	opiate agonist; analgesic	pain
drug delivery system, ANCHOR opioid agonist	Unspecified	opiate agonist; analgesic	pain

drug delivery system, transdermal fentanyl; TTS-fentanyl; fentanyl transdermal; KJK 4263; SUBLIMAZE; DURAGESIC; DUROGESIC	Unspecified	opiate agonist; analgesic	pain
LEF 576; BCH 3963	Unspecified	opiate agonist; analgesic	pain
ocfentanil; A 3217	N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)-4-piperidinyl]acetamide	opiate agonist; analgesic	pain
TRK 820	(2E)-N-[(5alpha,6beta)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-2-propenamide monohydrochloride	opiate agonist; analgesic; kappa agonist	pain
BW 373U86	[1(S*),2alpha,5beta]-(+,-)-4-[[2,5-dimethyl-4-(2-propenyl)-1-piperazinyl](3-hydroxyphenyl)methyl]-N,N-diethylbenzamide	opiate agonist; delta agonist; analgesic	pain
SB 235863	Unspecified	opiate agonist; delta agonist; analgesic	pain
SNF 8912	(H2N-(CH2)7-CO-NH)Asp-Tyr-(N-Me)Nle-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2	opiate agonist; delta agonist; analgesic	pain
SNF 9007	L-alpha-aspartyl-L-tyrosyl-D-phenylalanylglycyl-L-tryptophyl-N-methyl-L-norleucyl-L-alpha-aspartyl-L-phenylalaninamide	opiate agonist; delta agonist; analgesic	pain

opioid mimetic peptides	Unspecified	opiate agonist; delta agonist; analgesic; peptide	pain; addiction
Apadoline; RP 60180; RP 60180A; RPR 60180	(R)-10-[1-methyl-2-(1-pyrrolidinyl)ethyl]-N-propyl-10H-phenothiazine-2-carboxamide	opiate agonist; kappa agonist; analgesic	pain
BRL 53001A	(2S)-1-(1-oxo-3,4-dihydro-(2H)-naphth-6-yl)acetyl-2-dimethyl-aminomethyl piperidine hydrochloride	opiate agonist; kappa agonist; analgesic	pain
CL 891601	Unspecified	opiate agonist; kappa agonist; analgesic	pain
DUP 747	trans-(+,-)-3,4-dichloro-N-methyl-N-[1,2,3,4-tetrahydro-5-methoxy-2-(1-pyrrolidinyl)-1-naphthalenyl]benzene acetamide	opiate agonist; kappa agonist; analgesic	pain
E 2078; 66A078	N-methyl-L-tyrosylglycylglycyl-L-phenylalanyl-L-leucyl-L-arginyl-N2-methyl-L-arginyl-N-ethyl-D-leucinamide	opiate agonist; kappa agonist; analgesic	pain
EMD 60400	N-methyl-N((1S))-1-phenyl-2-((3S)-3-hydroxypyrrolidine-1-yl)-ethyl-2-amino-phenylacetamide	opiate agonist; kappa agonist; analgesic	pain
GR 102908	Unspecified	opiate agonist; kappa agonist; analgesic	pain
GR 107537	[S-(R*,R*)]-5-[(3,4-dichlorophenyl)acetyl]-4,5,6,7-tetrahydro-4-[(3-hydroxy-1-pyrrolidinyl)methyl]furo[3,2-c]pyridine	opiate agonist; kappa agonist; analgesic	pain

ICI 197067	(S)-3,4-dichloro-N-methyl-N-[2-methyl-1-(1-pyrrolidinylmethyl)propyl]benzeneacetamide monohydrochloride	opiate agonist; kappa agonist; analgesic	pain
ICI 204448	(+,-)-[3-[1-[(3,4-dichlorophenyl)acetyl]methylamino]-2-(1-pyrrolidinyl)ethyl]phenoxylacetic acid monohydrochloride	opiate agonist; kappa agonist; analgesic	pain
R 84760	(3R)-4-[(1S)-5,6-dichloro-2,3-dihydro-1H-inden-1-yl]carbonyl]-3-(1-pyrrolidinylmethyl)thiomorpholine monohydrochloride	opiate agonist; kappa agonist; analgesic	pain
Asimadoline; EMD 61753	[S-(R*,R*)]-N-[2-(3-hydroxy-1-pyrrolidinyl)-1-phenylethyl]-N-methyl-.alpha.-phenyl-, benzeneacetamide	opiate agonist; kappa agonist; analgesic; NSAID	pain
opiate analgesic,	Unspecified	opiate agonist; mu agonist	pain
BCH 2687; LEF 553	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, hydrogel morphine; morphine hydrogel; MORAXEN; MORPHINE HYCORE-R	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, oral sustained release morphine; morphine sustained release; KAPANOL; KADIAN; MORCAP SR	Unspecified	opiate agonist; mu agonist; analgesic	pain

drug delivery system, oral transmucosal fentanyl; fentanyl OTFC; ACTIQ; FENTANYL ORALET	Unspecified	opiate agonist; mu agonist; analgesic	anesthesia; pain
drug delivery system, OROS oral controlled release hydrocodone; hydrocodone OROS	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, OROS oral controlled release hydromorphone; hydromorphone OROS	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, OROS oral controlled release morphine; morphine OROS	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, OSAT morphine; morphine sustained release	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, subcutaneous hydromorphone; hydromorphone subcutaneous implant	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, sustained release DepoFoam morphine; morphine DepoFoam; C 0401; DepoMorphine	Unspecified	opiate agonist; mu agonist; analgesic	pain; cancer
drug delivery system, transdermal buprenorphine; buprenorphine transdermal	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, transdermal fentanyl; fentanyl transdermal	Unspecified	opiate agonist; mu agonist; analgesic	pain

HP 736	cis-7-bromo-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol (E)-2-butenedioate (1:1) (salt)	opiate agonist; mu agonist; analgesic	pain
morphine-6-glucuronide; CEE 04410; HN 33169; CAP	morphine-6-glucuronide	opiate agonist; mu agonist; analgesic	pain
pentamorphone; RX 77989; A 4492	7,8-didehydro-4,5a-epoxy-3-hydroxy-17-methyl-14-(pentylamino)morphinan-6-one	opiate agonist; mu agonist; analgesic	pain
DPI 3290	[2S-[1(S*),2alpha,5beta]]-3-[[2,5-dimethyl-4-(2-propenyl)-1-piperazinyl](3-hydroxyphenyl)methyl]-N-(3-fluorophenyl)-N-methylbenzamide monohydrochloride	opiate agonist; mu agonist; delta agonist; analgesic	pain
OHM 3295; ANQ 3295	Unspecified	opiate agonist; mu agonist; kappa agonist; analgesic	pain
SK 9709	Tyr-D-Ala-Phe-Leu-Arg (CH ₂ NH) Arg-NH ₂	opiate agonist; mu agonist; kappa agonist; peptide	pain
naloxone + pentazocine; pentazocine + naloxone	Unspecified	opiate agonist; opiate antagonist; analgesic	pain; cancer
tonazocine; WIN 42156; WIN 42156 2	(+,-)-(2alpha,6alpha,11S*)-1-(1,2,3,4,5,6-hexahydro-8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-yl)-3-octanone	opiate agonist; opiate antagonist; mu agonist; delta agonist; analgesic	pain

picenadol; LY 150720	trans-(+,-)-3-(1,3-dimethyl-4-propyl-4-piperidinyl)phenol	opiate agonist; opiate antagonist; mu agonist; mu antagonist; analgesic	pain
acetylmethadol; levomethadyl acetate hydrochloride; L-alpha acetylmethadol; LAAM; methadyl acetate; LAAM; MK 790; ORLAAM	beta-[2-(dimethylamino)propyl]-alfa-ethyl-beta-phenylbenzeneethanol acetate (ester)	opiate antagonist; analgesic	pain; addiction
SNC 80	[2S-[1(S*),2alpha,5beta]]-4-[[2,5-dimethyl-4-(2-propenyl)-1-piperazinyl](3-methoxyphenyl)methyl]-N,N-diethylbenzamide	opiate antagonist; delta antagonist; analgesic	pain
ibuprofen + propiram; propiram + ibuprofen; DIRATAB	Unspecified	opiate antagonist; opiate partial agonist; mu agonist; mu antagonist; analgesic	pain
propiram; propiram fumarate; BAY 4503; FBA 4503; DIRAME; ALGERIL	N-(1-methyl-2-piperdinoethyl)-N-2-pyridyl-propionamide fumarate	opiate antagonist; opiate partial agonist; mu agonist; mu antagonist; analgesic	pain
propiram + paracetamol; propiram + acetaminophen; paracetamol + propiram; acetaminophen + propiram; DIRAMAX	Unspecified	opiate antagonist; opiate partial agonist; mu agonist; mu antagonist; analgesic	pain
drug delivery system, transdermal buprenorphine; buprenorphine transdermal	Unspecified	opiate partial agonist; analgesic	pain
MR 2264	Unspecified	opiate partial agonist; analgesic	pain
analgesics,	Unspecified	peptide	pain
CEE 04420	Unspecified	peptide	pain
CEE 04421	Unspecified	peptide	pain

drug delivery system, analgesic, oral transmucosal	Unspecified	peptide	pain
drug delivery system, Polyfunctional Molecular Modification, enkephalin; enkephalin Polyfunctional Molecular Modification	Unspecified	peptide; analgesic	pain
MER W8020	Unspecified	peptide; analgesic; NSAID	inflammation; pain
drug delivery system, MICROPUMP oral controlled release aspirin; aspirin MICROPUMP; ASACARD	Unspecified	platelet antiaggregant; thromboxane synthetase inhibitor; analgesic; NSAID	thrombosis; pain; inflammation
ZD 4953	Unspecified	prostaglandin antagonist; prostaglandin endoperoxide 1 antagonist	pain
ZD 6416	Unspecified	prostaglandin endoperoxide 1 antagonist; analgesic	pain
ZD 6804	Unspecified	prostaglandin endoperoxide 1 antagonist; analgesic	pain
limaprost; lime prost; limaprost alfadex; OP 1206; ONO 1206; OPALMON; PRORENAL	(E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E)-(3S,5S)-3-hydroxy-5-methyl-1-nonenyl]-5-oxocyclopentyl]-2-heptenoic acid	prostanoid; analgesic	cardiovascular disease; pain
SC 42867	8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid 2-[3-(ethylsulfonyl)-1-oxopropyl]hydrazide	prostanoid; analgesic	pain

SCH 34826	N-[N-[2-[(2,2-dimethyl-1-3-dioxolan-4-yl)methoxy]-2-oxo-1-(phenylmethyl)ethyl]-L-phenylalanyl]-beta-alanine	proteinase inhibitor; analgesic	pain; hypertension
117m Sn DTPA; pentetate 117m Sn	Unspecified	radiotherapeutic; analgesic	cancer; pain
rhenium Re 186 etidronate; 186-Re HEDP; 186-Re HEDP; BETAMET	Unspecified	radiotherapeutic; analgesic	pain; cancer
Sm 153 hydroxyapatite; Sm 153 HA; samarium 153 hydroxyapatite	Unspecified	radiotherapeutic; analgesic	pain
strontium-89 chloride; METASTRON	strontium chloride (89SrCl ₂)	radiotherapeutic; analgesic	pain; cancer
PD 144418	1,2,3,6-tetrahydro-5-[3-(4-methylphenyl)-5-isoxazolyl]-1-propylpyridine	sigma antagonist; analgesic	pain
mu-conopeptides	Unspecified	sodium channel blocker	pain; epilepsy
4030W92; BW 4030W92	(5R)-5-(2,3-dichlorophenyl)-6-(fluoromethyl)-2,4-pyrimidinediamine	sodium channel blocker	pain
GW 286103	Unspecified	sodium channel blocker; analgesic	pain
LTA	Unspecified	sodium channel blocker; analgesic	pain
sodium channel blockers	Unspecified	sodium channel blocker; analgesic	pain
sodium channel blockers	Unspecified	sodium channel blocker; analgesic	pain

Octreotide; octreotide acetate; SMS; SMS 201995; SMS 201995ac; SMS 995; SANDOSTATIN; SANDOSTATINE; SANDOSTATINA; LONGASTATINA; SAMILSTATINA	[R-(R*,R*)]-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2-7)-disulfide	somatostatin analogue; analgesic	Alzheimer disease; cancer; viral infection; psoriasis; diarrhea; diabetes; pain; acromegaly
Vapreotide; octastatin; RC 160; BMY 41606	D-Phe-Cys-Trp-D-Trp-Lys-Val-Cys-Trp-NH ₂	somatostatin analogue; analgesic	cancer; pain
NKT 343; SDZ NKT 343	1-[(2-nitrophenyl)amino]carbonyl]-L-prolyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)-L-alaninamide	substance P antagonist; analgesic	pain
Etanercept; tumor necrosis factor receptor; TNFr; TNR 001;	Unspecified	TNF inhibitor; immunosuppressant; NSAID; analgesic	rheumatoid arthritis; heart failure; diabetes; pain; endometriosis; autoimmune disease

Table 34: Current Candidate Therapeutic Interventions for the Treatment of Parkinson's Disease

Product Name	Chemical Name	Action	Indication
KF 17837	(E)-8-[2-(3,4-dimethoxyphenyl)ethyl]-3,7-dihydro-7-methyl-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist	Parkinson disease
KW 6002	Unspecified	adenosine antagonist	Parkinson disease
Parkinson's disease therapy	Unspecified	adenosine antagonist	Parkinson disease
SCH 58261	2-(2-furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine	adenosine antagonist; adenosine A ₂ antagonist	Parkinson disease

Idazoxan; RX 781094; RX 781094-A	2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist; cardiovascular antiproliferative agent	Parkinson disease; depression; cardiovascular disease; retinopathy
alpha2 adrenoceptor antagonists,	Unspecified	alpha2 adrenergic antagonist; alpha adrenergic antagonist	Parkinson disease
SR 57667	Unspecified	Antineurodegenerative	Alzheimer disease; Parkinson disease
Parkinson's disease therapy,	Unspecified	antioxidant	Parkinson disease
VANTOX	Unspecified	antioxidant; NSAID	asthma; Parkinson disease; Alzheimer disease; stroke
CNS therapy, IDUN; CNS therapy	Unspecified	apoptosis inhibitor; caspase inhibitor	stroke; Parkinson disease; amyotrophic lateral sclerosis
CNS 1237	N-5-acenaphthyl-1-N'-(4-methoxy-1-naphthalenyl)-guanidine	Calcium channel blocker; glutamate release inhibitor	brain ischemia; Parkinson disease; neuropathy
drug delivery system, conopeptides	Unspecified	calcium channel blocker; sodium channel blocker; potassium channel blocker; analgesic	epilepsy; Parkinson disease; stroke; pain; brain ischemia
SIB 1508Y	(S)-3-ethynyl-5-(1-methyl-2-pyrrolidinyl)pyridine	cholinergic agonist; nicotinic agonist	Parkinson disease
SIB S1663; S 1663	2,3,3a,4,5,9b-hexahydro-7-methoxy-1-methyl-1H-pyrrolo[3,2-h]isoquinoline	cholinergic agonist; nicotinic agonist	Parkinson disease
CGP 28014	N'-(1,6-dihydro-6-oxo-2-pyridinyl)-N,N-dipropylmethanimidamide	COMT inhibitor	Parkinson disease
Entacapone; OR 611; COMTAN; COMTESS	(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide	COMT inhibitor	Parkinson disease

Tolcapone; Ro 407592; TASMAR	(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone	COMT inhibitor	Parkinson disease
drug delivery system, controlled release carbidopa + levodopa; carbidopa + levodopa	Unspecified	decarboxylase inhibitor; dopamine agonist	Parkinson disease
Dopaminergic neurotrophic factor; DNTF	Unspecified	DNTF growth factor	Parkinson disease
JA 116a; JA 116	1,2,6,7,8,8a-hexahydro-1-acenaphthylamine hydrochloride	dopamine agonist	Parkinson disease
levodopa methyl; CHF 1301	Unspecified	dopamine agonist	Parkinson disease
levodopa methyl + carbidopa; carbidopa + levodopa methyl; CHF 1512	Unspecified	dopamine agonist	Parkinson disease
Moxiraprine; 4-hydroxyminaprine; CM 30366	p-[5-methyl-6-[(2-morpholinoethyl)amino]-3-pyridazinyl]phenol	dopamine agonist	Parkinson disease
naxagolide; PHNO; dopazinol; MK 458; L 647339	(4aR-trans)-3,4,4a,5,6,10b-hexahydro-4-propyl-2H-naphth[1,2-b]-1,4-oxazin-9-ol	dopamine agonist	Parkinson disease
U 86170F	(R)-5-(dipropylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one monohydrobromide	dopamine agonist	Parkinson disease
WAY 124486	(S)-3-[[3-(3-aminophenoxy)propyl]amino]methyl]-2,3-dihydro-1,4-benzodioxin-6-ol	dopamine agonist	Parkinson disease

Quinelorane; quinelorane hydrochloride; LY 163502	(5aR-trans)-5,5a,6,7,8,9,9a,10-octahydro-6-propylpyrido[2,3-g]quinazolin-2-amine	dopamine agonist	Parkinson disease; hyperprolactinemia; hypertension
HW 165	trans-(+/-)-1,2,3,4,4a,5,6,10b-octahydrobenzo(f)quinolin-7-ol, hydrobromide	dopamine agonist	Parkinson disease; schizophrenia
Apomorphine; apomorphine hydrochloride; UPRIMA	(R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol hydrochloride hydrate (2:1)	dopamine agonist	sexual dysfunction; Parkinson disease
talipexole; BHT 920; DOMINE; DOMIN	6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine	dopamine agonist; alpha adrenergic agonist; alpha2 adrenergic agonist	Parkinson disease; glaucoma
drug delivery system, benserazide + levodopa; benserazide + levodopa, levodopa + benserazide; MADOPAR DR	Unspecified	dopamine agonist; decarboxylase inhibitor	Parkinson disease
A 68930	(1R,3S)-1-aminomethyl-5,6-dihydroxy-3-phenylisochroman	dopamine agonist; dopamine D1 agonist	hypertension; Parkinson disease
A 77636	(1R-cis)-1-(aminomethyl)-3,4-dihydro-3-tricyclo[3.3.1.13,7]dec-1-yl-1H-2-benzopyran-5,6-diol hydrochloride	dopamine agonist; dopamine D1 agonist	Parkinson disease
A 86929	trans-4,5,5a,6,7,11b-hexahydro-2-propylbenzo[f]thieno[2,3-c]quinoline-9,10-diol hydrochloride	dopamine agonist; dopamine D1 agonist	Parkinson disease

ABT 431	(5aR-trans)-4,5,5a,6,7,11b-hexahydro-2-benzo[f]thieno[2,3-c]quinoline-9,10-diol, diacetate (ester), hydrochloride	dopamine agonist; dopamine D1 agonist	Parkinson disease
dopamine agonist	Unspecified	dopamine agonist; dopamine D1 agonist	Parkinson disease
dopamine-D1 agonists, BLSI	Unspecified	dopamine agonist; dopamine D1 agonist	Parkinson disease
dihydrexidine; IP 202	trans-5,6,6a,7,8,12b-hexahydro-benzo[a]phenanthridine-10,11-diol	dopamine agonist; dopamine D1 agonist	Parkinson disease; Alzheimer disease
BAM 1110	(8 beta)-6-methyl-8-(1H-1,2,4-triazol-1-ylmethyl)ergoline (Z)-2-butenedioate	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	Parkinson disease
drug delivery system, transdermal pergolide; pergolide transdermal	Unspecified	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	Parkinson disease
pergolide; pergolide mesylate; LY 141B; LY 127809; PERMAX; CELANCE; PHARKEN; PARKOTIL	(8beta)-8-[(methylthio)methyl]-6-propylergoline	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	Parkinson disease; depression
CQA 206291	Unspecified	dopamine agonist; dopamine D2 agonist	Parkinson disease
drug delivery system, transdermal N 0923; N 0923 transdermal delivery system; N 0923; SPM 962	(S)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthalenol	dopamine agonist; dopamine D2 agonist	Parkinson disease
ropinirole; ropinirole hydrochloride; ropinerole; SKF 101468; SKF 101468A;	(4-2-(dipropylamino)ethyl)-1,3-dihydro-2H-indol-2-one monohydrochloride	dopamine agonist; dopamine D2 agonist	Parkinson disease

U 91356A	(R)-5,6-dihydro-5-(propylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one monohydrochloride	dopamine agonist; dopamine D2 agonist	Parkinson disease
Cabergoline; FCE 21336; CG 101; DOSTINEX; SOGILEN; CABASER	(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)ergoline-8-carboxamide	dopamine agonist; dopamine D2 agonist	Parkinson disease; hyperprolactinemia
PNU 95666; U 95666A	(R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one	dopamine agonist; dopamine D2 agonist; 5HT agonist; 5HT1A agonist	Parkinson disease
Pramipexole; pramipexole dihydrochloride; SND 919; U 98528E; SND919CL2Y; PNU 98528E; SIFROL; MIRAPEX; DAQUIRAN; MIRAPEXIN; FIROL	(S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)-benzothiazole	dopamine agonist; dopamine D2 agonist; dopamine D3 agonist	Parkinson disease; schizophrenia; depression
LEK 8829	(8beta)-9,10-didehydro-N,6-dimethyl-N-2-propynylergoline-8-methanamine	dopamine D1 agonist; dopamine D2 antagonist; 5HT antagonist; 5HT2A antagonist; dopamine agonist; dopamine antagonist	schizophrenia; Parkinson disease
Brasofensine; NS 2214; BMS 204756	[1R-[1alpha,2beta(E),3alpha,5alpha]]-3-(3,4-dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxaldehyde O-methyloxime	dopamine reuptake inhibitor	Parkinson disease
NS 2141	Unspecified	dopamine reuptake inhibitor	Parkinson disease
NS 2200	Unspecified	dopamine reuptake inhibitor	Parkinson disease; depression; addiction

drug delivery system, dopamine secreting implant; dopamine secreting implant; NeuroCRIB	Unspecified	Dopaminergic agonist	Parkinson disease
drug delivery system, dopamine secreting implants, Parkinson's disease; SPHERAMINE	Unspecified	Dopaminergic agonist	Parkinson disease
NB 355	3-hydroxy-L-tyrosine, 4-(2,2,-dimethylpropanoate)	Dopaminergic agonist, L-dopa prodrug	Parkinson disease
epidermal growth factor; EGF	epidermal growth factor	EGF growth factor	eye disease; Parkinson disease
Carboxylated buckminsterfullerenes; carboxyfullerenes	Unspecified	free radical scavenger; apoptosis inhibitor	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
Milacemide; CP 15525; CP 1552S	2-(pentylamino)acetamide	GABA agonist; MAO B inhibitor; MAO inhibitor	epilepsy; Parkinson disease
glial cell line-derived neurotrophic factor; GDNF	Unspecified	GDNF growth factor; neurotrophic factor	Parkinson disease; amyotrophic lateral sclerosis
glial-cell-line-derived neurotrophic factor; GDNF	Unspecified	GDNF growth factor; neurotrophic factor	Parkinson disease; amyotrophic lateral sclerosis
drug delivery system, neurturin secreting implant; neurturin secreting implant; GDNF secreting implant	Unspecified	GDNF; neurotrophic factor; growth factor	Parkinson disease
riluzole; PK 26124; RP 54274; RILUTEK	6-(trifluoromethoxy)-2-benzothiazolamine	glutamate antagonist	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
NS 072	Unspecified	glutamate antagonist	Parkinson disease
MRZ 2579; MRZ 2/579	Unspecified	glutamate antagonist; NMDA antagonist	Parkinson disease; addiction; stroke
CNS 5065	N-(2-chloro-5-ethylphenyl)-N'-(3-ethylphenyl)-N'-methylguanidine	glutamate antagonist; NMDA antagonist	Parkinson disease; neuropathy; brain ischemia

CP 283097	(3R-cis)-3-[4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]-3,4-dihydro-2H-1-benzopyran-4,7-diol	glutamate antagonist; NMDA antagonist	Parkinson disease; stroke; trauma
GPI 1046	1-(3,3-dimethyl-1,2-dioxopentyl)-L-proline 3-(3-pyridinyl)propyl ester	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
NIL-A	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
Neurotrophin agonist	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; neuropathy
V 10367; VA 10367	Unspecified	growth factor; neurotrophic factor	Parkinson disease
drug delivery system, neurotrophin-3 secreting implant; NT-3 implant	Unspecified	growth factor; neurotrophic factor; biotechnology	Alzheimer disease; Parkinson disease; neuropathy
m-NBA	2-amino-3-(3-nitrobenzoyl)propanoic acid	kynurenine 3 hydroxylase inhibitor	epilepsy; Parkinson disease; Alzheimer disease
MDL 72145	(E)-(beta-fluoromethylene)-3,4-dimethoxybenzeneethanamine hydrochloride	MAO B inhibitor; MAO inhibitor	depression; Parkinson disease
2 HxMP	N-(2-hexyl)-N-methylpropargylamine	MAO B inhibitor; MAO inhibitor	Parkinson disease
drug delivery system, transdermal selegiline; selegiline transdermal	Unspecified	MAO B inhibitor; MAO inhibitor	Parkinson disease
M 2 PP	N-(2-pentyl)-N-methylpropargylamine	MAO B inhibitor; MAO inhibitor	Parkinson disease
mofegiline; MDL 72974A; MDL 72974	(E)-4-fluoro-beta-(fluoromethylene)benzenebutanamine	MAO B inhibitor; MAO inhibitor	Parkinson disease

selegiline; selegiline hydrochloride; deprenyl; E 250; FPF 1100; ELDEPRYL; DEPRENYL; JULAP; NIAR; SELEDAT; DEPRILAN; SELEPARKIN; KINABIDE; NOVO-SELEGILINE; MOVERDIN	(R)-N, alpha-dimethyl-N-2-propynylbenzenethanamine	MAO B inhibitor; MAO inhibitor	Parkinson disease
lazabemide; Ro 196327; PAKIO; TEMPNIUM	N-(2-aminoethyl)-5-chloro-2-pyridine-carboxamide	MAO B inhibitor; MAO inhibitor	Parkinson disease; Alzheimer disease
LU 53439	3,4-dimethyl-7-(2-isopropyl-1,3,4-thiadiazol-5-yl)-methoxy-coumarin	MAO B inhibitor; MAO inhibitor	Parkinson disease; cognitive defect
SL 650477; SL 65.0477	[R-(R*,R*)]-5-(methoxymethyl)-3-[6-(4,4,4-trifluoro-3-hydroxybutoxy)-3-benzofuranyl]-2-oxazolidinone	MAO inhibitor; MAO A inhibitor; MAO B inhibitor; oxazolidinone	depression; Parkinson disease
SL 340026; SL 34.0026	3-(2-methoxyethyl)-5-[4-(4,4,4-trifluorobutoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one	MAO inhibitor; MAO B inhibitor	Parkinson disease
rasagiline; rasagiline mesylate; TVP 1012; TV 1012	(R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine	MAO inhibitor; MAO B inhibitor	Parkinson disease; Alzheimer disease
fatty acids, microalgal,	Unspecified	Microalgal extracts	hyperlipidemia; Parkinson disease; Alzheimer disease; eye disease
Neurophilins	Unspecified	Neurophilins	Alzheimer disease; Parkinson disease; neuropathy

LIGA 20; FID 012020	[R-[R*,S*-(E)]]-N-[1-[[[O-(N-acetyl-alfa-neuraminosyl)-(2->3)-O-[O-beta-D-galactopyranosyl-(1->3)-2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1->4)]-O-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranosyl]oxy]methyl]-2-hydroxy-3-heptadecenyl]-2,2-dichloroacetamide	Neuroprotectant	Parkinson disease
neurturin	Unspecified	Neurturin; growth factor; neurotrophic factor	Parkinson disease; amyotrophic lateral sclerosis
SIB 1765F; SIB 1765	3-ethynyl-5-(1-methyl-2-pyrrolidinyl)pyridine, (E)-2-butenedioate (1:1)	nicotinic agonist; cholinergic agonist	Parkinson disease
neurodegeneration therapy	Unspecified	Nicotinic cholinergic receptor ligands	Alzheimer disease; Parkinson disease
nitric oxide synthase inhibitors	Unspecified	nitric oxide synthase inhibitor	Parkinson disease; stroke
remacemide; FPL 12924; PR 934423; FPL 12924AA; PR 934423A; FPL 14144; PR 1032644; FPL 14145, PR 1032646	(+,-)-2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide	NMDA antagonist; glutamate antagonist	epilepsy; Parkinson disease; neurodegeneration
CO 101244	1-[2-(4-hydroxyphenoxy)ethyl]-4-[(4-methylphenyl)methyl]-4-piperidinol hydrochloride	NMDA antagonist; glutamate antagonist	Parkinson disease
PD 158473	3-(1-naphthalenyl)-5-(phosphonomethyl)-L-phenylalanine	NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
PD 159913	Unspecified	NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
Ro 256981	Unspecified	NMDA antagonist; glutamate antagonist	Parkinson disease; stroke

budipine; budipine hydrochloride; BY 701; PARKINSAN	1-(1,1-dimethylethyl)-4,4-diphenylpiperidine	NMDA antagonist; glutamate antagonist; analgesic	Parkinson disease; pain
aptiganel; CNS 1102; CDD 2515A; CERESTAT	N-(3-ethylphenyl)-N-methyl-N'-1-naphthalenyl-guanidine	NMDA antagonist; glutamate antagonist; analgesic	stroke; neuropathy; trauma; Parkinson disease; pain
antisense oligonucleotide, p75	Unspecified	P75 transcriptional coactivator antisense; oligonucleotide	Parkinson disease
alpha-conopeptides	Unspecified	peptide; cholinergic agonist; nicotinic agonist	schizophrenia; Parkinson disease; cancer; urinary incontinence
PNU 151774E	(2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]propanamide monomethanesulfonate	sodium channel blocker; calcium channel blocker; MAO B inhibitor; MAO inhibitor	epilepsy; Parkinson disease; brain ischemia
CEB 1097	Unspecified	Unknown	Parkinson disease
TV 1203	Unspecified	Unknown	Parkinson disease

Table 35. Current Candidate Therapeutic Interventions for the Treatment of Schizophrenia (and Other Psychoses)

Product Name	Chemical Name	Action	Indication
BW 1192U90; 1192U90	2-amino-N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]benzamide	5HT agonist; 5HT1A agonist; dopamine antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia
Ritanserin; R 55667	6-[2-[4-[bis(4-fluorophenyl)methylene]piperidino]ethyl]-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one	5HT antagonist; 5HT2 antagonist	addiction; anxiety; schizophrenia

Ziprasidone; ziprasidone hydrochloride; CP 88059; CP 880591; CP 8805901; ZELDOX	5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one	5HT antagonist; 5HT2 antagonist; 5HT1C antagonist; dopamine antagonist; dopamine D2 antagonist; 5HT1A agonist; 5HT agonist	schizophrenia; anxiety
Ocaperidone; R 79598	3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia
Olanzapine; LY 170053; ZYPREX; ZYPREXA; OLANZEK	2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia; psychosis; depression
Perospirone; SM 9018; LULLAN	cis-2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-hexahydro-1H-isodole-1,3(2H)-dione	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia
Risperidone; R 64766; RISPERDAL; BELIVON	3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia
Eplivanserin; SR 46349; SR 46349B	(1Z,2E)-1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-2-propen-1-one (2E)-2-butenedioate (2:1) salt	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	schizophrenia; insomnia; thrombosis
M 100907; MDL 100907	(R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol	5HT antagonist; 5HT2A antagonist	schizophrenia
Sertindole; LU 23174; S 1991; SERDOLECT	1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl]ethyl]-2-imidazolidinone	5HT antagonist; 5HT2A antagonist; 5HT2C antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia

AS 5370	N-[hexahydro-1-methyl-4-[(3-methylphenyl)methyl]-1H-1,4-diazepin-6-yl]-1H-indazole-3-carboxamide dihydrochloride	SHT antagonist; SHT3 antagonist	emesis; schizophrenia
BMY 33426		SHT antagonist; SHT3 antagonist	schizophrenia
BMY 33462	(4-amino-N-(1-azabicyclo-[2.2.2]oct-3-yl)-2-(butan-2-one-3-yl)oxy-5-chlorobenzamine 1.25 fumerate hydrate	SHT antagonist; SHT3 antagonist	schizophrenia
Ricasetron; BRL 46470; BRL 46470A	endo-2,3-dihydro-3,3-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indole-1-carboxamide	SHT antagonist; SHT3 antagonist	anxiety; schizophrenia; emesis
SHT7 receptor antagonists		SHT antagonist; SHT7 antagonist	depression; insomnia; schizophrenia
BTS 79018		SHT antagonist; dopamine antagonist	schizophrenia
Schizophrenia therapy,		AMPA receptor modulators	schizophrenia; depression
bretazenil; Ro 166028; Ro 166028001	(S)-8-bromo-11,12,13,13a-tetrahydro-9-oxo-9H-imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylic acid 1,1-dimethylethyl ester	benzodiazepine partial agonist	schizophrenia
dopamine release inhibitor,		calcium antagonist; dopamine release inhibitor	schizophrenia
SR 141716; SR 141716A	5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide	cannabinoid antagonist	schizophrenia

Cholecystokinin B antagonist		cholecystokinin antagonist; cholecystokinin B antagonist	schizophrenia; anxiety
LY 288513		cholecystokinin antagonist; cholecystokinin B antagonist	schizophrenia; anxiety
LY 262691	trans-N-(4-bromophenyl)-3-oxo-4,5-diphenyl-1-pyrazolidinecarboxamide	cholecystokinin B antagonist; cholecystokinin antagonist	schizophrenia
Alentemol; alentemol hydrobromide; U 68553B	(+)-2-(dipropylamino)-2,3-dihydrophenalen-5-ol	dopamine agonist	schizophrenia
CGS 15873A	trans-(+,-)-1,3,4,4a,5,10b-hexahydro-4-propyl-2H-[1]benzopyrano[3,4-b]pyridin-7-ol hydrochloride	dopamine agonist	schizophrenia
HW 165	trans-(+/-)-1,2,3,4,4a,5,6,10b-octahydrobenzo(f)quinolin-7-ol, hydrobromide	dopamine agonist	Parkinson disease; schizophrenia
Amisulpride; aminosulpride; AST; DAN 2163; SOCIAN; SOLIAN; ENORDEN; DENIBAN; SULAMID	4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy benzamide	dopamine agonist; dopamine antagonist	schizophrenia; depression
terguride; TDHL; VUFB 6638; ZK 31224; SH 406; DIRONYL; TELURON; TERULON	1,1-diethyl-3-(6-methylergolin-8alpha-yl)urea	dopamine agonist; dopamine antagonist	schizophrenia; hyperprolactinemia

Pramipexole; pramipexole dihydrochloride; SND 919; U 98528E; SND919CL2Y; PNU 98528E; SIFROL; MIRAPEX; DAQUIRAN; MIRAPEXIN; FIROL	(S)-2-amino-4,5,6,7- tetrahydro-6- (propylamino)- benzothiazole	dopamine agonist; dopamine D2 agonist; dopamine D3 agonist	Parkinson disease; schizophrenia; depression
PD 158771	trans-N-[4-[2-(4- phenyl-1- piperazinyl)ethyl]cycl ohexyl]-2- pyrimidinamine	dopamine agonist; dopamine D2 partial agonist; 5HT1A partial agonist; 5HT agonist	schizophrenia
CI 1007; PD 143188	(R)-1,2,3,6- tetrahydro-4-phenyl- 1-[(3-phenyl-3- cyclohexen-1-yl)m ethyl]pyridine	dopamine agonist; dopamine D2 partial agonist; dopamine D3 partial agonist	schizophrenia
GYKI 22441; BRENFUMOD	2-(4-chlorophenoxy)- 2-methylpropanoic acid 2-[4-[3-[2- (trifluoromethyl)- 10H-phenothiazin-10- yl]propyl]-1- piperazinyl]ethyl ester	Dopamine antagonist Phenothiazine ester	schizophrenia
Isofloxythepin; VUFB 10662	4-[3-fluoro-10,11- dihydro-8-(1- methylethyl)dibenzo[b,f]thiepin-10-yl]-1- piperazineethanol	Dopamine antagonist	schizophrenia
Bromperidol; R 11333; IMPROMEN; BRIDOL; IMPROMEN DECANOAS; ERODIUM; LUNAPRON; PRINDRIL; ROPEL	4-[4-(4- bromophenyl)-4- hydroxy-1- piperidinyl]-1-(4- fluorophenyl)-1- butanone	dopamine antagonist	schizophrenia
dopamine D4 antagonists, Taisho		dopamine antagonist	schizophrenia

Nemonapride; emonapride; YM 09151; YM 091512; EMILACE; SEPAN; NEPONID	cis-5-chloro-2-methoxy-4-(methylamino)-N-[2-methyl-1-(phenylmethyl)-3-pyrrolidinyl]benzamide	dopamine antagonist	schizophrenia
Savoxepin; cipazoxapine; CGP 19486	3-(cyclopentylmethyl)-2,3,4,5-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-d]azepine-7-carbonitrile	dopamine antagonist	schizophrenia
NGD 931; NGB 566		dopamine antagonist, SHT agonist, adrenergic agonist; Atypical neuroleptic,	schizophrenia
Quetiapine; quetiapine fumarate; ZD 5077; Zeneca 204636; ICI 204636; SEROQUEL	2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol	dopamine antagonist; SHT antagonist; SHT2 antagonist	schizophrenia
Berupipam; NNC 220010	(S)-8-chloro-5(5-bromo-2,3-dihydrobenzofuran-7-yl)-7-hydroxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine	dopamine antagonist; dopamine D1 antagonist	schizophrenia
CEE 03310; NNC 010687; NNC 687; NO 687; NNC 01-0687	(S)-5-(2,3-dihydro-7-benzofuranyl)-2,3,4,5-tetrahydro-3-methyl-8-nitro-1H-3-benzazepin-7-ol	dopamine antagonist; dopamine D1 antagonist	schizophrenia; insomnia
CEE 03320; NNC 220215	Unspecified	dopamine antagonist; dopamine D1 antagonist	schizophrenia
ecopipam; SCH 39166	(6aS-trans)-11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-12-ol	dopamine antagonist; dopamine D1 antagonist	schizophrenia

ZD 3638; M 275562	4-[2-(ethylsulfinyl)-3-pyridinyl]-1-(9,10-methanoanthracen-9(10H)-ylmethyl)-4-piperidinol	dopamine antagonist; dopamine D1 antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia
zotepine; LODOPIN; NIPOLEPT; ZOLEPTIL; ZOPITE; SETOUS; MAJORPIN	2-[(8-chlorodibenzo[b,f]thiophen-10-yl)oxy]-N,N-dimethylethylamine	dopamine antagonist; dopamine D1 antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist; noradrenalin reuptake inhibitor	schizophrenia
Mosapramine; clospipramine; Y 516; CREMIN	(+,-)-1'-(3-(3-chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl)hexahydrospiro[imidazo[1,2-a]pyridine-3(2H),4'-piperidin]-2-one	dopamine antagonist; dopamine D2 antagonist	schizophrenia
Remoxipride; remoxipride hydrochloride; FLA 731; A 33547; ROXIAM	(S)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenzamide	dopamine antagonist; dopamine D2 antagonist	schizophrenia
RWJ 25730	1-[[1-methyl-5-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]-1H-pyrrol-2-yl]methyl-2-piperidinone	dopamine antagonist; dopamine D2 antagonist	schizophrenia
DU 29894		dopamine antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT1A antagonist	schizophrenia
Blonanserin; AD 5423	2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine	dopamine antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia

ORG 5222	trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepin o[4,5-c]pyrrole maleate (1:1)	dopamine antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia
Amisulpride, (S); (-)-amisulpride	(S)-4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide	dopamine antagonist; dopamine D2 antagonist; dopamine D3 antagonist	schizophrenia
RGH 1756	6-[4-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butoxy]phenyl]imidazo[2,1-b]thiazole	dopamine antagonist; dopamine D3 antagonist	schizophrenia; psychosis
YM 43611	(S)-5-chloro-4-[(cyclopropylcarbonyl)amino]-2-methoxy-N-[1-(phenylmethyl)-3-pyrrolidinyl]benzamide	dopamine antagonist; dopamine D3 antagonist; dopamine D4 antagonist	schizophrenia
CP 293019	7-[4-(fluorophenoxy)methyl]-2-(5-fluoro-2-pyrimidinyl)octahydro-2H-pyrido[1,2-a]pyrazine	dopamine antagonist; dopamine D4 antagonist	schizophrenia
L 745870	3-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]-1H-pyrido[2,3-b]pyridine	dopamine antagonist; dopamine D4 antagonist	schizophrenia
NGD 941	2-[4-[(2-phenyl-1H-imidazol-4-yl)methyl]-1-piperazinyl]pyrimidine	dopamine antagonist; dopamine D4 antagonist	schizophrenia
NGD 944; NGD 94-4		dopamine antagonist; dopamine D4 antagonist	schizophrenia

PD 172760	7-[[4-(4-chlorophenyl)-1-piperazinyl]methyl-2H-1,4-benzoxazin-3(4H)-one	dopamine antagonist; dopamine D4 antagonist	schizophrenia
Sonepiprazole; PNU 101387; U 101387G	(S)-4-[4-[2-(3,4-dihydro-1H-2-benzopyran-1-yl)ethyl]-1-piperazinylbenzenesulfonamide	dopamine antagonist; dopamine D4 antagonist	schizophrenia
Belaperidone; LU 111995	(1alpha,5alpha,6alpha)-3-[2-[6-(4-fluorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]ethyl]-2,4(1H,3H)-quinazolininedione	dopamine antagonist; dopamine D4 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia
dopamine antagonist		dopamine antagonist; dopamine D4 antagonist; dopamine D2 antagonist	schizophrenia; psychosis
HMR 2934		dopamine antagonist; dopamine D4 antagonist; dopamine D2 antagonist; 5HT antagonist	schizophrenia
LEK 8829	(8beta)-9,10-didehydro-N,6-dimethyl-N-2-propynylergoline-8-methanamine	dopamine D1 agonist; dopamine D2 antagonist; 5HT antagonist; 5HT2A antagonist; dopamine agonist; dopamine antagonist	schizophrenia; Parkinson disease
levosulpiride; LEVOPRAID	(S)-5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide	dopamine D2 antagonist; dopamine antagonist	emesis; schizophrenia
LU 201640		dopamine D3 antagonist; dopamine antagonist	schizophrenia

fananserin; RP 62203	2-[3-[4-(4-fluorophenyl)-1-piperazinyl]propyl]-2H-naphth[1,8-cd]isothiazole, 1,1-dioxide	dopamine D4 antagonist; dopamine antagonist; 5HT antagonist; 5HT2A antagonist	schizophrenia
valproate semisodium; divalproex sodium; semisodium valproate; AB 50711; DEPAKOTE; EPIVAL; VALCOTE	2-propylpentanoic acid sodium salt (2:1)	GABAergic agonist	epilepsy; migraine; schizophrenia; depression
glycine reuptake inhibitors,		Glycine reuptake inhibitors, GlyT-1	schizophrenia
ciproxifan; compound 359; BP 2359	cyclopropyl[4-[3-(1H-imidazol-4-yl)propoxyl]phenyl]ethanone	histamine antagonist; histamine H3 antagonist	Alzheimer disease; schizophrenia; cognitive defect
compound 421		histamine antagonist; histamine H3 antagonist	Alzheimer disease; schizophrenia; cognitive defect
metabotropic glutamate receptor modulators		metabotropic glutamate receptor modulators , analgesic	pain; cognitive defect; schizophrenia; epilepsy
osanetant; SR 142801	(R)-N-[1-[3-[1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl]propyl-4-phenyl-4-piperidinyl]-N-methylacetamide monohydrochloride	neurokinin antagonist; neurokinin 3 antagonist	schizophrenia; anxiety
SR 48692	2-[[1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]tricyclo[3.3.1.13,7]deca-2-carboxylic acid	neurotensin antagonist	schizophrenia; cancer
conantokins		NMDA antagonist; glutamate antagonist; peptide; analgesic	epilepsy; stroke; schizophrenia; pain; ischemia

alpha-conopeptides		peptide; cholinergic agonist; nicotinic agonist	schizophrenia; Parkinson disease; cancer; urinary incontinence
lithium gamolenic acid; SC 111	(Z,Z,Z)-6,9,12-octadecatrienoic acid lithium salt	phospholipase inhibitor	schizophrenia
panamesine; EMD 57445	(S)-5-[[4-(1,3-benzodioxol-5-yl)-4-hydroxy-1-piperidinyl]methyl]-3-(4-methoxyphenyl)-2-oxazolidinone	sigma agonist; dopamine antagonist	schizophrenia
BMY 14802; BMY 148021	alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol	sigma antagonist	schizophrenia
CNS 1044		sigma antagonist	schizophrenia
CNS 1169		sigma antagonist	schizophrenia
CNS 1307		sigma antagonist	schizophrenia
CNS 3040		sigma antagonist	schizophrenia
MS 355		sigma antagonist	schizophrenia
NPC 16316		sigma antagonist	schizophrenia
MK 869		substance P antagonist	depression; anxiety; schizophrenia; emesis
CX 516; AMPALEX	1-(6-quinoxalinylcarbonyl)piperidine	Unknown	Alzheimer disease; schizophrenia
Maroxepine; CGP 13442A	2,3,4,5-tetrahydro-3-methyl-1H-dibenz[2,3:6,7]oxepin o[4,5-d]azepine	Unknown	schizophrenia

Table 36. Current Candidate Therapeutic Interventions for the Treatment of Spasticity

Product Name	Chemical Name	Action	Indication
Tizanidine; tizanidine hydrochloride; AN 021A; DS 103 282 CH; SIRDALUD; ZANAFLEX; TEMELIN	5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine	alpha adrenergic agonist; alpha2 adrenergic agonist; antispasmodic; muscle relaxant	muscle spasm

botulinum A toxin; Clostridium botulinum toxin type A; DYSPORT	Botulinum toxin A	cholinergic antagonist; muscle relaxant	muscle spasm; eye disease
botulinum toxin type A; Clostridium botulinum toxin type A; OCULINUM; BOTOX	Botulin A	cholinergic antagonist; muscle relaxant	muscle spasm; eye disease; migraine
riluzole; PK 26124; RP 54274; RILUTEK	6-(trifluoromethoxy)-2-benzothiazolamine	glutamate antagonist	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
GRI 2	Unspecified	Glycine reuptake inhibitors	muscle spasm
afloqualone; HQ 495; AROFUTO; ALOFT; PLENCO; AFROBARON	6-amino-2-(fluoromethyl)-3-oxotolyl-4(3H)-quinazolinone	muscle relaxant	surgery
lanperisone; lanperisone hydrochloride; NK 433	2-methyl-3-(1-pyrrolidinyl)-1-[4-(trifluoromethyl)phenyl]-1-propa none	muscle relaxant	muscle spasm; urinary incontinence
MS 322	(R)-(+)-3-phenyl-5-(2-(1-pyrrolidinylmethyl)butyryl)isoxazole hydrochloride	muscle relaxant	muscle spasm
threonine, L-; L-threonine; IP 204	L-threonine	unknown	muscle spasm

Table 37. Current Candidate Therapeutic Interventions for the Treatment of Stroke

Product Name	Chemical Name	Action	Indication
repinotan; BAY x 3702	(R)-2-[4-[[3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl-1,2-benzisothiazol-3(2H)-one 1,1-dioxide	5HT agonist; 5HT1A agonist	stroke; trauma
Levemopamil; emopamil, (S)	(2S)-2-isopropyl-5-(methylphenethylamino)-2-phenylvaleronitrile	5HT antagonist; 5HT2 antagonist; calcium antagonist; antihypoxic	stroke

SHT4 human neuroreceptor; neuroreceptor, 5HT4		SHT4 human neuroreceptor	irritable bowel syndrome; cognitive defect; anxiety; arrhythmia; stroke; urinary incontinence; migraine; research tool
A3 receptor regulator		Adenosine 3 receptor ligand	stroke
Adenosine A1 agonists		adenosine A1 agonist	stroke
AMP 579		adenosine agonist; adenosine A1 agonist; adenosine A2 agonist	myocardial infarction; stroke
GP 04012		adenosine antagonist; adenosine A1 antagonist	stroke; trauma
Adenosine allosteric modulators		adenosine regulating agent	cardiovascular disease; cancer; stroke
Adenosine regulating agents, stroke		adenosine regulating agent	stroke
CPC 407		adenosine regulating agent	stroke
GP 1668; GP 668	5-amino-1-[beta-D-5- phosphoribofuranosyl]-imidazole-1-N-[(4- nitrophenyl)methyl]c arboxamide)	adenosine regulating agent	angina; stroke
NS 257		AMPA antagonist; glutamate antagonist	stroke
NS 479		AMPA antagonist; glutamate antagonist	stroke; neuropathy
S 176252; S 17625	(6,7-dichloro-1,2- dihydro-2-oxo-3- quinolinyl)phosphoni c acid	AMPA antagonist; glutamate antagonist	stroke
SH 608		AMPA antagonist; glutamate antagonist	stroke

SPD 502; NS 1209	2-[[5-[4-((dimethylamino)sulfonyl)phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy]-4-hydroxybutanoic acid monosodium salt	AMPA antagonist; glutamate antagonist	stroke; neurodegeneration
SYM 2189		AMPA antagonist; glutamate antagonist	stroke; epilepsy
SYM 2206	8-(4-aminophenyl)-5-methyl-N-propyl-1,3-dioxolo[4,5-g]phthalazine-6(5H)-carboxamide	AMPA antagonist; glutamate antagonist	stroke; epilepsy
YM 872	3,4-dihydro-7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-1(2H)-quinoxalineacetic acid	AMPA antagonist; glutamate antagonist	stroke
losartan; losartan potassium; DUP 753; MK 954; DUP 89; E 3340; AVASTAR; COZAAR; LOORTAN; NULOTAN	2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl] -1H-imidazole-5-methanol	angiotensin II antagonist	hypertension; anxiety; stroke; heart failure; myocardial infarction
TN 871	1-(6-butyl-6,7-dihydro-5H-indeno[5,6-d]-1,3-dioxol-5-yl)-4-methyl piperazine dihydrochloride	Anoxia protection	stroke
apocuanzine; IDB 1057	(3alfa,16alfa,17alfa)-17,21-epoxy-12-methoxy-eburnamenine-14-carboxylic acid methyl ester	antihypoxic	stroke
hypoxia therapy		antihypoxic	heart ischemia; stroke
KF 17329		antihypoxic	stroke; brain ischemia
KF 19863		antihypoxic	stroke

MS 153	(-)-1-nicotinoyl-5-methyl-2-pyrazoline	anti-ischemic	stroke
YM 737	N-(N-L-gamma-glutamyl-L-cysteinyl)-glycine, 1-(1-methyl)ester	anti-ischemic	stroke
BXT 51072	3,4-dihydro-4,4-dimethyl-2H-1,2-benzoselenazine	antioxidant	stroke; inflammatory bowel disease
CEB 1370		antioxidant	stroke
LY 231617	2,6-bis(1,1-dimethylethyl)-4-[(ethylamino)methyl]phenol hydrochloride	antioxidant	stroke
Neurodegenerative disease therapy		antioxidant	stroke; Alzheimer disease
U 101033E	6,7,8,9-tetrahydro-9-[2-(4-morpholinyl)ethyl]-2,4-di-1-pyrrolidinyl-5H-pyrimido[4,5-b]indole dihydrochloride	antioxidant	stroke; neurodegeneration; brain ischemia
MDL 101002	3,4-dihydro-3,3-dimethylisoquinoline 2-oxide	antioxidant; free radical scavenger	stroke; neurodegeneration; septic shock
synthetic catalytic scavenger analogues; SCS analogues		antioxidant; free radical scavenger	stroke; trauma; atherosclerosis; neurodegeneration; asthma
VANTOX		antioxidant; NSAID	asthma; Parkinson disease; Alzheimer disease; stroke
secreted apoptosis related proteins; SARPs		apoptosis inducer; apoptosis inhibitor	cancer; myocardial infarction; stroke
CNS therapy, IDUN; CNS therapy		apoptosis inhibitor; caspase inhibitor	stroke; Parkinson disease; amyotrophic lateral sclerosis
VM 201		blood clotting factor IXa inhibitor; proteinase inhibitor	thrombosis; stroke
factor Xa inhibitor		blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis; stroke; myocardial infarction

JTV 803		blood clotting factor Xa inhibitor; proteinase inhibitor	stroke; myocardial infarction; thrombosis
deltibant; CP 0127; SB 238592; BRADYCOR	hexamethylene-bis-(succinimido-Cys(Leu)-Phe-Gly-Hyp-Pro-Arg)	bradykinin antagonist; cicatrizant	trauma; stroke
AJ 3941	11-(4-cinnamyl-1-piperazyl)-3-fluoro-6,11-dihydrodibenzo[6,e]oxepine-2 maleate	calcium antagonist	stroke
calcium antagonist		calcium antagonist	stroke
lifarizine; RS 87476; RS 87476000	1-(diphenylmethyl)-4-[[5-methyl-2-(4-methylphenyl)-1H-imidazol-4-yl]methyl]piperazine	calcium antagonist	stroke; brain ischemia
NCC 161; LY 042826		calcium antagonist	ischemia; stroke
S 830256	3-cyclo-pentyl-5-cyclopentyloxyethoxycarbonyl-4,7-dihydro-1,6-di methyl-4-(2-nitro-phenyl)pyrazolo-(3,4-b)pyridine hydrochloride	calcium antagonist	stroke
S 830327	methyl-4,7-dihydro-3-n-butyl-6-methyl-4-(3-nitrophenyl)thieno(2,3-b)pyridine-5-carboxylate	calcium antagonist	stroke
NPS 846		calcium antagonist; analgesic	stroke; epilepsy; pain
ziconotide; SNX 111; CI 1009	omega-conotoxin MVIIA	calcium antagonist; analgesic; peptide	stroke; pain; brain ischemia
rumbrin	(1Z,3E,5E,7E)-6-(8-(3-chloro-1H-pyrrol-2-yl)-1-methyl-1,3,5,7-octatetraenyl)-4-methoxy-3-methyl-2H-pyran-2-one	calcium antagonist; free radical scavenger	stroke

F 0401; D 31D	(E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-propenyl-methyl-1,4-dro-2,6-dimethyl-4-(3-nitrophenyl) 3,5-pyridinedicarboxylate	calcium antagonist; PAF antagonist; thromboxane synthetase inhibitor; vasodilator	stroke
S 312; S 312d; S 830312	4,7-dihydro-6-methyl-3-(2-methylpropyl)-4-(3-nitrophenyl)-thieno[2,3-b]pyridine-5-carboxylic acid methyl ester	calcium antagonist; vasodilator	stroke
U 92032	7-[[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]methyl]-2-[(2-hydroxyethyl)amino]-4-(1-methylethyl)-2,4,6-cycloheptatrien-1-one	calcium antagonist; vasodilator	stroke
calcium channel blocker		calcium channel blocker	stroke
Calcium channel blockers		calcium channel blocker	stroke
calcium channel blockers		calcium channel blocker	stroke
CPC 301		calcium channel blocker	stroke
CPC 304		calcium channel blocker	stroke
CPC 317		calcium channel blocker	stroke
CPC 8027		calcium channel blocker	stroke; epilepsy
CPC 8029		calcium channel blocker	stroke; epilepsy
NS 3034		calcium channel blocker	stroke
NS 638		calcium channel blocker	stroke

SB 201823A	4-[2(3,4-dichlorophenoxy)ethyl]-1-pentyl piperidine hydrochloride	calcium channel blocker	stroke
drug delivery system, conopeptides		calcium channel blocker; sodium channel blocker; potassium channel blocker; analgesic	epilepsy; Parkinson disease; stroke; pain; brain ischemia
DP 16	Acylglycerol derivative of BAPTA	Calcium chelator	epilepsy; stroke; heart ischemia
stroke therapy	N-1-naphthalenyl-1-(3-phenoxypropyl)-4-piperidinamine	Calcium lowering agent	stroke
DY 9760	3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-1-(1H-imidazol-4-ylmethyl)-5,6-dimethoxy-1H-indazole	calmodulin antagonist	brain ischemia; stroke
calpain inhibitors		calpastatin	stroke
calpain inhibitors,		calpastatin; proteinase inhibitor	stroke
caspase antagonists		caspase inhibitor; apoptosis inhibitor	stroke; myocardial infarction
KF 10632; IKY 432	2-methyl-1-[1-oxo-3-[4-(trifluoromethyl)phenyl]-2-propenyl]piperidine	Cerebroprotectant	stroke
acetyl-L-carnitine; acetylcarnitine, L-; ALC; ST 200; TA 803; NICETILE; BRANIGAN; ALCAR; NEUROACTIL; BRANIGEN	acetyl-L-carnitine	Cholinergic agonist stimulation of nerve growth	Alzheimer disease; stroke; diabetes; neuropathy
Aniracetam; Ro 135057; SARPUL; DRAGANON; APAMET; RESET	1-(4-methoxybenzoyl)-2-pyrrolidinone	cholinergic antagonist	cognitive defect; stroke

Citicoline; citicoline sodium; cytidil diphosphocholine; CDP choline; IP 302; NEUROX; ALPHCOLIN; HIPERCOL; NEUREX; SOMAZINA; TRAUSAN	P'-[2-(trimethylammonio)ethyl] citidine 5'- (trihydrogen diphosphate)	cholinesterase inhibitor	stroke
Fibroblast growth factor agonist,		cicatrizant; FGF agonist	skin ulcer; stroke
MAb, C5 single chain; Mab, complement C5; 5G1.1-SC		complement inhibitor; monoclonal antibody; NSAID	inflammation; myocardial infarction; stroke; ischemia
NBI 102		CRF antagonist	stroke
NBI 104		CRF antagonist	depression; stroke
interleukin-8 antagonists; IL-8 antagonists		cytokine antagonist	myocardial infarction; stroke; respiratory distress syndrome
endothelin B antagonist,		endothelin B antagonist; endothelin antagonist	stroke
endothelium-associated disease therapy,		Endothelin receptor ligand	stroke; asthma
ABPI 126		estrogen agonist	stroke
ABPI 127		estrogen agonist	stroke
excitatory amino acid antagonists		excitatory amino acid antagonist	epilepsy; Alzheimer disease; stroke
NPC 18123		excitatory amino acid antagonist; glutamate antagonist	epilepsy; stroke
excitatory amino acid receptor modulators		Excitatory amino acid receptor ligand	stroke
APO 99		free radical scavenger	stroke; ischemia; reperfusion injury
K 7259	hexahydro-1,4-bis[4-(3,4,5-trimethoxyphenyl)butyl]-1H-1,4-diazepine dihydrochloride	free radical scavenger	stroke
NXY 059		free radical scavenger	stroke

Pyrrolostatin	4-geranylpyrrole-2-carboxylic acid	free radical scavenger	stroke
resorstatin		free radical scavenger	stroke
stobadine; DH 1101; DP 1031	(4aR,9bS)-2,3,4,4a,5,9b-hexahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole dihydrochloride	free radical scavenger	ischemia; stroke
TAK 218	(S)-2,3-dihydro-2,4,6,7-tetramethyl-2-[(4-phenyl-1-piperidinyl)methyl]-5-benzofuranamine dihydrochloride	free radical scavenger	stroke; trauma
EUK 134	(SP-5-13)-chloro[[2,2'-[1,2-ethanediylbis[(nitrilo-kappaN)methylidyne]]bis[6-methoxyphenolato-kappaO1]]]-manganese	free radical scavenger; antioxidant	stroke
free radical scavengers		free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
SLH 301		free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
EPC K1; CHX 3107	[2R-[2R*(4R*,8R*)]]-2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl hydrogen phosphate] L-ascorbic acid esters, monopotassium salt	free radical scavenger; phospholipase inhibitor; cytokine antagonist; NSAID	stroke

OC 5186	(5Z,13E,15S)-15-hydroxy-9-oxo-prosta-5,8(12),13-trien-1-oic acid, homopolymer, ester with L-ascorbic acid	free radical scavenger; prostanoid	cancer; stroke; malaria
BMS 183729; BMY 20862	5,6-dihydro-11-methyl-11H-pyrimido[4,5-6][1,4]benzodiazepine	GABA agonist	neuropathy; stroke
clomethiazole; CMZ; HEMINEVRIN; ZENDRA		GABA modulator	insomnia; stroke
GM-1; ganglioside GM-1;	monosialotetrahexosylganglioside	ganglioside	stroke
siagoside; AGF 2	[R-[R*,S*-(E)]]-N-[1-[[[O-[1',2-anhydro]-N-acetyl-alpha-neuraminosyl-(2->3)-O-[O-beta-D-galactopyranosyl-(1->3)-2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1->4)-O-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranosyl]oxy]methyl]-2-hydroxy-3-heptadecenyl]octadecanamide	ganglioside	cognitive defect; stroke
stroke therapy		glutamate agonist; mGluR agonist	stroke
HF 7		glutamate antagonist	stroke
NNC 079202; FG 9202	1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo(f)quinoxaline-7-sulfon amide	glutamate antagonist	epilepsy; stroke
NS 409; PD 152247; PNQX	1,4,7,8,9,10-hexahydro-9-methyl-6-nitro-pyrido[3,4-f]quinoxaline-2,3-dione	glutamate antagonist	stroke
AMPA antagonist		glutamate antagonist; AMPA antagonist	stroke

CP 465022	3-(2-chlorophenyl)-2-[2-[6-[(diethylamino)methyl]-2-pyridinyl]ethenyl]-6-fluoro-4(3H)-quinazolinone (Z)-2-butenedioate (1:1)	glutamate antagonist; AMPA antagonist	stroke
NNC 070775		glutamate antagonist; AMPA antagonist	stroke
YM 90K; YM 900	1,4-dihydro-6-(1H-imidazol-1-yl)-7-nitro-2,3-quinoxalinedione monohydrochloride	glutamate antagonist; AMPA antagonist	stroke
sinnabidol; HU 211; PA 50211; DEXANABINOL	(6aS-trans)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol	glutamate antagonist; cannabinoid; NMDA antagonist; free radical scavenger	cognitive defect; stroke; trauma; myocardial infarction; glaucoma
ACPC; cycloleucine; cycloleucin; NSC 1026; WR 14997	1-aminocyclopentanecarboxylic acid	glutamate antagonist; NMDA antagonist	coronary artery disease; anxiety; depression; stroke; epilepsy; addiction
CP 283097	(3R-cis)-3-[4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]-3,4-dihydro-2H-1-benzopyran-4,7-diol	glutamate antagonist; NMDA antagonist	Parkinson disease; stroke; trauma
dizocilpine; dizocilpine maleate; MK 801	(+)-10,11-dihydro-5-methyl-5H-dibenzo[a,d]cyclohepten-5,10-imine	glutamate antagonist; NMDA antagonist	epilepsy; stroke; neuropathy
EAA 090	[2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid	glutamate antagonist; NMDA antagonist	stroke

GPI 3000; NPC 17742	[1R-[1alpha(R*),2alpha]]-alpha-amino-2-(2-phosphonoethyl)cyclohexane propanoic acid	glutamate antagonist; NMDA antagonist	epilepsy; stroke; neuropathy
L 701324	7-chloro-4-hydroxy-3-(3-phenoxyphenyl)-2(1H)-quinolinone	glutamate antagonist; NMDA antagonist	epilepsy; stroke
MRZ 2579; MRZ 2/579		glutamate antagonist; NMDA antagonist	Parkinson disease; addiction; stroke
2-PMPA; GPI 5000		glutamate release inhibitor	stroke; neurodegeneration
BW 1003C87	Ethanesulfonic acid cmpd. with 5-(2,3,5-trichlorophenyl)-2,4-pyrimidinediamine (1:1)	glutamate release inhibitor	stroke
sipatrigine; BW 619C89; BW 619C	2-(4-methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)-4-pyrimidinamine	glutamate release inhibitor	stroke
ACEA 1031		glycine antagonist	stroke
gavestinel; GV 150526; GV 150526A; GV 150526X; GG 526; GV 526A	(E)-4,6-dichloro-3-[3-oxo-3-(phenylamino)-1-propenyl]-1H-indole-2-carboxylic acid	glycine antagonist	stroke
HMR 2371		glycine antagonist	stroke
M 241247		glycine antagonist	stroke
M 244249		glycine antagonist	stroke
ZD 9379	7-chloro-3,5-dihydro-2-(4-methoxy-2-methylphenyl)-pyridazino[4,5-b]quinoline-1,4-10(5H)-trione, base and salts	glycine antagonist	stroke
glycoprotein IIb/IIIa antagonist; P246		glycoprotein IIb/IIIa antagonist; peptide; platelet antiaggregant	thrombosis; heart ischemia; stroke
cromafiban		glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; stroke

EMD 122347; YM 028		glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; angina; stroke
MK 852; L 367073	N-acetyl-L-cysteinyl-L-asparaginyl-(4R)-5,5-dimethyl-4-thiazolidinecarbonyl-4-(aminomethyl)-L-phenylalanylglycyl-L-alpha-aspartyl-L-cysteine, cyclic (1-7)-disulfide	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	stroke; thrombosis
SDZ GPI562	Unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; stroke
pimagedine; pimagedine hydrochloride; aminoguanidine; GER 11; YM 585	aminoguanidine	Glycosylation end-product inhibitor	diabetes; kidney disease; retinopathy; atherosclerosis; neuropathy; stroke
fibroblast growth factor-10		Growth factor, fibroblast growth factor-10	stroke; trauma
insulin-like growth factor-1; IGF-1		Growth factor, IGF-1	brain ischemia; trauma; stroke; neurodegeneration
transforming growth factor beta; TGFbeta		Growth factor, TGF-beta	brain ischemia; trauma; stroke; neurodegeneration
ersofermin; fibroblast growth factor, basic; basic fibroblast growth factor; bFGF; TROFAK	N-(N-glycyl-L-threonyl)-basic fibroblast growth factor (human clone lambdaKB7/lambdaH FL1 precursor reduced)	growth factor; cicatrizant	stroke
trafermin; fibroblast growth factor, basic; basic fibroblast growth factor; bFGF; trofermin; KCB 1; CAB 2001; FIBLAST	2-155-fibroblast growth factor, basic (human clone lambda KB7/lambda HFL 1 precursor reduced)	growth factor; cicatrizant	skin ulcer; osteoporosis; stroke; neuropathy; peripheral vascular disease; coronary artery disease

drug delivery system; proteinase inhibitor and trophic factor secreting implant; proteinase inhibitor secreting implant; trophic factor secreting implant		growth factor; neurotrophic factor; proteinase inhibitor	stroke
heat shock transcription factor modulators, ischemia; heat shock transcription factor modulators, cancer		heat shock transcription factor modulators	stroke; ischemia; reperfusion injury; cancer
RSR 13	2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid	Hemoglobin, allosteric modification	surgery; heart ischemia; stroke
RSR 4	2-[4-[2-[(3,5-dichlorophenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid	Hemoglobin, allosteric modification	cancer; surgery; heart ischemia; stroke
RSR 46	2-[4-[2-[(2,3-dihydro-1H-inden-5-yl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid	Hemoglobin, allosteric modification	cancer; surgery; heart ischemia; stroke
JP 7		Hemoglobin, synthetic allosteric modifiers of	cancer; surgery; heart ischemia; stroke
enoxaparin sodium; low molecular weight heparin; enoxaparin; enoxaparine; PK 10169; RPY 005; RP 54563; LOVENOX; CLEXAN; CLEXANE	heparin sodium salt	heparinoid	thrombosis; angina; stroke; myocardial infarction
GT 2016	1-(5-cyclohexyl-1-oxopentyl)-4-(1H-imidazol-4-yl)piperidine	histamine antagonist; histamine H3 antagonist	cognitive defect; stroke; attention deficit disorder
MAb, 1A29; MAb, ICAM-1		ICAM monoclonal antibody	stroke

NZ 097		IGF-1 ligand	brain ischemia; trauma; stroke; neurodegeneration
antibody-mediated stroke inhibitor		immunosuppressant; biotechnology	gynecological; stroke; thrombosis; myocardial infarction
insulin-like growth factor binding protein ligand inhibitors, IGFBP ligand inhibitors		insulin-like growth factor binding protein ligand inhibitors	stroke; neurodegeneration
neutrophil inhibitory factor; NIF; CORLEUKIN NIF		integrin antagonist; cell adhesion inhibitor; NSAID	reperfusion injury; inflammation; stroke
AM 36		Ion channel blocker	stroke; trauma
cation channel blocker		Ion channel blocker, cation channel blocker	stroke
Tirilazad; tirilazad mesylate; trilazad; U 74006F; FREEDOX	21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-alpha-me thyl-pregn-1,4,9-(11)-triene-3,20-dione	lazaroid	brain ischemia; stroke; trauma; heart ischemia; kidney disease
MAbs, leukocytes		Leukocytes monoclonal antibody	stroke
MAb, 23F2G; MAb, leukointegrin; Hu 23F2G		leukointegrin monoclonal antibody	multiple sclerosis; cardiovascular disease; myocardial infarction; stroke
stroke and trauma therapy, morphogenic proteins,		morphogenic proteins	trauma; stroke
Lubeluzole; R 87926; PROSYNAP	(S)-4-(2-benzothiazolylmethyl amino)-alpha-[(3,4-difluorophenoxy)methyl]-1-piperidineethanol	Neuroprotectant	stroke; Alzheimer disease
drug delivery system, neurotrophic peptide; neurotrophic peptide delivery system; TROFEXIN-A	Trofexin-A	Neurotrophic factor	stroke

Neurotrophic peptide TROFEXIN		neurotrophic factor; peptide; growth factor	stroke
NOX 101	Unspecified	nitric oxide scavenger	stroke; diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
NOX 151		nitric oxide scavenger	stroke
A 84643	[S-(E)]-N-(4-amino-5-hydroxy-2-pentenyl)-N'-nitroguanidine	nitric oxide synthase inhibitor	stroke; ischemia
Neuronal nitric oxide synthase inhibitors		nitric oxide synthase inhibitor	stroke; trauma
nitric oxide synthase inhibitors		nitric oxide synthase inhibitor	Parkinson disease; stroke
nitric oxide inhibitors		nitric oxide synthetase inhibitor; NSAID	stroke; rheumatoid arthritis
ARL 15896; FPL 15896; ARL 15896AR; FPL15896AR	(S)-alpha-phenyl-2-pyridineethanamine	NMDA antagonist; glutamate antagonist	stroke
BIII 277; BIII 277CL	[2R-[2alpha,3(R*),6alpha[1,2,3,4,5,6-hexahydro-3-(2-methoxypropyl)-6,11,11-trimethyl-2,6-methano-3-benzazocin-9-ol hydrochloride	NMDA antagonist; glutamate antagonist	stroke
CGP 40116	[R-(E)]-2-amino-4-methyl-5-phosphono-3-pentenoic acid	NMDA antagonist; glutamate antagonist	epilepsy; stroke
CNS 1118	N,N'-dimethyl-N,N'-bis(1-naphthyl)guanidine	NMDA antagonist; glutamate antagonist	stroke
CNS 1531	(+)-3-fluoro-10,5-iminomethano-10,11-dihydro-5H-dibenzo(a,d)cycloheptane	NMDA antagonist; glutamate antagonist	stroke

CP 101606	[(R*,R*)]-4-hydroxy-alpha-(4-hydroxyphenyl)-beta-methyl-4-phenyl-1-piperidineethanol	NMDA antagonist; glutamate antagonist	stroke; trauma; neurodegeneration
eliprodil; SL 820715	(+,-)-alpha-(4-chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol	NMDA antagonist; glutamate antagonist	neuropathy; stroke; trauma
ES 2421		NMDA antagonist; glutamate antagonist	stroke
L 703717	7-chloro-4-hydroxy-3-[3-(4-methoxyphenyl)methylphenyl]-2(1H)-quinolinone	NMDA antagonist; glutamate antagonist	epilepsy; stroke
L 708541		NMDA antagonist; glutamate antagonist	epilepsy; stroke
licostinel; ACEA 1021; CGP 63446	6,7-dichloro-5-nitro-1,4-dihydro-2,3-quinoxalidinedione	NMDA antagonist; glutamate antagonist	stroke; trauma
MDL 100453	4-oxo-5-phosphono-D-norvaline	NMDA antagonist; glutamate antagonist	epilepsy; neuropathy; stroke
NMDA antagonist		NMDA antagonist; glutamate antagonist	epilepsy; stroke; neuropathy
NMDA antagonist, subtype specific, SSNRA		NMDA antagonist; glutamate antagonist	stroke; trauma
NPS 1506		NMDA antagonist; glutamate antagonist	stroke; trauma
P 7189	2-amino-N-methyl-alpha-(3-methyl-2-thienyl)benzeneethan amine hydrochloride	NMDA antagonist; glutamate antagonist	stroke; neuropathy
PD 158473	3-(1-naphthalenyl)-5-(phosphonomethyl)-L-phenylalanine	NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
PD 159913		NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
Ro 256981		NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
selfotel; CGS 19755	cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid	NMDA antagonist; glutamate antagonist	stroke; trauma